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Investigation into aspects of the
Epidemiology of the common HFE gene
mutations and their effects on iron loading
Abstract of thesis
Background: The discovery ofmutations in the HFE gene has stimulated a great
deal of interest in the epidemiology of hereditary haemochromatosis,
its prevalence, questions about population screening, and the possible
role of the mutations in conditions other than haemochromatosis. In
addition, more and more information is becoming available about the
mechanisms controlling iron absorption in normal and pathological
states. There is some evidence that haemochromatosis and its associated
genetics are not widely understood within the medical community.
Aim: The aim of this project was to investigate some aspects of the
role ofHFE gene mutations in conditions other than hereditary
haemochromatosis in which iron loading might have a pathogenetic
role and to examine the hypothesis that heterozygosity for the C282Y
mutation offers some protection against iron deficiency. An additional
aim was to assess the level ofknowledge about haemochromatosis among
primary care physicians in the south east ofScotland and the feasibility
of using microplate array gel electrophoresis technology to facilitate the
laboratory assessment of the mutations.
Methods: DNA extracted from peripheral blood was amplified in a multiplex
amplification refractory mutation system (ARMS). The results were
analysed using microplate array diagnostic gel electrophoresis technology
(MADGE).
A number of separate studies were performed:
1. Haemoglobin concentration, iron stores and HFE genotypes of 366
male blood donors were studied as they donated blood over a period
of one year, with the aim of identifying any protection afforded by
HFE gene mutations against the development of iron deficiency
induced by blood donation.
2. Iron stores and HFE genotypes of 180 recipients oforthotopic liver
transplants were assessed and liver biopsy specimens were graded
for tissue iron deposition. Correlation was sought between HFE
genotypes and iron measurements as well as length of stay in the
transplant unit after the initial transplant procedure.
3. HFE genotypes were analysed for a population of 351 individuals
identified as iron deficient and compared with genotype results from
a control population of 521 individuals with no full blood count
evidence of iron deficiency.
4. Correlation between iron stores or HFE genotype and the severity of
coronary artery disease was assessed in a population of 286 patients
undergoing coronary angiography.
5. A postal questionnaire was sent to 540 general practitioners to assess
their level of awareness ofhereditary haemochromatosis.
Results: It was demonstrated that it was feasible to use the MADGE system to
facilitate rapid HFE genotyping of relatively large numbers of samples.
The prevalence ofHFE genotypes in these studies correlated well with
that reported for comparable populations in the literature. No evidence
was found to support the theory that heterozygosity for the C282Y
mutation can protect against the development of iron deficiency. There
was no evidence of a correlation between increasing iron stores or
HFE genotype and coronary artery disease in the population studied.
No influence ofHFE genotype on the outcome after orthotopic
liver transplantation was identified. The questionnaire to general
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1. Preface
The discovery, in 1996, of the HFE gene mutations associated with hereditary
haemochromatosis led to a burgeoning literature covering many aspects of this
condition. There was huge interest in the epidemiology ofHFE mutations and
especially the discovery that most patients of northern European ancestry with
hereditary haemochromatosis are homozygous for the C282Y HFE mutation. However,
while the C282Y mutation is prevalent in northern European populations, its frequency
is much lower in other populations in some ofwhich there are increasing numbers
of reports of non-HFE linked haemochromatosis. The maintenance ofC282Y at a
relatively high frequency in northern European populations has led to speculation that
its carriers may be at an evolutionary advantage, possibly through a degree ofprotection
against iron deficiency.
At the same time, knowledge of the cellular mechanisms governing human iron
absorption and of the pathways regulating this at both cellular and whole organism
levels is steadily advancing as more becomes clear about the possible role of the HFE
protein and its interaction with transferrin receptor -1. The possibility that iron might
be implicated in the pathogenesis of coronary heart disease has evoked considerable
interest, as has the related hypothesis that iron stores (and/or carriage ofC282Y) might
correlate with an increased incidence ofother disease states such as malignancy and
venous thrombosis.
With the discovery of a genetic marker for haemochromatosis has come a vigorous
debate about screening. Haemochromatosis is easily and effectively treated if diagnosed
before irreversible liver damage or diabetes has occurred and some have proposed mass
screening programmes to facilitate early detection. Others have argued equally strongly
against population screening on the basis of increasingly strong evidence that many
individuals with a "haemochromatosis genotype" may not ever develop clinically relevant
iron overload.
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Hie aim of this thesis was to examine the effects of iron overload in different patient
groups. Patients with coronary artery disease were investigated for any correlation
between the extent of their arterial disease and their iron stores and HFE genotypes.
None was found, which is an important contribution to the debate about the role
of iron in the pathogenesis of coronary artery disease. Because of some evidence that
patients with haemochromatosis fare less well after orthotopic liver transplantation
(OLT) than other patient groups, a group of patients who had had an OLT were
investigated for their iron stores and HFE genotypes. Several patients with previously
undiagnosed haemochromatosis were identified.
Because of the possibility that C282Y carriage affords protection against iron deficiency,
male blood donors were investigated for any evidence that C282Y heterozygotes could
donate blood more frequently than those without this mutation without becoming
deficient in iron. This study demonstrated that it is unlikely to be feasible to select
donors on the basis ofHFE gene mutations to donate blood more frequently - an
important negative result at a time when there is intense interest in attempts to augment
the blood supply. A further study showed no evidence of an increased prevalence of
C282Y in an iron-deficient, compared with a non-iron deficient population.
There is evidence in the literature to suggest that many in the medical profession
are unaware of the prevalence, clinical features and diagnosis of haemochromatosis.
To investigate this, a questionnaire on haemochromatosis was sent to all general
practitioners covering a population ofapproximately 750,000 in south east Scotland to
assess their clinical experience of diagnosing and treating this condition and their general
awareness of it. The returns suggested considerable variability in both experience and
awareness among the respondents.
The thesis also examined the possibility of using a microplate array system to facilitate
the simultaneous determination of the HFE genotype of large numbers of samples using
a multiplex amplification refractory mutation system and identified this as a means of
determining accurately the presence or absence of both the C282Y mutation and the
other common HFE mutation, H63D, simultaneously in a relatively large number of
DNA samples.
2
2. Background to thesis
and review of the literature
2.1 Historical Overview
The first recognition of the clinical effects of advanced haemochromatosis was made
by Trousseau, when he described the combination of diabetes mellitus and hyper-
pigmentation of the skin (Trousseau, 1865). The initial clue to the pathogenesis of
the disorder was provided by Troisier's description six years later of "diabete bronze et
cirrhose pigmentaire" (Troisier, 1871). von Recklinghausen who, in 1889, advanced a
theory that the pigmentation of the liver he saw at autopsy was due to the accumulation
of iron derived from the blood, was the first to use the term haemochromatosis
("Hamochromatose") (von Recklinghausen, 1889). In 1935 Sheldon reviewed the
extant literature on more than 300 cases and suggested that the condition could be
hereditary. He also drew attention to the age profile (90% over 35 years old) and the sex
incidence (over 90% in males) of sufferers (Sheldon, 1935). Twenty years later, Finch
and Finch reviewed a further 707 histologically proven cases of haemochromatosis that
had appeared in the literature since the appearance ofSheldon's monograph (Finch,
1955). They described haemochromatosis as uncommon and, based on records of
hospital admissions and deaths, estimated that there were about 20 000 sufferers in
the United States. The most useful clinical clue to alert the physician of the time to a
possible diagnosis of haemochromatosis was the "classical tetrad" of skin pigmentation,
diabetes, liver disease and heart disease.
Not everyone was initially convinced of the heritable nature of haemochromatosis,
however. In the mid 1960s MacDonald concluded that iron overload and
haemochromatosis resulted from the consumption of alcoholic beverages (MacDonald,
1964). In 1969, Saddi and Feingold proposed a recessive mode of inheritance (Saddi,
1969). Seven years later, the discovery that haemochromatosis in the population of
Brittany was linked to human leukocyte antigen allele A3 (HLA-A3) in the Major
Histocompatibility Complex (MHC) on the short (p) arm of chromosome 6 ushered
in the modern era of genetic investigation (Simon, 1975). This discovery enabled
the use ofHLA-typing to track the haemochromatosis allele in families containing a
haemochromatosis proband (Milman, 2000).
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The linkage to HLA-A3 was confirmed in other populations of northern European
extraction, in among other countries, the U.K. (Bomford, 1977), Germany (Dyrszka,
1979) and Sweden (Ritter, 1984).
2.1.1 Discovery of the "haemochromatosis gene"
The ability further to characterise the ancestral haplotype of haemochromatosis came
with the advent ofmicrosatellite mapping. This permitted the demonstration that the
microsatellite marker D6S105 was associated with haemochromatosis (Jazwinska, 1993).
In all populations studied using microsatellite mapping, it has been possible to identify
the alleles linked with haemochromatosis as: D6S265 —1, HLA-A3 and D6S105-
8, although the strength ofassociation of each of these alleles varies somewhat from
population to population (Raha-Chowdhury, 1995; Jazwinska, 1996; Gandon, 1996;
Camaschella, 1996).
In 1996, Feder and others used linkage disequilibrium studies and high resolution
haplotype analysis to build upon this information and identify as a candidate gene for
haemochromatosis an HLA class I-like gene. Initially, this was called HLA-H, but it was
soon renamed HFE in compliance with the accepted nomenclature for the HLA system
(Bodmer, 1997).
Feder et al (1996) endeavoured to identify the probable ancestral mutation that resulted
in the haemochromatosis phenotype. A likely candidate for this was a G to A change
at nucleotide 845, resulting in a substitution of tyrosine (Y) for cysteine (C) at amino
acid 282, a highly conserved residue involved in an intramolecular disulphide bond
(see Figure 2.1). In their group of 178 patients, this mutation, referred to from here
onwards as C282Y, was found on 85% of all haemochromatosis chromosomes. 3.2% of
control chromosomes carried the mutation. All the chromosomes that carried C282Y
also contained the ancestral haplotype. However, consideration of the number of
heterozygotes revealed an excess over that predicted by the Hardy-Weinberg equilibrium
(see Appendix 7), and led to a search for a second mutation. A second mutation
was found: a C to G change resulting in a change from histidine to aspartic acid at
amino acid 63 (H63D). This mutation was found with a high frequency on control
chromosomes and 4% of haemochromatosis patients were compound heterozygotes for
C282Y and H63D.
The structure of the molecule encoded by HFE and its potential role in iron metabolism
are discussed in section 2.7.4.4. The HFE molecule is illustrated schematically in figure 2.1.
4
H63D
Figure 2.1 Structure of HFE, its association with P2 microglobulin, and location
of the two common mutations (Adapted from Feder, 1996).
The blue lines indicate disulphide bridges.
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2.2 Epidemiology -
the distribution of HFE gene mutations in different populations
Over two decades ago, Simon proposed that the genetic mutation leading to
haemochromatosis might have originally arisen in Celtic populations before their Iron
Age migration from central Europe (Simon, 1980). It has also been suggested (Simon,
1987) that the haemochromatosis C282Y mutation occurred in history on a particular
chromosome carrying the HLA haplotype A3, B7, which was subsequently modified by
genetic recombination. This haplotype has been termed the ancestral haplotype and is
about 6 Mb in size.
HLA data have lent support to the hypothesis of a possible Celtic origin for the
C282Y mutation. This is supported by the work of Ryan et al which found an allele
frequency of 14% (the highest reported) for the C282Y mutation ofHFE in an Irish
population (Ryan, 1997). Lucotte and colleagues analysed data from other studies
and combined results from Celtic populations in south Wales and Brittany to obtain a
frequency of6.88% for C282Y in this composite population (Lucotte, 1998). This was
significandy higher than values for composite Nordic, southern European and Russian,
but not Anglo-Saxon populations. Smith and colleagues screened employees of the
Massachusetts Polaroid Corporation in the U.S.A. and found a significant association of
hereditary haemochromatosis with Celtic ancestry (although this was based on analysis
of the ancestry of only five individuals with haemochromatosis) (Smith, 1997).
Studies on populations in south east Asia have suggested that the C282Y and
H63D mutations might have arisen more than once, independently, in different
populations. (Rochette, 1999). Subsequently, by a series of genetic recombinations,
the haemochromatosis allele was introduced onto chromosomes having different HLA
haplotypes, thus accounting for the association of haemochromatosis with HLA-A3,
B7 in, for example, Germany (Dyrszka, 1979) and Canada (Lloyd, 1978) and with
HLA-A3, B14 in England (Bomford, 1977). H63D, appears to be an older mutation,
occurring on a wider variety of haplotypes in a greater diversity of population groups
(Rochette, 1999; Merryweather-Clarke, 1997).
After the discovery of the HFE gene mutations, it was possible to screen both normal
populations and patients already diagnosed with haemochromatosis for the genetic
defect. Some of the results of these studies are summarised in tables 2.2 and 2.3.
Merryweather-Clarke and others (1997) have analysed chromosomes from populations
around the world.
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Table 2.2 Allele frequencies of HFE mutations in control populations
Allele Frequency (%)
& 95% confidence intervals"
Reference No of subjects Country C282Y H63D
Willis, 1997 200 England 8.5 (5.8-11.2) 0.16
Miedzybrodzka, 1999 188 Scotland 8.4 (6-12) 15.7 (12-19)
Merryweather-Clarke, 1998 411 Jersey 8.3 ±1.9 15± 2.5
UK Haemochromatosis
Consortium, 1997 101 UK 5.4 15.8




Ryan, 1998 109 Ireland 14 16
Olynyk, 1999 3011 Australia 6.5 NDb




Cardoso, 1998 117 Sweden 3.8 12.4
Brissot, 1999 278 France 2.9 16.5
Carella, 1997 50 Italy 1 10
Papanikolaou, 2000 158 Greece 0.6 14.5
Notes
a confidence intervals quoted where given in article
b ND indicates insufficient or no data in article
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Table 2.3 Frequency of HFE genotypes in haemochromatosis patients
Genotype*












lazwinska, 1996 112 Australia 112(100) 0(0) 0(0) 0(0) 0(0) 0(0)
UK haemochrom¬
atosis consortium
(1998) 115 UK 100(91) 1 (1) 5(4) 0(0) 1 0) 3(3)
Brissot, 1999 217 France 209 (96) 2(3) 0(0) 1 (0.5) 1 (0.5) 4(2)
Willis, 1997 18 England 18 (100) 0(0) 0(0) 0(0) 0(0) 0(0)
Miedzybrodzka,
1999 54 Scotland 49 (91) 0(0) 2(4) 0(0) 0(0) 3(6)
Ryan, 1998 78 Ireland 70 (90) 2(3) 2(3) 1 (1) 0(0) 3(3)
Cardoso, 1998 87 Sweden 80 (92) 1 (1) 1 0) 1 0) 1 (1) 3(3)
Feder, 1998 178 USA 148 (83) 9(5) 12(7) 0(0) 1 (0.5) 8 (4.5)
Papanikolaou,
2000 10 Greece 3(30) 0(0) 5(50) 0(0) 0(0) 2(20)
Carella, 1997 75 Italy 48 (64) 2 (2.7) 16(21) 3(4) 1 (1.3) 5(7)
Piperno, 1998 158 Nth Italy 69% 6.3% 11.3% 7.6% 1.3% 4.4%
30 Sth/central
Italy
33.3% 3.3% 36.7% 13.3% 3.3% 10%
Notes:
'
genotypes notated as follows:
HY/HY homozygous for C282Y
HY/HC heterozygous for C282Y
HC/HC homozygous wild-type
HC/DC heterozygous for H63D
DC/DC homozygous for H63D
HY/DC heterozygous for both C282Y and H63D
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They found worldwide allele frequencies of 1.9% for C282Y and 8.1% for H63D.
Their results were consistent with those of others (see table 2.2) who have shown the
highest prevalence ofC282Y in populations ofnorthern European origin. The mutation
is rare or absent in non-Caucasian populations (Merryweather-Clarke, 1997; Cullen,
1998). Broadly speaking, the frequency ofC282Y in Europe decreases in north-to-
south and west-to-east directions, away from the areas ofnorth eastern Europe that were
inhabited by early Celtic populations, again providing evidence in favour of an origin for
this mutation in that population (Lucotte, 2001). H63D was more widely distributed
with the highest frequency being found among the Basques (Merryweather-Clarke, 1997).
Other studies have demonstrated significant variations in the prevalence ofHFE gene
mutations even within the same countries (Rivard, 2000; Cardoso, 2001).
Among patients already diagnosed with haemochromatosis, it is clear that the vast
majority in northern European populations is homozygous for C282Y (see table 2.3).
However, the proportion in the south of Europe (for example, in Greece and Italy) is
much lower, suggesting genetic heterogeneity of haemochromatosis in these populations.
(Carella, 1997; Piperno, 1998; Papanikolaou, 2000).
2.3 Genetic heterogeneity of haemochromatosis
As discussed below, there appears to be no simple relationship between homozygosity for
C282Y and clinical expression of iron overload (Shaheen, 1998). This fact, in conjunction
with the existence of a significant minority of haemochromatosis patients who are wild-
type for C282Y and H63D, has led investigators to search for other mutations ofHFE.
In addition, the occurrence of iron overload in HFE mutation-negative patients has
indicated the existence of other genetic modifiers of iron metabolism.
2.3.1 Nomenclature
As more information has come to light about the genetic heterogeneity of
haemochromatosis, so the potential for confusion in nomenclature has increased. HFE-
linked haemochromatosis (C282Y homozygosity, H63D/C282Y or clinically milder
forms linked with S65C) is often referred to as "classical" hereditary haemochromatosis.
All references to haemochromatosis in this thesis may be taken to refer to this condition,
unless otherwise specified.
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2.3.2 Mutations of HFE apart from C282Y
2.3.2.1 The significance of H63D
The precise role ofH63D in hereditary haemochromatosis remains uncertain. In the
large amount of data published after the discovery ofHFE (Feder, 1996), it appeared
clear that no chromosome ever carried both C282Y and H63D. Such was the weight
of evidence that some authors stated categorically that the two never occurred in "cis"
(Brissot, 1999). Recent case reports suggest that this assumption is not valid as this
occurrence has been recorded in three, geographically widely separated, individuals.
Two were homozygous for C282Y and heterozygous for H63D (Thorstensen, 2000;
Best, 2001) and one was heterozygous for C282Y and homozygous for H63D (Lucotte,
2001). The genotype in all three cases was confirmed by more than one method
including DNA sequencing. This is significant in having potential misdiagnosis of
compound heterozygosity as a consequence. However, given that upwards of 60 000
individuals have been genotyped (Best, 2001; Jackson, 2001; Beutler, 2002a) and
only these three have been described who were homozygous for one mutation and
heterozygous for the other, it seems likely to be a very rare phenomenon.
In their original report in 1996, Feder et al found 4.5% of the haemochromatosis
probands studied were compound heterozygotes for C282Y and H63D. Some
researchers (Carella, 1997) have suggested that H63D is a polymorphic change, without
clinical significance, but this is disputed by others (Beuder, 1997; Aguilar Martinez,
1997). It was noted by Feder and colleagues (Feder, 1996) that the H63D allele was
over-represented among their iron overloaded patients compared with the control
group. Cell transfection studies have provided an insight into the possible functional
significance ofH63D (Feder, 1998)
Beutler (1997) analysed all the published data then available on the relationship
between the presence or absence of the H63D mutation and iron overload in C282Y
heterozygotes. He concluded that there was a relationship between iron overload and
H63D in these patients and very low probability that this association occurred by
chance (p <10"10). The point must be made, however, that he assumed that only C282Y
non-bearing chromosomes were at risk for H63D. On the basis of data collated from a
number of studies, the clinical penetrance of the compound heterozygous genotype has
been estimated at 1-2% (Bacon, 1999b). McDonnell and colleagues found a relative
risk of 9 for haemochromatosis for homozygotes for H63D, although the confidence
limits were wide (McDonnell, 1999). Sham and co-workers found H63D homozygosity
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in three out of 61 patients who had already been diagnosed with haemochromatosis by
"classical" criteria, including liver biopsy (Sham, 1997). Beuder et al reported raised
iron indices in carriers of H63D among over 10 000 screened individuals (Beutler,
2000). Porto et al reported strong linkage disequilibrium between the H63D mutation
and HLA allele A29. The H63D/HLA-A29 haplotype appeared to be associated with
what the authors termed non-classical haemochromatosis. The patients with non-
classical haemochromatosis (NCH) did not fulfil the diagnostic criteria for classical
haemochromatosis studies either because they had other clinical conditions which can be
associated with iron overload or their total body iron stores were lower (<5g) than those
typically found in classical haemochromatosis. Seven of the 25 patients with NCH had
hepatic iron overload, but normal transferrin saturation (Porto, 1998). Some of these
may overlap with the dysmetabolic iron overload syndrome described by Moirand et al
(1997b), but the clinical data given in the paper of Porto and colleagues are insufficient
to be certain of this.
The frequency ofH63D and its effect on iron stores in 2531 inhabitants of an Australian
town were recendy determined (Gochee, 2002). No influence ofH63D genotype
on serum ferritin levels was reported, but both homozygotes and heterozygotes had
significandy increased transferrin saturation compared with wild-types. Homozygotes
for H63D were not at increased risk of clinically significant iron overload. The authors
concluded that H63D in the absence ofC282Y is not clinically significant.
2.3.2.2 Other Mutations
Since the discovery ofHFE in 1996, several polymorphisms in the gene have been
reported (Totaro, 1997; Douabin, 1997.) Many of these are located in intron sequences
and are of no clinical significance.
While in northern Europe, the vast majority of cases with the hereditary
haemochromatosis phenotype are either homozygous for C282Y or compound
heterozygous for C282Y and H63D, this is not the case in many parts of the south of
the continent. Genetic heterogeneity is a particular feature of haemochromatosis in the
Italian population (Carella, 1997; Piperno, 1998; Pietrangelo, 1999). Some patients in
whom at least one chromosome lacks one of the "classical" HFE mutations have other
mutations in HFE (Piperno, 2000).
Additionally, a number of low-frequency "private" mutations have been discovered
to contribute to the iron-loaded phenotype in some patients (Wallace, 1999; Beuder
2002b; Douabin, 1997).
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One polymorphism, 193A—»T, leads to a serine to cysteine substitution (S65C) in
exon 2 of the gene and may be quite frequent in the general population. (Arya, 1999;
Beutler, 2000; Beckman, 2001). Mura and co-workers analysed HFE mutations among
711 haemochromatosis probands from Brittany. As expected, the majority (80%)
of probands were homozygous for C282Y. Taken together, the C282Y and H63D
mutations accounted for 90.8% ofhereditary haemochromatosis alleles. S65C was
present with significandy greater frequency (7.2% vs. 2.49%) on the non-C282Y or
H63D bearing chromosomes of haemochromatosis probands than of controls. 16%
ofC282Y heterozygotes and 7.4% ofH63D heterozygotes from among the probands
carried S65C, leading the authors to postulate that S65C could contribute to iron
overload in mildly affected haemochromatosis patients (Mura, 1999). An association
between S65C carriage and mild to moderate hepatic iron overload was recently
confirmed in a Swedish population (Holstrom, 2002), but its clinical significance is still
uncertain as S65C was not associated with an increased transferrin saturation in a study
of healthy blood donors (Arya, 1999).
2.3.3 Non-HFE-linked haemochromatosis
It is clear that not all patients with inherited iron overload carry mutations in the HFE
gene. It was noted soon after the identification ofHFE that some patients lacking HFE
mutations nonetheless suffered from typical haemochromatosis with severe iron overload
(Shaheen, 1998). Additionally, there were identifiable geographic areas, particularly
southern Europe, with a higher proportion of patients lacking HFE mutations than
other areas (Piperno, 1998).
In recent years, there has been tremendous progress in the identification of the genetic
mutations implicated in the causation ofprimary iron overload other than those
linked to HFE. Some of these (transferrin receptor 2-associated haemochromatosis
and juvenile haemochromatosis) share many features in common with HFE linked
haemochromatosis, while ferroportin-associated iron overload has quite different
epidemiology, clinical presentation and natural history (Pietrangelo, 2004a).
The term "juvenile haemochromatosis" has been used to refer to an iron overload
syndrome with a similar phenotype to adult haemochromatosis, but typically presenting
much earlier in life. Typically, affected individuals present with hypogonadism in the
second decade of life, while cirrhosis of the liver develops only later (de Gobbi, 2002).
It is now clear that this condition is genetically heterogeneous. There is evidence for
linkage to a gene on chromosome lq (Roetto, 1999; Roetto 2000) and a candidate
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gene originally named HFE 2 and now HJV has been cloned in this region. The gene
product ofHJV, hemojuvelin, may modulate expression of hepcidin (Papanikolaou,
2004). It is also possible that mutations of the HAMP gene on chromosome 19,
affecting the production or function of hepcidin, may result in a similar phenotype
(Pietrangelo, 2004a). There is increasing evidence to suggest that HAMP may act as
a modifying gene to increase the phenotypic expression of the HFE mutation C282Y
(Jacolot, 2004; Merryweather-Clarke, 2003). This may effect the phenotype ofboth
heterozygotes and homozygotes for C282Y (see also section 2.3.4)
After the discovery that the HFE protein interacts with the transferrin receptor
(discussed in detail in section 2.7.4.4), attention turned to the gene for the transferrin
receptor (TfR) as a possible site for mutation. Complementary DNA (cDNA)
sequences of 21 patients with hereditary haemochromatosis were sequenced, and no
likely mutation was found (Tsuchihashi, 1998). In 1999, a second transferrin receptor
molecule, transferrin receptor 2 (TfR2) was cloned (Kawabata, 1999). A number of
mutations inTfR2 have been discovered (Camaschella, 2000; Girelli, 2002; Mattman,
2002; Roetto, 2002) in Italian patients with iron overload, who lack HFE gene
mutations. Examination of liver histology in two patients and of biochemical markers
of iron status in heterozygotes led to the suggestion that haemochromatosis in these
patients may behave clinically very similarly to classical haemochromatosis (Girelli, 2002).
A further type of haemochromatosis has been described in a number of patients in
many different countries with mutations in the SLC40A1 gene (previously called
SLCl 1A3) on chromosome 2q, which encodes the iron transport protein ferroportin
(Njajou, 2001; Montosi, 2001). Whereas the inheritance of classical haemochromatosis
follows an autosomal recessive pattern, these patients displayed autosomal dominant
inheritance (Pietrangelo, 1999; Montosi, 2001). Additionally, the histological pattern of
hepatic iron overload was distinct from that seen in classical haemochromatosis in that
reticuloendothelial rather than hepatocellular iron deposition predominated. Patients
were often anaemic early in life with a normal transferrin saturation but a raised ferritin
and demonstrated low tolerance to phlebotomy (Montosi, 2001). A valine deletion at
position 162, possibly resulting in haploinsufficiency of ferroportin 1 and impairment of
iron export from macrophages (Fleming, 2001), is a frequent finding in this form of iron
overload (Montosi, 2001; Roetto, 2002; Devalia, 2002; Wallace, 2002)
One family with another form of autosomal dominandy inherited iron overload has
been identified in Japan. The genetic basis of this is a mutation in the gene encoding the
H sub-unit of ferritin (Kato, 2001)
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Some of these non-HFE mutations such as that in the H subunit of ferritin, which has
been reported in one family worldwide, seem at present to be rare. "The prevalence of
the mutations in the genes for transferrin receptor-2 and ferroportin is not yet certain.
Transferrin receptor 2 mutations were not responsible for iron overload in French
patients (Aguilar-Martinez, 2001), white, Asian or African Americans (Lee, 2001a),
Caucasian patients from Alabama or Caucasian (including individuals of Italian descent)
or African-American controls (Barton, 2001). Lee et al sequenced the coding and
flanking regions of the transferrin receptor-1, ferroportin, caeruloplasmin, ferritin light
and heavy chains, iron regulatory proteins-1 and -2 and hepcidin in a relatively small
number ofwhite, Asian and African American normal or iron-overloaded individuals
(Lee, 2001b). They found no significant association between iron stores and any of a
number ofpolymorphisms in the genes studied. Ferroportin mutations have, however,
been reported in Dutch, French, French Canadian and Asian families (Pietrangelo, 2004a).
It had been thought that the iron overload seen in sub-Saharan Africa was due to
environmental factors, especially excess dietary intake of iron. However, there is now
some evidence of a non-HLA genetic linkage (Moyo, 1998). This also is unrelated to
classical HFE-linked haemochromatosis.
Primary iron overload is also a feature of congenital atransferrinaemia (Hamill, 1991)
and caeruloplasmin deficiency (Morita, 1995)
Non-transfusional secondary iron overload occurs in a number of unrelated conditions,
among which are:
♦♦♦ p-thalassaemia major and some other haemoglobinopathies in which only part of
the iron overload is attributable to transfusion therapy (Bottomley, 1998).
*1* Congenital dyserythropoietic anaemias types I and II, which may present with iron
overload (Halpern, 1985)
❖ Hereditary sideroblastic anaemia (Cazzola, 1983)
❖ Porphyria cutanea tarda (Lundvall, 1970)
❖ Hereditary haemolytic anaemias - in some cases, iron overload may result from
co-inheritance of haemochromatosis alleles (Edwards, 1982; O'Mahony, 1987).
These will not be discussed further here.
14
2.3.4 The iron status of heterozygotes for hereditary haemochromatosis
A large study was conducted in Utah, USA, examining clinical and biochemical
abnormalities in heterozygotes for haemochromatosis (Bulaj, 1996) defined by HLA-
linkage studies. The analysis of serum iron, transferrin saturation and ferritin was
broken down by age and sex of the subjects. In all age groups, the mean serum iron
concentration and transferrin saturation were higher in heterozygotes than in normal
subjects. The mean serum ferritin was higher in all groups of heterozygotes apart from
the youngest group of females. However, statistical significance was reached only in
the group ofmale subjects aged 31 to 60 years and in women of 31 to 60 and 61 to
90 years of age. In total, 18 percent ofmale heterozygotes and 11 percent of female
heterozygotes had transferrin saturation values more than 2 standard deviations above
the mean values for normal subjects. Four percent ofmale heterozygotes had an initial
transferrin saturation greater than 62 percent, taken by the study's authors to be the
threshold for homozygous haemochromatosis in men. However, all those in whom re-
testing while fasting was possible had transferrin saturation values of62 percent or less.
Of the 44 of 553 female heterozygotes (8 percent) with an initial transferrin saturation
of greater than 50 percent (taken as the equivalent threshold for women), 2 subjects had
a value ofmore than 50% on re-testing. Three percent ofwomen in the normal control
population had transferrin saturation values in excess of 50 percent (although it is not
clear whether these individuals were subjected to re-testing). The authors concluded that
heterozygotes for haemochromatosis do have an increased body iron burden, but that
this seems to have few if any clinical consequences. Comparable conclusions had been
previously reached by Adams et al in a study of 255 heterozygotes, again identified by
HLA typing (Adams, 1994).
Crawford and colleagues examined the phenotypes and HFE genotypes of 300 subjects
ofwhom 115 met the clinical diagnostic criteria for haemochromatosis. Of 8 (4.8%)
iron-overloaded subjects heterozygous for C282Y, 7 were compound heterozygotes
with H63D. (Crawford, 1998). A study of over 1000 randomly selected individuals in
New Zealand confirmed that heterozygotes for C282Y or H63D had higher values of
transferrin saturation than those lacking such mutations (Burt, 1998).
The awareness that heterozygotes for C282Y may have larger iron stores than those
without this mutation has stimulated research into whether these increased iron
stores are potentially harmful. The risk of organ damage in patients with hereditary
haemochromatosis is clear, but whether carriers are also at some risk is not yet known.
Chapters 6 and 7 of this thesis present data to examine this question, with reference
to patients with coronary artery disease and patients undergoing orthotopic liver
transplantation, respectively.
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2.3.4.1 Iron Deficiency in Heterozygotes
The Utah study (Bulaj, 1996) showed that female heterozygotes for haemochromatosis
had a lower incidence of iron deficiency than normal females. Datz and co-workers, too,
have suggested that heterozygosity for C282Y protects women from the development
of iron deficiency (Datz, 1998), but their study did not make a distinction between
C282Y/wildtype heterozygotes and C282Y/H63D compound heterozygotes, making
their data more difficult to interpret. This distinction was made in a cross-sectional
analysis of 1327 women in Australia (Rossi, 2000), which showed no influence of the
C282Y/wildtype genotype on iron stores. However, further support for a possible
protective effect against iron deficiency was made in a study ofpatients with coeliac
disease (Butterworth, 2002). This study made the interesting observation that C282Y
in the coeliac patients studied, in contrast to the control patients, was in linkage
disequilibrium with HLA-A*01 and B*08.
The issue of the persisting high prevalence ofC282Y in northern European populations,
as discussed in section 2.2 above, merits further study. It has been suggested that the
putative protection against iron deficiency afforded by carriage ofC282Y may have
offered heterozygotes an evolutionary advantage, so ensuring that the mutation was
not gradually selected out. If the theory of protection against iron deficiency is correct,
a corollary should be that C282Y is under-represented in iron deficient populations
compared with non-iron deficient populations. This hypothesis is examined further in
chapter 5 of this work. Another consequence could be that carriers of C282Y might be
protected to some degree against not only "natural" iron deficiency but also that induced
iatrogenically, for example by blood donation. Chapter 4 of this thesis examines a
population of male blood donors who gave blood regularly over a period of up to one
year, to investigate whether this is indeed the case.
2.4 Making the Diagnosis of Haemochromatosis
2.4.1 Assessment of Iron Overload
2.4.1.1 Blood measures of iron load
In iron overload, serum iron is typically increased, with a reduced serum transferrin, a
reduced iron-binding capacity and a raised transferrin saturation (Zilva, 1998). A raised
transferrin saturation provides an early indication of iron overload at which stage serum
ferritin may still be normal (Edwards, 1993). A recent study examined the correlation
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between total body iron stores, as calculated from the volume of blood removed in
phlebotomy and serum ferritin, serum iron, unsaturated iron binding capacity and
transferrin saturation, measured before commencement of phlebotomy (Beutler, 2002b).
The correlation between all the measurements and total iron burden was greater in
patients homozygous for C282Y than in other patients, and overall ferritin was found
to be the best predictor of body iron stores. Unfortunately, there are many causes other
than iron overload of both a raised transferrin saturation and an elevated serum ferritin.
Despite evidence that serum ferritin does correlate with body iron stores in normal
individuals and those with uncomplicated iron overload (Jacobs, 1972; Lipschitz, 1974;
Halliday, 1977), elevated serum ferritin values must be interpreted in the light of clinical
information. A study of the causes ofserum ferritin values in excess of 1000 ng/mL
demonstrated that even extremely elevated ferritin concentrations may not be a good
guide to the presence of tissue iron overload in patients with, for example liver disease,
renal disease, infection and malignant disease (Lee, 1996). Specific disease states, for
example, adult onset Stills Disease (Schwarz-Eywill, 1992) or the recently characterised
syndrome ofhyperferritinaemia and cataracts (Girelli, 1995) are also characteristically
associated with high serum ferritin values. Liver disease may make the interpretation
of serum ferritin values particularly difficult (Chapman, 1982; Di Bisceglie, 1992; Bell,
1994). The choice of test in screening for haemochromatosis is discussed in more detail
in section 2.6.3.
Because of these concerns about the validity of blood tests for iron overload, histological
examination of liver tissue has been considered an essential step both in confirming the
diagnosis of haemochromatosis and assessing the degree of liver damage present (Witte,
1996). The benefits ofhistological evaluation have been felt to outweigh the (relatively
small) risks of liver biopsy (Witte, 1996).
2.4.1.2 Liver biopsy in the diagnosis of haemochromatosis
Intracellular iron is normally stored as ferritin. As iron accumulates, ferritin molecules
eventually coalesce to form haemosiderin, and it is in this form that most tissue
iron is found in haemochromatosis. Haemosiderin is an amorphous deposit of iron
and peptide that probably consists of degraded ferritin protein and ferric hydroxide
polymers or cores of varying size (Ward 1989). It can be visualised using Perls' acid
ferrocyanide technique, considered the most sensitive and specific means of staining
for iron (Searle, 1994). Hepatic iron deposition in haemochromatosis follows a
characteristic pattern. Typically, iron deposition is observed initially in periportal (zone
1) hepatocytes with hepatocytes in zones 2 (midzone) and 3 (centrilobular) becoming
17
iron loaded as the disease progresses. This gradient in iron deposition across lobules is
typically maintained throughout the course of the disease. The relative paucity of iron
in hepatic reticuloendothelial cells in the early stages of iron overload is an important
feature of hereditary haemochromatosis (Searle, 1994; McLaren, 1989). This contrasts
with the situation in secondary iron overload, such as may be seen in patients with
haemoglobinopathies or other forms of chronic haemolysis. In these conditions, iron
accumulation occurs principally in Kupffer cells. A reticuloendothelial pattern of iron
deposition has been found, in a study of 103 liver biopsies from patients with various
liver diseases, to predict reliably the absence ofC282Y homozygosity. In the same study,
however, the converse was shown not to be true: a hepatocellular pattern with zonal
gradient did not correlate well with haemochromatosis (42 out of 72 biopsies showing this
pattern were C282Y homozygotes (Brunt, 2000)). This indicates that the hepatocellular
pattern of iron deposition should not be used as a surrogate marker for haemochromatosis.
A variety ofhistochemical grading systems are in use for the recording of hepatic iron
load. One of the most widely used is that of Scheuer in which iron deposition is
assigned one of four grades, with grade 1 the least and grade 4 the most intense staining
for hepatic iron (Scheuer, 1962). Only hepatocellular iron is graded. Scheuer s paper
gives no written description of the criteria he used; the grading is illustrated merely by
means of four photomicrographs and is thus, perhaps, open to somewhat subjective
interpretation. Although other systems are available (described, for example, by Brissot
(Brissot, 1981)), the practice guideline for haemochromatosis developed by the College
ofAmerican Pathologists (Witte, 1996) recommends the use of a modification of
Scheuer s system.
Quantitation of hepatic iron by chemical means can also provide useful
information. The hepatic iron concentration can be measured by atomic absorption
spectrophotometry. As the iron content of the liver rises with increasing age, the iron
concentration may be adjusted to take account of age by calculation of the hepatic iron
index (HII) (Bassett, 1986). This is achieved by dividing hepatic iron concentration
(pmol iron/g dry weight) by the age in years of the individual. The HII has been
considered ofparticular use in discriminating iron overload associated with alcoholism
from that ofhaemochromatosis. Witte quotes the following "reference" values (Witte, 1996):
♦♦♦ Normal individuals: HII s 1.1
❖ Alcoholic liver disease: HII s 1.7
❖ Haemochromatosis heterozygotes: HII s 1.9
❖ Haemochromatosis homozygotes: HII a 1.9
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A number of reports have suggested that the HII may be less specific in the presence of
cirrhosis which may, regardless of the underlying liver disease, be associated with an HII
greater than 1.9 (Deugnier, 1997; Ludwig, 1997; Press, 1998).
The importance ofhistological examination of the liver lies also in its utility in
detecting fibrosis and cirrhosis which have prognostic implications for patients with
haemochromatosis.
The possibility of non-invasive quantification of hepatic iron using magnetic resonance
imaging has been investigated. The use of gradient-recalled-echo sequences has
produced encouraging results (Bonkovsky, 1999). However, this means of assessment of
hepatic iron overload is not widely available in the UK at present and would probably
not eliminate the need for liver biopsy entirely as a means to assess hepatic fibrosis or
cirrhosis and the presence of iron-free foci, which may be pre-malignant (Deugnier,
1992). Magnetic susceptibility (SQUID) allows accurate quantification of hepatic
iron (Brittenham, 1988), but access to this technology is extremely limited worldwide
(British Committee on Standards in Haematology, 2000).
The advent ofHFE genotyping has led to a change in the role of liver biopsy in
the diagnosis of hereditary haemochromatosis. A study of 197 French patients, all
homozygous for C282Y, revealed that severe fibrosis was absent in all of 96 patients
who had a serum ferritin s 1000 ng/ml, a normal value for aspartate aminotransferase
and no hepatomegaly (Guyader, 1998). Current guidelines (British Committee on
Standards in Haematology, 2000; EASL, 2000; Powell, 2000) suggest that liver biopsy is
unnecessary in C282Y homozygous patients meeting these criteria. However, in those
who do not, and perhaps in those aged over 46 with an alcohol intake ofmore than 60g
per day (Powell, 2000), biopsy still has an important role, although in prognostication
rather than making the diagnosis. There is less agreement over the need for liver biopsy
in patients compound heterozygous for C282Y and H63D. The Australian Broadsheet
on hereditary haemochromatosis (Powell, 2000) suggests that these patients should
be biopsied, in contrast to the British guidelines (British Committee on Standards
in Haematology, 2000). Advice in this area seems likely to be subject to further
modification as knowledge increases. A recent paper from the USA has suggested that
biopsy may be unnecessary in haemochromatosis patients with serum ferritin levels less
than 1000 pg/L, regardless of age or serum liver enzymes (Morrison, 2003)
Finally, there are miscellaneous other methods ofestimating of body iron stores. The
amount of iron removed in a phlebotomy programme can be calculated if it is assumed
that one unit of blood contains approximately 225 mg iron (Powell, 2000). In the
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majority ofpatients with haemochromatosis, more than 4-5g of iron can be removed
before iron deficiency is precipitated. The use of circulating markers of hepatic fibrosis
in haemochromatosis has also been investigated. A study of 42 patients with hereditary
haemochromatosis and 19 controls showed that a serum concentration of type IV
collagen of >115 ng/ml was 100% sensitive and 69% specific in detecting the presence
of severe fibrosis or cirrhosis (George, 1999).
2.4.2 Clinical Features
The classical clinical features ofhereditary haemochromatosis, diabetes, increased skin
pigmentation and hepatic cirrhosis are nowadays unusual presenting features of the
disease. More frequently, patients present (often in early middle age) with non-specific
symptoms of fatigue, abdominal or joint pain. A significant number may have no
symptoms at all, a high ferritin having been discovered incidentally during investigation
of an unrelated complaint. When symptomatic organ involvement does occur, liver
disease usually predominates, but iron overload may also affect the endocrine organs
(causing diabetes, thyroid dysfunction and hypogonadal hypogonadism), the heart
(cardiac failure and dysrhythmias) and the joints (arthritis). Although the prognosis
of untreated haemochromatosis is poor, institution of therapeutic phlebotomy and
successful reduction of tissue iron load results in a normal life expectancy for those
patients without hepatic cirrhosis or diabetes mellitus (Niederau, 1996).
2.4.3 Diagnostic algorithm
A possible algorithm for the diagnosis of hereditary haemochromatosis is given in figure
2.4. The exact order in which tests are performed may vary depending on setting. For
example, it may be considered preferable or convenient to perform HFE genotyping at
the same time as the assessment of fasting TS. Subjects who have been identified as a
result of family screeningwill, as a rule, be genotyped as part of their initial testing.
2.5 Prevalence of Haemochromatosis and Penetrance of the HFE Genotypes
The data given in table 2.2 and discussed above indicate an allele frequency for C282Y
in populations of northern European extraction of between 6 and 8.5%. This equates to
a frequency for homozygotes in these populations of about 1 in 200, although in some
countries this may be an underestimate (Ryan, 1997). As discussed in detail below, it is
incorrect to think of haemochromatosis as an uncommon disorder. However, there is
a gap between the prevalence ofC282Y homozygosity (and compound heterozygosity
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with H63D) and that ofphenotypic haemochromatosis, expressed as iron overload
(Ho, 2001). This is illustrated by data showing that in Jersey in 1998, 18 patients were
receiving treatment for haemochromatosis (ca 0.02% of the population). According
to the population frequency ofC282Y homozygosity (ca 0.7%), however, there are
approximately 586 homozygotes among the Jersey population (Merryweather-Clarke, 1998).
In 1955, Finch and Finch stated that haemochromatosis was recognised in 20 000
hospital admissions in the United States, and once in 7000 hospital deaths (Finch,
1955). However, even as early as the 1960s, there was there some evidence that this
was might be an underestimate in Scotland (MacSween, 1966). A clinico-pathological
review of 520 cirrhotic patients who had died in Glasgow between 1900 and 1969
revealed a diagnosis ofhaemochromatosis in 7.5% (MacSween, 1973) although it is
difficult to infer a population frequency from that report as only cirrhotic livers were
examined. Two Swedish studies suggested a prevalence of between 0.5% (Olsson,
1983) and 0.1% (landmark, 1985) in different regions of that country. Other studies
have suggested a population prevalence of iron overload of between 0.34% and 0.45%
(Edwards, 1988; Bradley, 1996b)
The reason for this disparity seems likely to be due either to under-diagnosis of
haemochromatosis or to a low penetrance of the C282Y genotype. As discussed below,
there seems to be litde doubt that cases of haemochromatosis do go undetected, for a
variety of reasons. However, it is very difficult to assess the magnitude of this effect.
In the United States, the National Hospital Discharge Survey (1979, 1983-1987)
indicated an estimated hospitalisation rate for haemochromatosis as the first-listed
diagnosis of 13.4 per 100 000 hospitalisations (0.01%) (Gayle, 1992). The age-adjusted
rate of haemochromatosis-associated death in the US was 1.2 per million in 1979 and
1.8 per million in 1992 (Yang, 1998). The apparent increase in the rate of death due
to haemochromatosis (which was evident also before 1972 (Yang, 1998)) might be best
explained in terms of increasing recognition of the disease.
In the years immediately following the cloning of the HFE gene the opinion was
expressed by some researchers that most individuals homozygous for C282Y would
eventually become symptomatic of iron-overload (Edwards, 1998; EASL, 2000).
There is now increasingly convincing evidence to suggest that this may not be so.
Olynyk and colleagues studied 3011 randomly selected individuals from the town of
Busselton, Australia. They found that 0.3% (95% confidence intervals 0.1-0.6%) were
homozygous for C282Y. Eleven of these 16 individuals underwent a liver biopsy for
assessment of hepatic iron load. Fifteen of them had a transferrin saturation greater
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Figure 2.4 Alogrithm for the diagnosis of haemochromatosis
See text for details
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than 55%. The one who did not had a raised serum ferritin concentration. In all the
biopsied subjects, hepatic iron levels were above normal, although three had a hepatic
iron index of less than 1.9 pmol/g/year. Eight of the 16 homozygotes had clinical
features of haemochromatosis and four had hepatic cirrhosis or fibrosis. There was,
however, no assessment of symptoms and signs in non-homozygous controls, which
may make questionable the implicit attribution of the symptoms of these eight subjects
to iron overload (Olynyk, 1999). A similar figure was obtained by Bradley et al who
analysed 5 published series in which family studies in haemochromatosis had been
performed by HLA-typing. They concluded that 48% of homozygous family members
had at least one clinical manifestation of haemochromatosis (Bradley, 1996a).
There is evidence that the rate of non-expression of iron overload in individuals
homozygous for C282Y may be higher in women than in men. In the Busselton
study, referred to above (Olynyk, 1999), four homozygotes (all women aged 30-45)
had had normal serum ferritin concentrations for years previously and these remained
normal when re-measured at the time of the study. Similar results, indicating that
around 30% ofwomen who are homozygous for C282Y are not iron overloaded were
obtained in an examination of 300 Australian subjects. The same study also found
non-expression of iron overload in 6.7% ofC282Y homozygous men (Crawford,
1998). In their examination of iron levels and HFE genotypes in 10 500 Welsh blood
donors, Jackson et al found 72 (0.7%) to be homozygous for C282Y. Twenty-five of
29 male homozygotes and 18 of 41 female homozygotes had TS >50%, suggesting that
screening using a TS cut-offof 50% would fail to identify up to 20% ofmen and over
50% ofwomen (Jackson, 2001). None of 63 homozygotes who were interviewed had
symptoms or signs of iron overload. In the United States, 152 C282Y homozygotes
and 616 compound heterozygotes for C282Y and H63D were identified among 41 038
individuals attending a health appraisal clinic (Beuder, 2002c). Seventy-five percent of
male homozygotes (76% after exclusion of frequent blood donors) and 40% of females
(41%) had TS >50%. The majority of homozygotes (76% ofmen and 54% ofwomen)
had elevated serum ferritin levels. There was no significant increase among homozygotes
or compound heterozygotes in the prevalence of symptoms commonly associated with
haemochromatosis, compared with the rest of the study population. One homozygous
male had probable "fully manifest" haemochromatosis, with diabetes, heart failure and
possible hyperpigmentation of the skin. The results led the author to estimate that
fewer than 1% of homozygotes develop frank clinical haemochromatosis. McCune and
colleagues identified all patients currently being treated in two health authority areas in
South Wales and found a maximum of 76 homozygotes (it was not possible to genotype
all the patients because of the unavailability of some medical records). They calculated
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the expected number ofhomozygotes in the population of 1.3 million resident in these
health authority areas, based on previously published allele frequencies for the C282Y
mutation in that population. Based on these data, 6292 individuals would be expected
to be homozygous for C282Y. Only 1.2% had been diagnosed and were receiving
treatment, leading the authors to conclude that the majority ofC282Y homozygotes
will remain healthy and not express a phenotype leading to a diagnosis of hereditary
haemochromatosis (McCune, 2002). A Danish group examined the rate of progression
of iron loading in 23 C282Y homozygotes, identified by genotyping participants in the
Copenhagen City Heart Study, over a 25 year period (Andersen, 2004). None of these
individuals developed what the authors termed "clinically overt" haemochromatosis,
although these individuals did have higher serum ferritins than individuals with non-
mutated HFE. They found that C282Y homozygotes only accumulated iron at a
"modest" rate, probably no greater than that seen in individuals not homozygous for
C282Y. However, clinical evaluation was incomplete, and it is difficult to be certain that
some of the individuals identified (3 had a serum ferritin in excess of 1000 pg/L) would
not have benefitted from phlebotomy.
Beutler et al also made the observation that, ifhomozygous individuals died prematurely,
the prevalence of homozygotes in the population should fall, and the number of
homozygotes detected should be lower than that predicted by the Hardy-Weinberg
equilibrium (see Appendix 7). This was not the case in their study population (Beutler,
2002c). Willis and colleagues genotyped blood from 600 elderly men, 500 ofwhom
were over 80 years old. Although making the point that the samples investigated
came from patients already under medical care, and were therefore possibly biased
towards patients with haemochromatosis, they did attempt to exclude samples from
patients known to have the condition. They found no under-representation ofC282Y
homozygosity in the samples they studied, suggesting that many remain free of life-
threatening haemochromatosis-related disease well into old age (Willis, 1999). Further
support for this is provided by the work ofCoppine and colleagues who found no
under-representation ofeither heterozygotes or homozygotes for C282Y in a group of
492 French centenarians (Coppine, 2003).
A study of Irish patients with haemochromatosis and C282Y homozygotes detected
by family screening led Ryan and colleagues to conclude that under-diagnosis of
haemochromatosis resulted from the non-specific nature of early symptoms rather than
a low penetrance ofC282Y (Ryan 2002). However, their assumption that screening
asymptomatic relatives of patients with haemochromatosis is a satisfactory surrogate for
population screening is questionable, as it is possible that other unidentified heritable
modifiers ofC282Y expression may be operating in these families.
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The presence ofother genetic modifiers ofHFE that might modulate the expression of
C282Y-associated hereditary haemochromatosis has been suggested to explain the wide
variation in phenotypic expression ofC282Y homozygosity (Piperno, 1996). A study
(Pratiwi, 1999) using linkage disequilibrium analysis in Australian haemochromatosis
patients has shown that iron stores in C282Y homozygotes might be influenced by
a modifier in the region ofD6S105 on chromosome 6p. Specifically, male patients
homozygous for D6S105 allele 8 had significantly greater liver iron stores than patients
heterozygous for or lacking this allele. Experiments with HFE knockout mice carrying
other mutations that impair normal iron metabolism have lent weight to the theory
that the activity of genes other than HFE is important in modifying the human
haemochromatosis phenotype (Levy, 2000).
2.6 Screening for Haemochromatosis
Criteria laid down by the United States Preventive Services Task Force (U.S Preventive
Services Task Force, 1996) state that for a condition to be suitable for a screening
programme, it must fulfil the conditions listed below:
1. Prevalence: it must be "relatively common".
2. Burden of suffering: it must be a condition of "major clinical importance", that is, it
must be the cause of significant morbidity and/or mortality in the general population
3. Effectiveness of screening test: the screening intervention must detect cases earlier than
they would have been detected without screening and with sufficient sensitivity and
specificity to avoid producing large numbers of false positive and false negative results.
4. Effectiveness of treatment: detection by screening and subsequent treatment should
improve the likelihood of a favourable health-outcome (reduced disease-specific
morbidity or mortality) compared to treatment initiated when subjects present with
signs or symptoms of the disease.
5. Population benefit and adverse events: potential benefits of the screening intervention
to the population as a whole should outweigh possible adverse effects of screening
6. Cost-effectiveness: the screening intervention should be cost-effective.
Some authors are convinced that hereditary haemochromatosis fulfils these and other,
similar criteria (Adams, 1999a). Others, however, recommend against screening because
of persisting uncertainty about the magnitude of the burden of suffering caused by
haemochromatosis and unanswered questions about its natural history (Haddow,
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1999; Cogswell, 1999; Jackson, 2001; McCullen, 2002). This has been discussed in
some detail in section 2.5. There are a number ofother possible factors to explain the
continuing debate about whether widespread population screening for this disease is
warranted. First and most important is the continued lack of a consensus diagnosis
ofwhat constitutes hereditary haemochromatosis. The discovery of the HFE gene
(Feder, 1996) and the subsequent development of a widely available genetic test
for haemochromatosis has added to difficulties ofdefinition in recent years. The
second factor is lack of knowledge about haemochromatosis among both the medical
community and the general population. This may have led to misconceptions about the
prevalence of haemochromatosis among medical staff and a failure of the condition to
catch the imagination of the public as a potential health problem. Finally, the evidence
for the cost effectiveness of screening may not have been effectively presented to
developers ofPublic Health Policy.
2.6.1 Case Definition of Haemochromatosis
Four groups of patients who may be considered to have haemochromatosis can be
distinguished. First, those who present with the classic triad of diabetes, hepatic
cirrhosis and skin pigmentation or other evidence of iron-related organ damage. The
diagnosis in this group is not controversial, but such florid presentations are rare.
However, perhaps reflecting what was until relatively recendy taught to medical students
(Cartwright, 1974; Bothwell, 1982), the equation of haemochromatosis with these
clinical features may contribute to the persistence within the medical community of
the notion that haemochromatosis is uncommon (Edwards, 1993; McDonnell, 1998a;
Adams, 2000a). The second group comprises those who are found to have biochemical
evidence of iron overload. This group may also contain individuals with organ damage
as a result of iron accumulation, particularly when screening is performed in disease-
specific clinics (O'Brien, 1990; Singh 1992, Olynyk, 1994). Often, however, persons
in this group are asymptomatic or have non-specific symptoms such as tiredness,
weakness or abdominal pain. (Witte, 1996; Niederau, 1996; Adams, 1997). The third
group is those individuals who were identified as having haemochromatosis linked
with HLA serotype A3 after this association was recognised in the mid 1970s (Simon,
1975; Lipinski, 1978; Doran 1981). The final group comprises those found to have the
mutations in the HFE gene associated with haemochromatosis (homozygosity for the
C282Y mutation or, less frequently, dual heterozygosity for both that mutation and the
H63D mutation).
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The problem that this poses for screening is that it has led to considerable variability
in the definition of haemochromatosis used by different workers. (Wetterhall, 1998;
McDonnell, 1998b; Cogswell, 1998; Franks, 1999, Adams, 1999a; Edwards, 2000).
This question has been considered by the British Society for Haematology (British
Committee for Standards in Haematology, 2000), the College ofAmerican Pathologists
(Witte, 1996), the Royal College of Pathologists ofAustralasia (Powell, 2000) and others
(European Association for the Study of the Liver (EASL), 2000). There is a measure of
agreement that the case definition should include a combination of biochemical markers
of iron overload and the presence of homozygosity for the C282Y mutation ofHFE or
compound heterozygosity for the C282Y and H63D mutations (see also the discussion
in Section 2.5, above).
2.6.2 Education of health-care workers and the public
I As mentioned above, there is evidence of lack of awareness among the medical
community about the prevalence and clinical presentation of haemochromatosis. The
need for strategies to heighten health care providers' awareness about haemochromatosis
is recognised in the current recommendations of the United States Centers for Disease
Control on screening for iron overload (Reyes, 2002) and also emphasised elsewhere
(Bradley, 1996b; Cogswell, 1999; Rosenberg, 1999).
Barton and colleagues conducted an education programme about haemochromatosis and
iron overload among health care professionals and the public in Birmingham, Alabama
(Barton, 1997). They performed 15 slide and lecture presentations to various groups of
health-care workers. After the education programme, each of 55 physicians who had
never previously diagnosed a case of haemochromatosis identified at least one case.
The programme to increase awareness among the public consisted in interviews or
presentations for radio, television and newspapers, community information programmes
and patient support groups. As a result, 22 people presented themselves for evaluation,
and three were found to have haemochromatosis.
McDonnell et al emphasise the need for better education about haemochromatosis
from medical school onwards and the imperative to disseminate as effectively as possible
information about haemochromatosis case-detection among doctors (McDonnell,
1998a). In addition, they demonstrated the benefits ofphysician education in the
context of four different screening programmes (McDonnell, 1998b).
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There has been very little published about the state of knowledge of haemochromatosis
among healthcare workers in the United Kingdom. The rationale behind McDonnell s
studies applies equally well in the UK, and chapter 8 of this thesis presents the results of
a survey of awareness of haemochromatosis among general practitioners working in the
southeast of Scodand.
2.6.3 Which initial test to use in screening?
The use ofdiffering case definitions (see section 2.6.1) can make the comparison of data
from screening studies complicated. However, the move towards a genetic definition
fuels the debate about whether screening programmes should be phenotypic (using
biochemical tests to detect iron overload) or genotypic (looking for HFE gene mutations
as the initial step).
Phenotypic screening involves the detection by biochemical tests of evidence of iron
overload. The transferrin saturation (TS, derived in most studies as the ratio of serum
iron to total iron binding capacity) is the preferred initial test (Bassett, 1988; Edwards,
1993; Witte, 1996; British Committee on Standards in Haematology, 2000). The
threshold used affects the sensitivity and specificity of the test. Looker and Johnson
examined the prevalence of raised TS among over 15 000 American adults using
a variety of threshold values (Looker, 1998). The results ranged from 6.3% (both
sexes combined) with a cut-offof >45% to 0.9% with a threshold of >60%. At each
threshold, the prevalence of elevated TS was 1.3 to 1.8 times greater in men than
women. Blood samples were drawn once only from each subject in this study and
no conclusions could therefore be drawn about the prevalence in the population of
persistently elevated values ofTS. Single values may be affected by the presence of
inflammatory conditions (Zilva, 1988), by dietary iron intake (Crosby, 1984) and by
diurnal variation (Hamilton, 1950; Statiand, 1976) (although diurnal variation in
haemochromatosis homozygotes may be minimal (Edwards, 1989)). The use of two
different phlebotomy times and variable periods of pre-test fasting is acknowledged
by the authors of Looker s paper as a potential weakness. In order to control for such
factors, many studies using TS have required that subjects with an initial TS above a
determined threshold return for a second, fasting determination ofTS.
McLaren and colleagues screened 1652 asymptomatic Australian adults using an initial
TS cut-offof45% (McLaren, 1998). Those with a TS above this value were re-tested. If
the repeat value was also >45% and the serum ferritin was elevated as well, the diagnosis
was confirmed with a liver biopsy. Those whose ferritin was not raised had a TS checked
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a third time, under fasting conditions. In addition, TS values in a group of 485 subjects
known to be heterozygous or homozygous for haemochromatosis were measured. The
authors found, by means ofmixture modelling analysis, that using an initial TS cut-off
of45% would obviate unnecessary testing in unaffected subjects and allow detection
of 98% of expressing homozygotes. Other studies have set the threshold for further
evaluation at 55% (Bassett, 1988; Phatak, 1998), 55% for men and 45% for women
(Bradley, 1996b), 60% for men and 50% for women (Adams, 1995), 60% (Bhavnani,
2000), 62% (Baer, 1995, Edwards, 1988). Recent UK guidelines (British Committee
for Standards in Haematology, 2000) have suggested that 55% for males and 50% for
females be accepted as the threshold for an abnormal TS "until an appropriate threshold
has been determined for the UK". This demonstrates the difficulty in agreeing upon
a threshold TS that will achieve an acceptable balance of sensitivity and specificity. It
should also be noted that the TS value appropriate in studies on screening blood donors,
such as those by Edwards (Edwards, 1988) and Adams (Adams, 1995) is not necessarily
identical to that most suitable for a general population in which most individuals have
not undergone any iron-depleting procedure such as blood donation.
Adams and colleagues (Adams, 2000) have suggested that the unsaturated iron-binding
capacity (UIBC) performs better in detecting haemochromatosis homozygotes and
is more cost-effective than TS. This strategy was used also byWitte (Witte, 1997).
Immunochemical measurement of transferrin may be preferable to derivation ofTS
from iron-binding capacity (Crawford, 2000). However, this method has not been
standardised. Although reference methods have been proposed for the measurement of
TIBC (International Committee for Standardization in Haematology, 1978; National
Committee for Clinical Laboratory Standards, 1990), these have not gained widespread
international currency. This has led to concerns being raised (McDonnell, 1998) about
possible variability of derived TS values resulting from inadequate standardisation and
quality control in the measurement ofTIBC. Such concerns apply equally to estimation
ofUIBC and are given weight by evidence of an imperfect correlation between
chemically measured TIBC and immunologically measured transferrin concentrations
(Gambino, 1997).
Transferrin saturation alone has been used as the initial test in many screening studies
(for example: Edwards, 1988; Edwards, 1993; Phatak, 1998; McDonnell, 1998;
McDonnell, 1999a; Leggett, 1990). Those who are recalled for further assessment on
the basis of an elevated TS usually have their serum ferritin measured. Niederau and
co-workers (Niederau, 1998) suggest that both ferritin and TS should be performed
initially as this facilitates detection of iron deficiency and, potentially, other disorders.
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This is opening up a new question ofwhether screening for haemochromatosis should
be combined with screening for iron deficiency. If the detection of iron deficiency is to
be a declared aim of a screening programme, then it merits separate consideration and
the case is not made for inclusion of serum ferritin as a first-line test. However, any
phenotypic screening programme for iron overload will detect a number of individuals
who might be iron deficient and a decision must be taken ab initio how these individuals
will be dealt with. This might have significant implications for cost-effecdveness.
After the linkage between haemochromatosis and HLA-A3 was discovered in the mid
1970s (Simon, 1975), many subjects suspected ofhaving haemochromatosis were tissue
typed. After the discovery ofHFE, this is no longer appropriate. The precise role of
genetic testing in screening remains controversial.
Voices have been raised in support of the use of first-line genetic testing (Allen, 1999;
Beutler, 1996). However, these papers assumed a high penetrance ofC282Y, which, as
has been pointed out in response to Allen (Willis, 2000), may not be a valid assumption.
The choice between phenotypic and genotypic screening may be influenced by the
population being screened: universal screening of neonates would of necessity involve
genetic testing only, and has been advocated by some (Allen, 1999; Olynyk, 1999)
An expert panel was convened in 1997 by the United States Centers for Disease Control
and Prevention and the National Human Genome Research Institute specifically
to evaluate the role of genetic testing in screening for hereditary haemochromatosis
(Burke, 1998). The consensus reached was that genetic testing should not be used in
population screening for hereditary haemochromatosis as it offered no advantage over
phenotypic testing and could introduce unnecessary risk. Others share the view that the
uncertainty about the penetrance of the C282Y mutation and inability to provide all
detected homozygotes with a reliable estimate of the risk that theywill develop clinical
haemochromatosis are of themselves sufficient to recommend against the use of first-
line genetic testing (Burke, 1998; Worwood, 2000; Crawford and Hickman, 2000;
Asberg, 2001). This is also the recommendation of the current UK guidelines (British
Committee on Standards in Haematology, 2000)
2.6.4 Cost-effectiveness of screening
There have been many evaluations of the cost-effectiveness ofputative screening
programmes for hereditary haemochromatosis, dating from both before and after
the discovery ofHFE. This discovery has had significant implications for the cost
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of screening, as it has led to a re-evaluation and gradual lessening of the role of liver
biopsy in confirming the diagnosis, as discussed above. Studies dating from before
the availability ofa genetic test on the whole reflected the established dogma that liver
biopsy was essential in confirming the diagnosis of haemochromatosis (Sallie, 1991;
Powell, 1996, Witte, 1996). Liver biopsy, while retaining a place in the evaluation of
iron overload, is no longer considered imperadve in all patients (British Committee on
Standards in Haematology, 2000; Powell, 2000)
Cost-effectiveness studies may have limited relevance outside the particular health-care
system in which they are set and there has been no study looking at this issue in the
context of the U.K. National Health System. However, studies from the US, Canada and
Australia all lend weight to the evidence that screening may be beneficial and there is
general agreement that detecting and initiating treatment of haemochromatosis before the
development of serious complications is cheaper than treating those complications. Baer et
al performed TS on 3977 men aged 30 years or older when they attended for routine health
checks. Subjects having an initial TS a62% underwent a second, fasting measurement
ofTS and ferritin. IfTS was still a62% and ferritin was &500 ng/ml, subjects were
referred for liver biopsy. The personal physician ofall individuals with a TS < 15% was
alerted. A year after the completion of the initial examinations, a review ofall subjects'
medical records took place. Initial testing identified 40 subjects with raised TS ofwhom
36 attended for follow-up. All were asymptomatic. Fourteen patients were subsequently
referred for liver biopsy and 12 underwent this procedure. Eight of these were identified
as having haemochromatosis. Screening the relatives of subjects with haemochromatosis
identified three additional affected persons. Costs were those applicable in northern
California. The cost per case ofhaemochromatosis identified (including screening of
relatives) was estimated at US$17 000. Had they limited screening to white men only, they
estimated that the costs would have been approximately halved (Baer, 1995).
In a larger study, Balan and co-workers screened 12 258 patients at the Mayo Clinic. Fasting
serum iron was the initial test. TS and ferritin were determined in those who had a serum
iron concentration of>180 mg/dl. TS >62% and ferritin >500 ng/ml was found in 44
patients and was unexplained in eight. Of these eight, six were found to have evidence of
haemochromatosis on liver biopsy. The cost per case discovered was US$5261 (Balan, 1994).
Buffone and Beck performed a detailed analysis combining a standard decision-tree
and a Markov cycle tree, which allowed them to simulate the various health states that
sufferers from haemochromatosis could occupy during the course of their illness. Their
analysis was limited to men aged s25 years and compared three initial choices: treatment
of the entire population with lifelong phlebotomy without prior testing, phenotypic
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screening (initial TS, followed by fasting TS, ferritin and, if both were raised, liver
biopsy) and no intervention until the development of clinical symptoms. The Markov
model used allowed six possible outcomes: no health problem; haemochromatosis under
treatment with phlebotomy; haemochromatosis not under treatment; haemochromatosis
with disease-related complications; death from a non haemochromatosis-related cause;
death from haemochromatosis. The authors acknowledge that the costs they have used
for the treatment of haemochromatosis are estimates because of uncertainties around the
incidence of possible complications of haemochromatosis and the probability of disease
occurring in homozygotes. They concluded that there was a reasonable likelihood that
screening would be cost-effective (Buffone, 1994).
Phatak et al used decision-tree analysis to examine screening in hypothetical cohorts of
30 year old white men, compared with initiating treatment only at the appearance of
symptoms. The assumption was made that undetected homozygotes become symptomatic
at age 50. The screening strategy involved an initial TS. The threshold was set at 55%
and subjects recalled underwent a fasting TS and ferritin. If the repeat TS was a55%
and serum ferritin was >200 ng/ml, a liver biopsy was offered. It was assumed that 50%
ofpatients would decline biopsy and these would be offered hepatic iron quantification
by magnetic resonance imaging (MRI). Assumptions made about the prevalence of
haemochromatosis, the proportion of homozygotes who develop organ dysfunction, the
costs of the initial screening tests and the discount rate (a measure of the present value of
future benefits) were ofmajor importance in the outcome of the model. Screening was
found to be cost-effective provided that haemochromatosis had a prevalence of at least 3
per 1000, that at least 40% of homozygotes developed symptomatic disease, that the TS
cost $12 or less and that the discount rate was less than 3% (Phatak, 1994).
Bassett and colleagues estimated the cost of a hypothetical Australian screening
programme, and evaluated eight different strategies:
1. Non-fasting TS followed by liver biopsy ifTS a45%;
2. Non-fasting TS. IfTS ^45%, TS and ferritin repeated, fasting. Liver biopsy advised
for those with persistently elevated TS and elevated ferritin.
3. As for (1) above, but with TS threshold of 55%.
4. As for (2) above, but with TS threshold of 55%.
5. Non-fasting TS. IfTS s45%, genetic test performed.
6. Non-fasting TS. IfTS >45%, fasting TS and ferritin assessed. Genetic test for those
with persistently elevated TS and raised ferritin.
7. As for (5) above, but with TS threshold of 55%.
8. As for (6) above, but with TS threshold of 55%.
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The study revealed that strategies involving a genetic test (priced at US$120) were
cheaper than those in which liver biopsy was recommended. Strategy 8 gave a cost
per genetic haemochromatosis case detected (including family screening) ofUS$2457,
while the cost ofstrategy 4 was US$3245 per case. The costs for strategies 3 and 7
were US$3598 and US$2484 respectively. The authors made the point that these costs
compare very favourably with those reported for screening for breast cancer, prostrate
cancer, colon cancer and cystic fibrosis (Bassett, 1997).
Adams and Valberg used decision analysis techniques to compare screening using
genotypic or phenotypic screening in a hypothetical cohort of 10 000 blood donors
and 50 siblings of the identified homozygotes. They set the threshold for TS at 50%
for women and 60% for men. The phenotypic strategy involved performing a liver
biopsy on those subjects with persistently raised TS and elevated ferritin. Genotypic
screening comprised first-line testing for the C282Ymutation ofHFE. Homozygotes
were further assessed by measurement of ferritin. Those with elevated values were
treated, while those with normal values were followed up with 5 yearly re-evaluation
of serum ferritin. Heterozygotes were not followed up and it was acknowledged that
compound heterozygotes, who might be iron overloaded, would have been missed.
An assumption was made that 43% ofmen and 28% ofwomen would develop life-
threatening manifestations of haemochromatosis if not detected by screening. The
authors concluded that screening programmes have the potential to save money and
that phenotyping is cheaper than genotyping unless the cost of the genetic test falls
below $28 (Adams, 1999b). Commenting on this, Tavill concurs that issues of cost-
effectiveness may be paramount in determining whether or not screening programmes
are established, but reiterates that other issues such as uncertainty about penetrance are
important factors in determining how screening should be carried out (Tavill, 1999).
2.6.5 Potential harm of screening
Although cost-effectiveness is clearly of great importance in the evaluation of potential
screening programmes, there are other issues which, while harder to quantify, are
especially pertinent to genetic testing. These were highlighted by an expert panel
convened in the United States in 1997 to evaluate the role of genetic testing in screening
(Burke, 1998). The problem of identifying homozygotes for the C282Y mutation of
HFE as having a disease is one potential problem. Many such individuals would be
entirely healthy when they were detected (the proportion would be likely to depend
on the age at which screening was carried out as well as on the penetrance of the
homozygous state). They would need to be followed up with repeated phenotypic
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testing. Concerns have been raised about possible stigmatisation, diminished self-worth
and intra-familial strife (Burke, 1998). In the United States, there have been calls for
scrutiny of genetic tests because of these worries (Task Force on Genetic Testing of
the NIH-DOEWorking Group on Ethical, Legal and Social Implications ofHuman
Genome Research, 1997) and similar calls have been made within the United Kingdom
too (Advisory Committee on Genetic Testing, 1998). Zimmern has argued that
there is confusion between what he terms "gene testing" (i.e. tests on DNA, RNA or
chromosomes) and "genetic testing" (any type of test that indicates that an individual
is likely to have a genetic or familial disorder) (Zimmern, 1999). He contends that if
this distinction is observed, there is no need for special treatment of testing involving
nucleic acids or chromosomes and that the concerns oudined should be taken to
apply to any genetic test, as defined by him. With this line ofargument, testing for
haemochromatosis using biochemical markers of iron overload could be considered
"genetic". However, his analysis fails to take into account the fact that screening tests for
iron overload are not specific to genetic haemochromatosis, and I would argue that the
testing only becomes "genetic" when confirmatory testing with either a liver biopsy or
with HFE mutation analysis (the "gene" test) is performed. Thus in the case of screening
for haemochromatosis there may indeed be an ethical distinction between first-line
testing using iron indices and testing using DNA-based tests, in contradistinction to
Zimmern's contention.
Power and Adams were unable to identify any adverse psychological or social effects of
genetic testing for haemochromatosis. They studied homozygotes for C282Y, discovered
through a screening programme of blood donors and also a group of patients referred
to a specialist haemochromatosis clinic by their family physicians. The latter group
was referred because of suspicious symptoms, family history or abnormal iron tests.
Study participants completed two widely used health questionnaires before and a year
after learning of the result of their genetic test. The investigators found no significant
deleterious psychological effects of testing on anxiety or on mental or physical health
status. Moreover, anxiety decreased significantly in homozygotes and heterozygotes for
C282Y after testing, while remaining constant in C282Y-negative individuals. Two
patients reported feelings ofguilt engendered by the effect of testing on their families
(no further details given) and none reported adverse effects on work or insurance
(Power, 2001).
There is evidence from the United States of insurance discrimination against persons
found to be homozygous for haemochromatosis (Alper, 1994; Barash, 2000). The
likelihood of this happening or not will depend on the existence of national agreements
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or legislation to prevent it. Such an agreement appears to exist in Australia (Delatycki,
2002) and the researcher was given a similar written assurance by the British Association
of Insurers during preparation of the work presented in this thesis. More recendy, the
British government has imposed a moratorium for five years on the use of genetic testing
to determine insurance premiums (Adam, 2001).
2.6.6 Which population to screen: case finding or population screening?
The appropriate population to target for screening also requires further clarification.
World wide, there are marked differences in the prevalence of HFE-associated
haemochromatosis and it is rare in Asia, the Middle East and parts ofAfrica
(Merryweather-Clarke, 1997). Blood donors at their first attendance to give blood
have been suggested (Adams, 1995), but only a small fraction of the population in any
country is likely to be a blood donor. Women express haemochromatosis at a lower
frequency than men but can have full phenotypic expression of the disease (Adams,
1997; Garry, 1997; Moirand, 1997a). There is, therefore, no evidence to suggest that
it is justifiable to exclude women from screening programmes (Adams, 1995; Moirand,
1997a). Others have suggested that screening be directed only at first degree relatives
of haemochromatosis sufferers or at patient groups with symptoms that might be
caused by iron-overload (Cogswell, 1998). The cost-effectiveness ofgenetic testing
of first degree relatives of affected patients has been demonstrated (El-Sareg, 2000).
Krawczak and co-workers calculated that up to 40% of individuals at-risk for hereditary
haemochromatosis would be identifiable by screening first- to third-degree relatives of
known sufferers from the condition. They contended that the efficiency of this method
of screening may be 50 times greater than that of full population screening under
conditions obtaining in 2001 (Krawczak, 2001).
There have been a number of studies performed to examine the frequency with which
haemochromatosis can be detected among patients already attending other specialist
disease clinics. These have used both phenotypic and (since 1997) genotypic screening
strategies. Unfortunately, many of these studies have lacked an appropriate control
group, hindering the interpretation of their findings. Their conclusions have been
varied, and no consensus has emerged about, for example, the benefits of screening a
rheumatology (Olynyk, 1994; Willis, 2002) or a diabetic (George, 1995; Braun, 1998)
clinic population. However, this case-finding approach is advocated by the Centers for
Disease Control (CDC) in the United States (Reyes, 2002). The CDC recommends that
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...persons experiencing the unexplained symptoms compatible with
hemochromatosis (these symptoms include severe weakness or fatigue; unexplained
joint or abdominal pain; signs of liver disease, diabetes or heart problems; impotence;
infertility; and loss ofmenstrual periods) should ...be tested.
Table 2.5 summarises some papers that have examined the case-finding approach to
screening for haemochromatosis in various different patient populations.
Table 2.5 Screening for haemochromatosis in specific patient populations
Disease N' Country Contb Screening
method
Conclusion Reference







































406 England No TS/HLA type 0.5% HC Singh, 1992
Type II
diabetes mellitus














aN = number of subjects in study
b cont indicates the presence (yes) or absence (no) of a control group
c testing for both the C282Y and H63D mutations was performed
d HC = hereditary haemochromatosis
e HII = hepatic iron index
fhepatic iron content raised
g testing for the C282Y mutation alone was performed
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There is one aspect in which case-finding within such patient-groups performs much less
well than population screening: by definition, the individuals with haemochromatosis
are not being detected at an early stage. The majority ofdiabetic haemochromatosis
sufferers are already cirrhotic (Strohmeyer, 2000), and many others may have other
irreversible complications, which lead to a reduced life expectancy even with iron-
depleting therapy. This has led to renewed calls for the search for haemochromatosis
in the presence of clinical disease to be abandoned in favour ofpopulation screening
(Niederau and Strohmeyer, 2002).
2.7 Iron Metabolism
Iron plays an indispensable role in many metabolic processes, but in excess can be toxic
(see section 7.1). Under physiological conditions, iron loss from the male human body
is minimal (approximately 1 mg per day in the sloughing of cells from skin and gut,
with additional small amounts in sweat, bile and faeces). Menstruating females lose
on average an extra milligram daily from menstruation, and about 500 mg with each
pregnancy. Because of the limitations on iron loss, control over iron absorption appears
crucial in maintaining iron homoeostasis and preventing the development of iron
deficiency or overload. Although much has become known in recent years about the
mechanisms involved in this process and their perturbation in states of iron overload,
many uncertainties remain.
Healthy adults have a body iron content of 3 to 5 grams, the great majority ofwhich is
incorporated into haemoglobin. Of the remainder, most is in the form of storage
proteins (ferritin and haemosiderin) in reticulo-endothelial cells in the liver, spleen and
bone marrow. The flow of iron between these various compartments, and the major
postulated sites of regulation is illustrated in figure 2.6.
2.7.1 Storage and transport of iron
The majority of storage iron in normal individuals is present in ferritin. Human ferritin
consists of 24 subunits of two immunologically distinct types, H and L, coded for by
genes on chromosomes 11 and 19 respectively. A spherical apopoprotein shell encloses
up to 4000 iron atoms. The proportion ofL and H subunits varies from tissue to tissue,
with L-rich ferritin predominating in the spleen, liver, placenta and serum and H-rich
ferritin in heart and red cells. Circulating ferritin is about 60% glycosylated.
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Haemosiderin is a water-soluble protein-iron complex, with an amorphous structure.
It may be formed by the partial digestion of ferritin aggregates by lysosomal enzymes
(Pippard, 1999). In conditions of iron overload, the proportion of iron stored as
haemosiderin rises. Normally, haemosiderin is located mainly in reticulo-endothelial
cells, but in iron overload it is found in increased quantities in hepatocytes, too.
Under normal conditions, iron is transported in the plasma bound to transferrin, a
single chain glycoprotein synthesised mainly in the liver. Synthesis is inversely related to
iron stores. Each molecule can bind two atoms of ferric iron. Transferrin uptake into
cells depends on the presence of transferrin receptors on the cell surface. Two forms of
transferrin receptor have been discovered. The type 1 transferrin receptor consists of
two monomers joined by a disulphide bridge, each subunit able to bind one transferrin
molecule. It is encoded by a gene on chromosome 3 and synthesised mainly in the liver
(Pippard, 1999). Like transferrin receptor type 1 receptors, transferrin receptor type
2 also binds diferric transferrin (Kawabata, 1999). However, transferrin receptor 2 is
expressed mainly in the liver (Fleming, 2000) and appears unable to bind HFE (West,
2000) in contrast to transferrin receptor type 1. Its function remains to be further
characterized.
2.7.2 Absorption of Iron
Only a small fraction of the 15 mg iron provided daily by a normal western diet is
absorbed across the intestinal mucosa into plasma (Pippard, 1999): about half is
solubilised in the gut lumen, approximately 3 mg is taken up by mucosal cells and
only 1 mg reaches the portal blood. The uptake of iron derived from haemoglobin or
myoglobin in red meat (haem iron) is less affected by luminal and mucosal factors than
is that of non-haem dietary iron which predominates in the diet ofmost populations in
the world. Non-haem iron absorption is inhibited by alkaline conditions (see below),
and by binding to phosphates and phytates in the diet. Iron absorption requires the
iron to be in a solubilised form, and dietary components which promote this under
the acidic conditions that prevail in the proximal small intestine facilitate absorption of
iron. Certain amino acids, sugars and ascorbic acid thus favour iron absorption by the
formation of low molecular weight soluble chelates (Conrad, 2000).
The mechanisms ofabsorption of haem and non-haem iron across the luminal
membrane of enterocytes differ. Haem iron binds to specific membrane receptors and
is then taken up into the cell in vesicles. Once within the cell, iron is released from the
porphyrin ring by the action ofmucosal haem oxygenase. (Pippard, 1999).
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Figure 2.6 Iron distribution and flux in a 70kg man









*A total of about 1 g iron
is stored in liver spleen
and bone marrow
The existence of a pathway for the direct absorption of ferric (Fe3t) non-haem iron
has been suggested by one group (Umbreit, 1998). They postulate that ferric iron is
chelated at the intestinal mucosal surface by mucin. Transmembrane transport of iron
is mediated by a P3-integrin, and once in the cytoplasm, iron may be bound to a 56
kDa protein called mobilferrin, either in its monomeric form or as part of paraferritin, a
520 kDa multipolypeptide complex. However, questions remain about the evidence in
support of this theory (Wolf, 1994) and it is more generally accepted that the absorption
of non-haem iron from the intestinal lumen requires its reduction to the ferrous (Fe2+)
form (Fleming, 2002; Philpott, 2002; Pietrangelo, 2002).
Antibodies against duodenal cytochrome b (Dcytb) are able to block iron reduction
at the enterocyte brush border, and this molecule is likely responsible for the ferric
reductase activity at this site (McKie, 2001). After reduction, transport of iron across
the cell membrane is the role ofdivalent metal transporter 1 (DMTl, also called DCT1
and Nramp2). Gunshin and co-workers identified DMTl as responsible for the ability
of rat duodenum mRNA to stimulate iron uptake when injected into Xenopus oocytes
(Gunshin, 1997) and Fleming and colleagues found that a mutation in DMTl was
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responsible for the defective intestinal iron uptake that occurs in the microcytic anaemia
(mk/mk) mouse (Fleming, 1997). In situ hybridisation in rats has demonstrated that the
expression ofDMT1 mRNA in the crypt and villus enterocytes falls in iron overloaded
animals, compared with control and iron deficient ones. DMT1 protein, on the other hand,
was localised at the luminal membrane ofvillus enterocytes in iron deficient rats and entirely
in the cytoplasm of these cells in iron overload (Trinder, 2000). These findings lend further
support to a role for DMTl in the uptake of iron from the intestinal lumen.
Once within the cell, iron may be incorporated into ferritin for storage or it may cross the
basolateral cell membrane to enter the circulation. Using positional cloning techniques,
Donovan and colleagues identified the gene responsible for the hypochromic anaemia of
the Zebrafish mutant weissherbst. They named the gene ferroportin 1 (FP1) and found
that it encoded a transmembrane protein which could function as an iron exporter when
expressed in Xenopus oocytes (Donovan, 2000). Two other independent groups (McKie,
2000; Abboud, 2000) also identified the gene using different techniques, accounting for
its various designations as Iregl and MTP1 in addition to ferroportin. Mutations of the
ferroportin 1 gene have been implicated in the pathophysiology of a form of non-HFE
linked haemochromatosis (Njajou, 2001; Montosi, 2001) (see section 2.3.3).
Once across the basolateral cell membrane, ferrous iron must be re-oxidised to ferric in
order to bind to circulating transferrin (Philpott, 2002). A candidate ferroxidase has been
identified by studies on the sex-linked anaemia (sla) mouse (Vulpe, 1999). Mice carrying
the sla mutation develop moderate to severe microcytic anaemia resulting ffom a failure of
iron taken up ffom the intestinal lumen to enter the circulation. A novel gene, Heph, was
found which was mutant in these mice and which was highly expressed in villus enterocytes.
The gene encoded a transmembrane protein termed hephaestin, which is a homologue of
caeruloplasmin, a copper-binding protein with ferroxidase activity. As mentioned above
(section 2.3.3), deficiency ofcaeruloplasmin is associated with iron overload.
2.7.3 Iron uptake by somatic cells
Diferric transferrin binds to type 1 transferrin receptors on the cell surface and the iron-
transferrin-receptor complex localises to clathrin-coated pits, whence they enter the cell
by endocytosis. At the acidic pH within the endosome, iron is released from transferrin
and transferrin and the transferrin receptor are recycled to the cell surface (Pietrangelo,
2002). Before it can be transported across the endosomal membrane, ferric iron is
reduced to ferrous by an unidentified reductase (Philpott, 2002). It is likely that the
transmembrane transport is effected by DMTl, as this DMTl occurs in various tissues
and has been detected in endosomes (Trinder, 2000; Gruenheid, 1999)
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2.7.4 Regulation of iron absorption
The site of regulation of iron absorption is the villus enterocyte. This regulation occurs
at two levels: iron homoeostasis at the level of the individual cells is controlled at least
in part by a system of iron regulatory proteins responding to changes in the cellular
labile iron pool; at the level of the whole organism, humoral factors are thought to act as
regulators, transmitting messages about iron balance from reticulo-endothelial stores and
the erythron to the enterocyte (Roy, 2000).
Both of these systems are examined in greater detail below.
2.7.4.1 Iron regulation at the level of the whole organism
The so-called stores regulator (figure 2.6) increases or decreases iron uptake at the
level of the enterocyte in conditions of iron depletion or excess, respectively. The
variation in iron absorption brought about by the stores regulator is limited in extent to
approximately 1 mg per day (Pietrangelo, 2002). Hepcidin, a possible candidate for the
humoral factor that acts as stores regulator, has recendy been discovered. Its expression
is predominantly hepatic (Park, 2001). Targeted disruption of the gene encoding
upstream stimulatory factor 2 (USF2) in mice results in the failure of expression of
hepcidin and the development of an iron-loading phenotype resembling that ofhuman
haemochromatosis (Nicolas, 2001). Pigeon and colleagues showed that hepcidin
mRNA is increased both with dietary iron loading and in (^-microglobulin knockout
mice (Pigeon, 2001). These observations and the fact that mutations in the HAMP
gene may be associated with a haemochromatosis phenotype (section 2.3.3) support a
role for hepcidin in iron homoeostasis, but whether it does indeed function as the stores
regulator remains to be proved.
The existence is postulated of a second humoral regulator, the erythropoietic
regulator, which responds to the erythropoietic needs of the organism. As marrow
iron requirements increase, iron absorption may be upregulated even in the presence
of normal or increased iron stores. Iron absorption can be substantially increased in
anaemic individuals who are treated with therapeutic doses of iron (Finch, 1994),
indicating that the variation induced by the demands of erythropoiesis in iron
absorption is much greater than that resulting from the action of the stores regulator.
This difference may indicate that the two factors act on different iron absorption
pathways. The soluble transferrin receptor has been proposed as one possible candidate
for erythropoietic regulator (Cazzola, 1999).
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2.7.4.2 Iron regulatory proteins as iron sensors at the cellular level
The sensing of iron needs at the cellular level and the post-transcriptional control of the
expression ofmany of the proteins involved in iron homoeostasis are coordinated by a
system of iron regulatory proteins. Initial evidence that the translation of ferritin mRNA
varied in response to cellular iron balance led to the discovery of a stem-loop structure
in the 5' untranslated region (UTR) of ferritin mRNA, termed the iron responsive
element (IRE). This structure was found to interact with a cytoplasmic protein called
iron regulatory protein (IRP). Binding of IRP occurs in conditions of low cellular iron
availability and inhibits the translation of the mRNA. Conversely, when cellular iron
supply is high, IRP does not bind mRNA and translation is able to proceed, resulting
in increased ferritin synthesis. Transferrin receptor 1 synthesis is also regulated by the
IRE/IRP system, but in the opposite direction from ferritin, so that receptor synthesis
increases when iron is scarce and falls in conditions ofplentiful iron. In transferrin
receptor 1 mRNA, 5 IREs have been found in the 3' UTR. As described in the case
of ferritin, IRPs are active and can bind to an IRE when cellular iron is low. However,
in the case of transferrin receptor 1 mRNA, the effect of this binding is to stabilise the
mRNA, probably by sterically hindering degradation by an endonuclease. This has the
effect ofallowing iron deplete cells to synthesise and present at the cell surface increased
amounts of transferrin receptor 1 and so to internalise increased amounts of transferrin
with bound iron (Kiihn, 1998). Transferrin receptor 2 mRNA, on the other hand, does
not contain an IRE (Kawabata, 2001) and is not regulated by iron at the cellular level.
Ferroportinl mRNA has an IRE at the 5' UTR (Abboud, 2000) suggesting upregulation
in conditions of high availability as is the case with ferritin. DMTl exists in two
isoforms, one lacking an IRE and the other, contrary to ferroportin, with an IRE in its 3'
UTR (Lee, 1999), suggesting that the mRNA would be stabilised and protein synthesis
increased when iron availability is low. However, analysis ofDMTl and ferroportinl
expression in human duodenal biopsy specimens reveal that mRNA and protein levels
of both of them are increased in iron deficiency (Zoller, 2001). This could be explained
by IRP/IRE interaction for DMTl, but is the opposite from what would be predicted
by the IRP system for ferroportinl. Furthermore, doubts have been expressed about the
functionality of the IRE on DMTl mRNA (Zoller, 2001). It seems likely, therefore
that other regulatory factors are also involved (Philpott, 2002).
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2.7.4.3 Molecular characterisation of iron regulatory proteins
There are two distinct IRPs, IRP-1 and IRP-2, both ofwhich are activated to be able
to bind mRNA in the presence of low levels of intracellular iron. The proteins are
homologous in structure, but while IRP-1 appears ubiquitous, the tissue distribution of
IRP-2 is more limited (Kiihn, 1998).
Under conditions of adequate normal iron availability, IRP-1 functions as a cytoplasmic
aconitase - an enzyme responsible for the conversion of citrate to iso-citrate. Its
fulfilment of this role depends on its having incorporated into its structure a 4Fe-4S
cluster. The holo-protein, containing the iron-sulphur cluster cannot bind IREs. When
cellular iron levels fall, however, a cytoplasmic apoprotein lacking the iron-sulphur
cluster is found, which has no aconitase activity, but which can bind to IREs.
IRP-2, on the other hand, does not contain an iron-sulphur cluster and has no aconitase
activity. It is not found in the cytoplasm other than under conditions of restricted iron
availability. Once iron becomes available, IRP-2 is probably subject to proteosomal
degradation (Kiihn, 1998)
2.7.4.4 The structure and possible function of HFE
The HFE gene encodes a 343-residue transmembrane protein, which is homologous to
class I MHC molecules and associates with the class I light chain, (^-microglobulin. It
has six domains: a 22-amino acid signal peptide, three extracellular domains (designated
al, a2 and a3), a transmembrane region and an intracellular domain (figure 2.1)
(Feder, 1996). The C282Y mutation in the HFE gene results in the substitution of a
tyrosine for a cysteine residue. This eliminates a disulphide bond in the a3 domain and
prevents the association between HFE protein and P2-microglobulin, which is essential
for expression ofHFE at the cell surface (Feder, 1997; Waheed, 1997). The H63D
mutation, resulting in an aspartate for histidine substitution in the al domain has no
effect on either the association ofHFE with (^-microglobulin or cell-surface expression.
Support for the contention that HFE is involved in the regulation of iron homoeostasis
was provided by the discovery that HFE knockout mice rapidly developed iron overload
while their HFE normal littermates did not (Zhou, 1998).
Feder and colleagues provided an important insight into the possible function ofHFE
when they found that wild type HFE protein and H63D protein form stable complexes
with the transferrin receptor. The C282Y mutation nearly completely prevents this
association (Feder, 1998). Crystallographic studies with high concentrations ofHFE
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and transferrin receptor 1 have further characterised the nature of the interaction and
have suggested a stoichiometry of 2:2 (HFE:transferrin receptor) under equilibrium
conditions (Bennett, 2000), which would probably prevent binding of iron-loaded
transferrin to transferrin receptor. Studies with lower concentrations ofHFE and
transferrin receptor in solution have suggested the formation of a ternary complex of
HFE, transferrin receptor and iron-loaded transferrin with a stoichiometry of 1:2:1
(Lebron, 1999). It is much less clear whether or not transferrin receptor 2 interacts
direcdy with HFE (Pietrangelo, 2004a).
An increase in the duodenal expression ofDMT 1 and ferroportinl in mouse models
of haemochromatosis and haemochromatosis patients has been reported by several
groups (Fleming, 1999; Griffiths, 2001; Zoller, 2001). In addition, duodenal ferritin
mRNA expression is low in at least a high proportion ofpatients with hereditary
haemochromatosis, with a high spontaneous activity ofduodenal iron related protein
(Pietrangelo, 1995).
Duodenal crypt cells migrate towards the tip of the villi, maturing into absorptive
enterocytes as they go. The distribution ofHFE and other proteins involved in iron
metabolism in crypt and villus enterocytes is different: HFE is expressed strongly in crypt
cells, but to a far lesser extent in villus cells (Parkkila, 1997; Waheed, 1999). Conversely,
other proteins involved in iron homoeostasis, Dcytb, DMT1 and ferroportinl are
expressed strongly in villus but not crypt cells (McKie, 2001; Griffiths, 2000; Donovan,
2000). These findings have suggested that crypt cells may act as the site for sensing of
iron balance, both on a cellular and whole body level, on the basis ofwhich the level of
iron absorption is set and maintained as the cells mature and travel up the villi.
Recent work (Waheed, 2002) has suggested that over-expression ofHFE without P2-
microglobulin in a Chinese hamster ovary cell line results in a decrease in transferrin
receptor mediated iron uptake. However, when both HFE and (^-microglobulin
were over-expressed, the opposite effect, an increase in iron uptake, was found. This
is contrary to the results of earlier work by other groups (eg Feder, 1998) which found
that the association ofHFE and transferrin receptor resulted in a lowered affinity of
transferrin receptor for iron-laden transferrin.
Although the details of the role ofHFE in iron homoeostasis are still unclear, the
information summarised has allowed the formulation of a model to explain how dietary
iron absorption might be regulated (Philpott, 2002). Duodenal crypt cells sense the
body's requirements for iron via humoral factors such as the stores and erythropoietic
regulators discussed above. They are informed about the availability of transferrin-
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bound iron via the transferrin receptor/transferrin receptor 2 system. The signals
received by the cell and the intracellular iron pool act together, in part via the IRP/IRE
system to set the level of transcription ofDcytb, DMT1, ferroportin 1 and ferritin.
This level ofactivity is then maintained as the maturing cell migrates up the villus and
develops the ability to absorb iron from the gut lumen. In the absence of functional
HFE, uptake and sensing via the transferrin receptor is impaired. This results in the
translational activity ofDMT 1 and ferroportin 1 being set at an inappropriately high
level, and an inappropriately low level of ferritin synthesis. In turn, this leads to the
absorption of amounts ofdietary iron in excess of requirements and, in time, the
development of the iron overloaded phenotype.
The discovery ofhepcidin and the emergence of evidence of its possibly central role in
iron homoeostasis (Pietrangelo, 2004b) has led to a challenge to the crypt-programming
2.8 Conclusion
The diversity of current research into genetic iron overload and iron metabolism can be
appreciated from the survey of the literature presented in this chapter. In the remainder
of this thesis, the author seeks, in chapters 4 to 7, to examine in more detail the iron
status ofvarious groups of individuals and, in chapter 8, to assess awareness of hereditary
haemochromatosis among primary care physicians.
There is a considerable body of published literature speculating about the reasons for
the continued high prevalence of the C282Y mutation ofHFE in northern European
populations. The possibility that it may offer carriers some protection from the
development of iron deficiency led to the work presented in chapters 4 and 5 of this
work. Chapter 4 looks at the influence ofHFE genotype on the development of iron
deficiency in male blood donors, and chapter 5 at the relative prevalence of different
genotypes in patients with and without iron deficiency.
Chapter 6 examines HFE genotypes and iron stores in patients who have undergone
orthotopic liver transplantation, with the aim of identifying both the prevalence of
undiagnosed haemochromatosis in this group and also any influence ofHFE genotype
on clinical outcome after this procedure. Chapter 7 re-examines the suggestion that iron
stores have a bearing upon the development of coronary artery disease. Strong arguments




This chapter contains details ofall the experimental methods used in the work that
comprises this thesis.
3.1 Extraction of DNA from peripheral blood
DNA was extracted from whole blood anticoagulated in EDTA by an in-house method




5M sodium perchlorate (BDH, Poole, UK)
Chloroform (BDH, Poole, UK) - ice-cold
Absolute ethanol (BDH, Poole, UK) - ice-cold
Tris-EDTA buffer, pH 7.6
Rotatory mixer
Denly AutoBench centrifuge
Water bath to provide water at 65° C
15 ml centrifuge tubes (Helena Bioscience)
Disposable pastettes (Alpha laboratories)
Glass Pasteur pipettes
3.1.2 Preparation of reagents
1M tris (hydroxymethylmethylamine) (Tris)
In each litre:
121.14 gTris
The Tris was dissolved in 1 litre distilled water and the pH adjusted to 7.4 with
hydrochloric acid. The solution was autoclaved at 121° C.
0.5Mdisodium EDTA
In each litre:
186.12 g disodium EDTA
20 g sodium hydroxide
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The pH was adjusted to 8 using 1M sodium hydroxide.
ReagentA
In each litre:
10 ml 1M tris (hydroxymethyl) methylamine (BDH, Poole, UK)
109.54 g sucrose (BDH, Poole, UK)
0.47 g magnesium chloride (BDH, Poole, UK)
10 ml Triton X-100 (Sigma-Aldrich, Poole, UK)
The above components were dissolved in distilled water and the pH adjusted to 8 with
sodium hydroxide. The volume was made up to 1 litre with distilled water and the
solution was autoclaved at 121° C.
ReagentB
In each litre:
400 ml 1M Tris (BDH)
120 ml 0.5M EDTA (pH 8)
8.76 g sodium chloride (BDH)
10 g sodium dodecylsulphate (SDS) (BDH, Poole, UK)
The components except the SDS were dissolved in distilled water and the pH was
adjusted to 8. The volume was made up to 1 litre with distilled water and the solution
was autoclaved at 121° C. After autoclaving, while the solution was still warm (to
facilitate dissolution), the SDS was added.
5Msodium perchlorate
In each litre:
700 g sodium perchlorate
Tris-EDTA buffer (TE)
In each litre:
10 ml lMTris, pH 7.4
1 ml 0.5M EDTA, pH 8
The total volume was made up to 1 litre in each case with distilled water and the
solutions were autoclaved at 121° C.
47
3.1.3 Method
The principle of the method is lysis of red cells using reagent A, white cell membrane
and nuclear lysis and protein digestion by reagent B and sodium perchlorate,
deproteination with chloroform and precipitation ofDNA using ethanol.
In detail:
3 to 5 ml whole blood was placed in a 15 ml polypropylene centrifuge tube and diluted
to 12 to 13 ml with reagent A (approximately 1 volume blood to 3 volumes reagent A.)
After mixing for 4 minutes at room temperature, the tube was centrifuged at 1500g for
5 minutes. The resultant supernatant was decanted offwithout disturbing the cell pellet.
1 ml reagent B was then pipetted into the tube and the cell pellet was re-suspended by
vortexing. After addition to the tube of 250 pi sodium perchlorate, the tube was sealed
and mixed thoroughly by inversion. The tube was then incubated for 20 minutes at 65°
C. 2 ml ice-cold chloroform was pipetted into the tube and a rotatory mixer was used
to mix for 30 to 60 minutes to emulsify the phases. The tube was then centrifuged at
1300g for 2 minutes. This resulted in separation of the layers as illustrated (figure 3.1):
Figure 3.1 Separation of aqueous and chloroform layers after centrifugation
The aqueous phase was then decanted into a fresh tube using a sterile pastette taking care
not to disturb the cell debris layer. To the fresh tube was added 2.5 ml ice-cold ethanol
and the tube was inverted until a precipitate ofDNA was visible. The tip of a glass
Pasteur pipette was heated in a flame until the end was sealed and a small hook formed.
When cool, this was used to transfer out the precipitated DNA to an Eppendorf tube
containing 100 pi TE buffer. The DNA-containing tube was stored at 4° C until use,
and then frozen for long term storage at minus 80° C.
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3.2 Measurement of DNA concentration
DNA concentration was not measured routinely, for logistic reasons relating to the
number of samples. However, it was performed on a number of samples during the
process ofoptimisation of the ARMS reaction.
Samples were diluted 100 fold in distilled water to a volume of 1 ml. A
spectrophotometer with an integral ultra-violet lamp was calibrated against a blank of
distilled water and the absorbance at a wavelength of 260nm (A260) of the diluted DNA
sample was measured. The concentration of the DNA ([DNA]) could be calculated
from the equation (Maniatis, 1982):
[DNA] ng/pl = A2G0x 50 x dilution factor (i.e. 100)
This enabled solutions ofDNA with a standardised concentration (100 ng/pl) to be
made up.
3.3 Extraction of DNA from paraffin blocks
Although it proved impossible to extract DNA from paraffin blocks of sufficient









A 15 pm paraffin section was placed in a microfuge tube, to which 600 pi xylene was
added to remove the paraffin. The tube was left to stand for 5 minutes and then spun
at 20000g for 10 minutes. The supernatant was discarded and the xylene addition and
centrifugation repeated. 600 pi absolute ethanol was then added to the tube to remove
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excess xylene. The tube was spun at 20000g for 10 minutes. The supernatant was
poured off and the addition ofalcohol and centrifugation repeated. The microfuge tube
was inverted on a clean paper towel to dry.
3.3.2 DNA extraction method 1
QLAamp" Tissue Kit (Qiagen GmbH, Germany)
3.3.2.1 Materials
The kit, designed for 50 extractions, included the following:
Lysis buffer ATL
Buffer AL







Water baths to provide water at 55 and 70° C
3.3.2.2 Preparation of reagents
Proteinase K was reconstituted in 1.4 ml distilled water.
BufferAL was prepared by decanting all of reagent AL1 into reagent AL2 and shaking to
mix.
Buffers AW1 and 2: 40 ml absolute alcohol was added to buffer AW1 and AW2
concentrate.
20 pi proteinase K was added to each sample, mixed thoroughly by vortexing and
incubated at 56° C until the tissue was completely lysed. Lysis was aided by regular
vortexing during the incubation period, which was often several hours. 200 pi buffer
AL was then added, vortexed to mix and incubated at 70° C for 10 minutes. Next, 200
pi ethanol was added and mixed. The mixture thus obtained was placed in a QLAamp
spin column, within a 2 ml collection tube, and centrifuged at 6000g for 1 minute. The
spin column was placed in a clean collection tube and 500 pi buffer AW1 was added.
3.3.2.3 Method
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After centrifiigation at 6000g for 1 minute, the spin column was again placed in a clean
collection tube and 500 pi buffer AW2 was added followed by centrifugation at 20000g
for 3 minutes. The spin column was then placed within a 1.5 ml microcentrifuge tube
and 200 pi buffer AE was added. A 5 minute incubation at room temperature was
allowed before centrifugation at 6000g for 1 minute. The elution step with buffer AE
was repeated twice more and the eluate ofDNA in AE was stored at 4° C until used.
3.3.3 DNA extraction method 2
In-house method
Because attempts to amplify DNA extracted by the QIAamp method (method 1, above)
were unsuccessful, DNA was extracted from some samples by a second, in-house,




Waterbaths to provide water at 50° C and 100° C
Microcentrifuge
Microfuge tubes
3.3.3.2 Preparation of reagents
Lysis buffer
In each litre:
0.3728 g potassium chloride
0.1211 gTris
0.0238 g magnesium chloride
1.01 g gelatin
IGEPAL
0.45 ml Tween 20
The above components were dissolved in distilled water to a total volume of 1 litre, and
the pH was adjusted to 8.3
Proteinase K
10 mg proteinase K was added to 1 ml distilled water.
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3.3.3.3 Method
200 pi of proteinase K solution was added to 1 ml of lysis buffer. 200 pi of this solution
was added to the microfuge tube containing the tissue sample from which the paraffin
had been removed (see above). The microfuge tube was incubated for 2 hours in a
waterbath at 50° C, and vortexed once after 1 hour. The tube was then centrifuged
at 20000g for 10 seconds. Next, the tube was boiled in a waterbath to inactivate the
proteinase K. The tube was spun at 20000g for 10 seconds, cooled on ice and stored at
4° C until use.
3.4 Detection of mutations in the HFE gene
by a multiplex amplification refractory mutation system (ARMS)
3.4.1 Principle of method
The presence or absence C282Y and H63D mutations in the HFE gene was analysed
using a slight modification of the multiplex amplification refractory mutation system
(ARMS) described by Baty and colleagues (Baty 1997). The principle ofARMS is a
combination of two polymerase chain reactions (PCR) using the same substrate DNA.
The ARMS assay for a given mutation uses three primers: along with a sense primer,
two other primers (referred to below as "normal" and "mutant", differing only at the 3'
nucleotide) are used. Each of these two primers is specific for one of the allelic variants
being studied. This specificity is conferred by the 3' nucleotide of the primer which
complements only one of the two alleles and by the absence of 3' to 5' proof-reading
activity in Taq DNA polymerase. Therefore, in the present study, three primers were
used to detect C282Y and three to detect H63D. To safeguard against false negative
results, a pair of internal control primers (in this case for the human growth hormone
(HGH) gene) that amplify a different area of the genome is included in the reaction
mixture. The two possible PCR reactions are illustrated for C282Y in figure 3.2.
The alleles present in the reaction mixture can be determined by gel electrophoresis and
ethidium bromide staining.
3.4.2 Interpretation of PCR results
For each sample ofDNA, PCR reactions were performed in 2 tubes, labelled A and
B. The composition of each reaction mixture was as stated in table 3.3. PCR product
bands were identified initially by comparison with a molecular weight marker, although
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Figure 3.2 Amplification refractory mutation system (ARMS)

























If the DNA is all wildtype, only PCR reaction 1 occurs with amplification of the
wildtype product; ifC282Y is carried, reaction 2 occurs and if both are present (ie in the
heterozygous state) both reactions occur.
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this was not feasible when the MADGE system was employed. When MADGE was
employed, PCR bands were identified by pattern recognition. This approach was
validated by the duplicate analysis ofmany samples in a reference laboratory and
comparison of the results.
For each sample, PCR fragments corresponding to the C282Y mutation were observed
as a band of approximately 325 base pairs in the lane containing reaction mixture A.
IfC282Y was absent, a 325 base pair band appeared in the lane containing reaction
mixture B. PCR fragments corresponding to the H63D mutation appeared as a
band of about 175 base pairs in the lane containing reaction mixture B. Fragments
corresponding to an allele lacking H63D were observed as a band of 175 base pairs in
the lane containing reaction mixture B.
The following patterns were observed:
Pattern 1 — wildtype C282Y and H63D
Molecular Weight Tube A Tube B
450 base pairs wmmmammmtm
325 base pairs ■■■■■■■■■
175 base pairs
Pattern 2 — C282Y heterozygote; H63D wildtype




Pattern 3 — C282Ywildtype; H63D heterozygote
Molecular Weight Tube A Tube B









Pattern 5 - C282Ywildtype; H63D homozygote
MolecularWeight Tube A Tube B
450 base pairs
325 base pairs
175 base pairs wmmmmmm





3.4.3 Preparation for and execution of the PCR
3.4.3.1 Materials
Peltier Thermal Cycler (PTC-225)
HotStarTaq DNA polymerase (Qiagen GmbH, Germany)
lOx PCR buffer (Qiagen GmbH, Germany)
Deoxynucleotide triphosphates: lOOmM solution of each of: dATP, dCTP, dGTP,
dl"IP (Promega, Southampton, UK)
Oligonucleotide primers (MWG Biotech AG, Germany). (See below)
Distilled water
Tube A Tube B
Tube A Tube B
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Oligonucleotideprimers
The following primers were used (all supplied by MWG-Biotech AG, Germany):
1. Sense primers as described by Feder and colleagues (Feder 1996)
2. Antisense ARMS primers (Baty 1997)
C282Y-normal: 5' - CTGATCCAGGCCTGGGTGCTCCACCTGCC - 3'
C282Y-mutant: 5' - CTGATCCAGGCCTGGGTGCTCCACCTGCT - 3'
H63D-normal: 5' - AGTTCGGGGCTCCACACGGCGACTCTCAAG - 3'
H63D-mutant: 5' - AGTTCGGGGCTCCACACGGCGACTCTCAAC - 3'
3. Human growth hormone (HGH) primers used as internal amplification controls
(Kirschbaum 1995)
HGH-forward: 5' - TGCCTTCCCAACCATTCCCTTA - 3'
HGH-reverse: 5' - CCACTCACGGATTTCTGTTGTGTTTC - 3'
For each substrate DNA, two separate 25 pi reaction mixtures were set up, referred to
below as "A" and "B" respectively. Each reaction mixture contained one of the pair of
primers specific for the allelic variant at each of the two possible mutation sites.
3.4.3.2 Preparation of Reagents
The four dNTPs were mixed together in equal volumes to a concentration of25mM.
The mixture was further diluted 12.5 times to the desired concentration of 2 mM.
Oligonucleotide primers were diluted to the following concentrations:
HGH primers: 0.05 pM
C282Y primers: 0.25 pM
H63D primers: 1.0 pM
Every PCR mixture contained the components listed in table 3.3. For each batch of
reactions, a "master-mix" was made up, in which all the volumes given were multiplied
by (N+k), where N = number of (samples + controls + blanks) and k provides extra
volume to allow for wastage (for 1-20 samples, k = 1; 21-40 samples, k = 2; 41-60
samples, k = 3; 61 —80 samples, k = 4; 81 —100 samples, k = 5.)
C282Y:
H63D:
5' -TGGCAAGGGTAAACAGATCC - 3'
5' - ACATGGTTAAGGCCTGTTGC - 3'
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3.4.3.3 Method
The Taq polymerase was activated by an initial incubation of the reaction mixtures at 95°
C for 15 minutes. DNA amplification was then achieved by 30 cycles of the following
steps:
60 seconds at 94° C denaturation step;
60 seconds at 59° C annealing step;
60 seconds at 72° C extension step.
The product was then subject to electrophoresis on either polyacrylamide gel (PAGE) or
agarose gel (see section 3.7) to separate DNA fragments.
Table 3.3 Contents of PCR reaction mixtures
Reagent Mixture A Mixture B
HotStarTaq polymerase 0.2 |jl 0.2 Ml
1 Ox buffer 2.5 Ml 2.5 Ml
dNTP 2.5 Ml 2.5 Ml
HGH - forward 0.625 Ml 0.625 Ml
HGH - reverse 0.625 Ml 0.625 Ml
C282Y - sense 0.625 Ml 0.625 Ml
C282Y - normal 0.625 Ml
C282Y - mutant 0.625 Ml
H63D - sense 2.5 Ml 2.5 Ml
H63D - normal 2.5 Ml
H63D - mutant 2.5 Ml
MBG water 11.3 Ml 11.3 Ml
Solution of DNA 1 Ml 1 Ml
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3.5 HFE mutation detection by PCR and restriction enzyme digestion
Because it proved impssible to determine HFE gene mutations on DNA from tissue
samples using ARMS (above), a further attempt to do this using restriction enzyme
digestion ofamplified DNA was made, as described by Feder and colleagues (Feder, 1996).
3.5.1 Polymerase chain reaction
3.5.1.1 Materials
Peltier Thermal Cycler PTC-225
Vertical polyacrylamide gel electrophoresis system (Bio-Rad, Hemel Hempstead, UK)
Oligonucleotide primers (MWG Biotech GmbH, Germany)
Platinum Taq polymerase (Gibco BRL)
lOx PCR buffer (Gibco BRL)
Deoxynucleoside triphosphates (dNTP) - concentration 2mM (see section 3.4.3.2)




HH1: 5' - CTCAGGCACTCCTCTCAACC - 3'
HH2: 5' - TGGCAAGGGTAAACACATCC - 3'
For H63D mutation:
H631: 5' - ACATGGTTAAGGCCTGTTGC - 3'
H632: 5' - GCCACATCTGGCTTGAAATT - 3'
3.5.1.2 Method
This method employs a simple PCR amplification of each mutation separately, followed
by restriction enzyme digestion of the PCR products and gel electrophoresis to display
the resultant DNA fragments.
Table 3.4 shows the composition of the mastermix used in the PCR. To each reaction
tube was added 0.5 pi DNA. DNA amplification was then attempted with the following
thermal cycle: an initial step of 95° C for 5 minutes was followed by denaturation at
94° C for 20 seconds, annealing at 59° C for 25 seconds and extension at 72° C for 30
seconds to a total of 32 cycles. There was a final incubation step at 72° C for 5 minutes.
58
3.5.2 Restriction enzyme digestion
3.5.2.1 Materials
Bovine serum albumin (BSA) 20 mg/ml
lOx buffer (Gibco BRL)
Bel 1 restriction enzyme (BRL)
Rsa 1 restriction enzyme (BRL)
Water baths to provide water at 50° C and 37° C
3.5.2.2 Method
C282Y mutation
For each sample tested, the restriction digest mix consisted of:
BSA 0.5 pi
lOx buffer 2 pi
Bel 1 1.5 pi
3 pi of this mix was added to a PCR tube containing 8 pi PCR product (see section
3.5.1.2) and incubated at 50° C for 4 hours. The product was then subject to
polyacrylamide gel electrophoresis (PAGE) (see section 3.7.1) to separate DNA
fragments.
H63D mutation
For each sample tested, the restriction digest mix consisted of:
BSA 0.5 pi
lOx buffer 2 pi
3 pi of this mix was added to a PCR tube containing 8 pi PCR product (section 3.5.2.1)
and incubated at 37° C for 4 hours. DNA fragments were then separated using PAGE
(section 3.7.1).
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Table 3.4 Mastermix for PCR for restriction digest analysis
Component Volume per sample (pi)
1 Ox buffer 2.5
dNTP (2mM) 1.25





A separate mastermix was made for each mutation, containing primers HH1 and HH2
for the C282Y mutation and H631 and H632 for the H63D mutation.
3.6 HFE intron 4 polymorphism and inaccuracy in diagnosis
There has been a suggestion that the presence of a common single nucleotide
polymorphism (5569G/A) could cause inaccuracies in the detection of homozygotes
for C282Y (Jeffrey, 1999b). The polymorphism is located in the binding site of the
antisense primer originally described by Feder et al (Feder, 1996) and concern was
expressed that its presence could lead to the misdiagnosis of heterozygotes for C282Y
as homozygotes (Jeffrey, 1999b) by preventing amplification of the wild type allele
in heterozygous individuals. It has, however, been shown that under suitable PCR
conditions, this does not occur (European Haemochromatosis Consortium, 1999),
although the selection ofother primers when possible may be ideal. The primers used
in this study were those of Feder et al, but analysis of duplicate samples and comparison




3.7 Polyacrylamide and agarose gel electrophoresis
3.7.1 Polyacrylamide gel
3.7.1.1 Materials
Power pack (Gibco BRL)
Vertical electrophoresis tank
16 x 18 cm glass plates
1.5 mm spacers
15 well combs
40% acrylamide solution (BDH, Poole, UK)
2% N,N' - methylene-bisacrylamide (BDH, Poole, UK)
Ammonium persulphate powder (BDH, Poole, UK) made up to 10% solution (lg
powder in 10 ml distilled water)
20x Tris-acetate-EDTA (TAE) buffer
N,N,N',N' - tetramethylethylenediamine (TEMED) (Sigma-Aldrich, Poole, UK)
Ethidium bromide (10 mg/ml) (Sigma-Aldrich, Poole, UK)
Distilled water
Loading buffer
Gel Doc 1000 ultra-violet light box with integral camera (Bio-Rad, Hemel Hempstead, UK)
3.7.1.2 Preparation of reagents
2Ox Tris-acetate-EDTA buffer
In each litre:
96.8 gTris (hydroxymethyl) methylamine
22.8 ml glacial acetic acid
500 ml 0.5M disodium EDTA (pH 8)
Loading buffer
1.5 g Ficoll 400 dissolved in 10 ml distilled water. To this was added:
25 mg bromophenol blue
25 mg xylene cyanol
Used in dilution of 1 part buffer to 6 parts PCR product for electrophoresis.
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» 3.7.1.3 Methods
In this project, the separation ofDNA fragments produced by ARMS reactions relied
heavily on the use of polyacrylamide gel electrophoresis (PAGE). 8% gels were used.
For the full-sized gels, 16x18 cm glass plates were separated by 1.5 mm-thick spacers.
10 ml 40% acrylamide was mixed with 10 ml 2% bisacrylamide and 2.5 ml 20x TAE.
The volume was made up to 50 ml with distilled water. Immediately before pouring,
500 pi ammonium persulphate and 20 pi TEMED was added to initiate polymerisation.
Gels were left to polymerise for approximately 60 minutes before use. Running buffer
(lx TAE) was made by diluting 50 ml 20x TAE in 900 ml distilled water and 50 ml tap
water. Approximately 2.5 litres of buffer was placed in the lower tank and 500 ml in
the upper tank. The reaction products to be separated, mixed with loading buffer, were
loaded into the wells in the gel and electrophoresis was performed at a constant voltage
of 250 V for 90 minutes.
After they had been stained with ethidium bromide (0.5 mg/1) for 10 minutes, (no de-
staining step was performed) the gels were viewed under UV light (see figure 3.5)
3.7.2 Agarose gel
3.7.2.1 Materials
Power Pack (Gibco BRL)
Electrophoresis tank
35 well comb
MBG agarose powder (Technocomp Ltd, Hong Kong) or NuSieve 3:1 agarose gel
powder (Flowgen, Lichfield, UK)
Distilled water
Horizontal electrophoresis tank (Bio-Rad, Hemel Hempstead, UK)
Ethidium bromide (10 mg/ml)
Gel Doc 1000 ultra-violet light box with digital camera
3.7.2.2 Methods
Agarose gels were used only in the initial stages ofoptimisation of the PCR. A 3% gel
was made by dissolving 3 g agarose in 100 ml distilled water. Dissolution was aided
by heating in a microwave oven. The gel was poured onto the platform of a horizontal
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Figure 3.5 Photograph of standard polyacrylamide gel electrophoretic
pattern after ARMS PCR for HFE gene (see text for details)
Control A B C D E F Molecular Weight
Marker
J_^JLJLJLJLXJL1









Each pair of adjacent lanes shows the PCR products from a single sample (details in text)
Control: no DNA
Sample A: wild type for both C282Y and H63D
Sample B: wild type for C282Y; heterozygous for H63D
Sample C: heterozygous for both C282Y and H63D
Sample D: wild type for C282Y andH68D
Sample E: wild type for C282Y; heterozygous for H63D
Sample F: heterozygous for both C282Y and H63D
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» electrophoresis tank to a thickness of about 0.5 cm. A 35 well comb was inserted
and the gel left for 60 minutes to set. Samples were loaded and electrophoresis was
performed for at 140 V for 90 minutes in lx TAE buffer.
3.8 Microplate array diagonal gel elctrophoresis (MADGE)
3.8.1 Materials
FlowMADGE 96 well gel former (Flowgen, Lichfield, UK)
Glass plate to fit gel former
Power Pack
Electrophoresis tank
Gel Slick (AT Biochem)
Sticky silane
Ethidium bromide (10 mg/ml)
3.8.1.1 Preparation of reagents
Sticky silane
0.5 % v/v y-methacryloxypropyltrimethoxysilane (silane) (Sigma-Aldrich, Poole, UK)
absolute alcohol
0.5% glacial acetic acid
5 pi silane was dissolved in 1 ml absolute alcohol. Immediately before use, 30 pi acetic
acid was added.
3.8.1.2 Method
A glass plate of an appropriate size to fit neady inside the rim of the MADGE gel former
was siliconised on one side by coating it with Gel Slick using a tissue. After five minutes'
drying, the coated surface was wiped with a damp paper towel and then dried with a
dry paper towel. 1 ml ofsticky silane was then poured onto the siliconised surface and
spread out evenly using the edge of another glass plate. After three minutes, the excess
liquid was wiped offwith a dry paper towel. The surface was wiped with a damp tissue
prior to use.
8% polyacrylamide gel was mixed using 2 ml 40% acrylamide, 2 ml 2% bisacrylamide,
0.5 ml 20x TAE. The total volume was made up to 10ml by the addition ofdistilled
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water. The 96 well gel former was placed on a flat surface in preparation for pouring
of the gel. Just before pouring, 100 pi 10% ammonium persulphate and 8 pi TEMED
was added to initiate polymerisation. The gel mixture was then poured into the gel
former and the prepared glass plate laid with the treated face downwards on top of the
gel former so that the plate was in contact with the gel, ensuring that no air bubbles were
trapped beneath it. An empty glass botde was placed on top of the glass plate during the
solidification of the gel to ensure good contact between the plate and the gel. The gel was
allowed 30 minutes to set, after which the glass plate was prised away from the gel former.
The gel, with its array of 96 micro-wells, was now stuck on the glass plate and was placed
in a water bath containing ethidium bromide (0.5 mg/1) on a horizontal rotatory mixer
for 20 minutes for pre-staining. ARMS products mixed 6 parts to 1 with loading buffer
were then loaded into the micro-wells. Thereafter, the gel, still adhering to the plate, was
placed in an electrophoresis tank and subject to 150 V for 40 minutes. The gel was then
visualised under UV light (see figure 3.6).
3.9 Optimisation of PCR and electrophoresis techniques
Although a published method for mutation detection was used (Baty, 1996), difficulty
was experienced in attaining clear separation ofDNA fragments of the desired sizes.
Attempts were therefore made to optimise both the reaction conditions for the PCR and
also the electrophoresis technique.
Initial attempts using published PCR conditions, and electrophoresis on 0.8% agarose
gel resulted in severe smearing of bands after staining. The following factors were
investigated in an attempt to achieve clearer separation of bands:
1. Magnesium concentration ([Mg]) in the PCR mix
2. Number ofPCR cycles
3. Primer concentrations
4. Presence or absence ofQ solution in PCR mix
5. DNA concentration
6. Gel composition
7. Destaining of gel
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Figure 3.6 Photograph of MADGE gel showing PCR products after ARMS
PCR for HFE gene mutations (see text for details)
Key
Paired samples were pipetted into adjacent wells
Sample A: heterozygous for H63D, heterozygous for C282Y
Sample B: wild type for C282Y and H63D
Sample C: heterozygous for H63D, wild type for C282Y
Note: the orientation of each pair of samples is opposite to that in figure 3.5.
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3.9.1 Magnesium concentration
Mg2' ions affect the sensitivity and specificity of PCR reactions. They are essential for
incorporation of dNTPs and increase the melting temperature of the double-stranded
DNA and the primer/template interaction (Newton, 1997). In an attempt to improve
the yield of the reaction, [Mg] was increased in 0.5 mM steps between 1.5 and 5 mM.
As expected, at the higher [Mg] (>4 mM) there was a suggestion of loss ofspecificity but
overall, variation of [Mg] did not result in increased band clarity.
3.9.2 Number of PCR cycles
Reducing the number of thermal cycles had the effect of reducing the PCR yield
significandy when the cycle number was reduced from 30 to 24. There was no
improvement in the sharpness of the bands.
3.9.3 Primer concentration
The method described by Baty and colleagues (Baty, 1996) uses H63D primers in the
PCR mastermix at twice the concentration of the C282Y and HGH primers. For
reasons of economy, the present study began with lower concentrations ofall the primers
(H63D, 0.0125 pM, C282Y and HGH, 0.003125 pM). On agarose gel, the problems
with streaking, outlined above, were encountered. On polyacrylamide gel (see below),
adequate amplification and sharp bands were achieved with these lower concentrations.
However, band intensity was consistendy lower for H63D primer products and higher
for products of the HGH primers than for the C282Y primers. This was dealt with by
further alteration in the primer concentrations, such that the final concentrations in the
mastermix were:
HGH primers: 0.1 pM
C282Y primers: 0.00625 pM
HGH primers: 0.00125 pM
3.9.4 Q solution
Q solution (Qiagen GmbH, Germany) modifies the melting behaviour ofDNA (Qiagen,
1999) and can aid amplification. The presence or absence ofQ in the PCRs in the
present study had no significant effect on the yield of the reaction and it was not used.
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3.9.5 DNA concentration
During the optimisation process, standardisation of the DNA concentration (see section
3.2) of a number of test samples was performed. The specificity and yield of the PCR
was not significantly better in the samples with standardised DNA concentrations than
in those in which this procedure had not been performed. It was, therefore, not carried
out routinely in this project.
3.9.6 Gel composition
A range of agarose gel concentrations (0.8%, 1.5%, 3% and 4%) was tried. With each,
the definition of the DNA fragment bands was equally poor, regardless ofwhich of the
manoeuvres described above was tried in addition. The use ofpolyacrylamide gel instead
of agarose was the most effective factor in the eventual attainment of a sharp and easily
interpretable band pattern.
3.9.7 Gel destaining
Destaining the gel in distilled water after the initial ethidium bromide application was
not effective in promoting band clarity on agarose or polyacrylamide and was, therefore,
not performed routinely.
3.10 Quality assurance
During optimisation of the ARMS as above, samples of known HFE genotype were
used. These had already been processed within our department, using PCR followed by
restriction enzyme digestion (section 3.5). Comparison of the results achieved with ARMS
with those obtained with the established technique provided assurance of reliability. 100%
concordance was achieved before analysis of unknown samples was begun.
A blank (i.e. PCR reaction without DNA) and a wild-type and double heterozygote
control were included in each batch ofPCR reactions performed during the study. If
the blank showed any evidence ofDNA contamination, the batch was repeated after
replacement of all reagents. Ifeither control failed to give the expected results, the batch
concerned was repeated. Any sample that yielded dubious results was repeated until
unequivocal results were obtained on two occasions. In addition, throughout the project
a number of samples were sent for repeat testing by the Scottish Molecular Genetics
Consortium, Ninewells Hospital, Dundee. There was full agreement between results
obtained by the Consortium and the results for the present study.
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A molecular weight (MW) marker (<j)X-174) was run routinely with the test samples
when vertical PAGE was used to confirm that bands ofappropriate molecular weight
were being visualised. In fact, the band pattern obtained in the ARMS PCRs, confirmed
in each batch by the controls, was sufficiendy characteristic to render this unnecessary.
It was technically difficult to include a MW marker in the MADGE system, and for
these reasons, the MW marker was omitted when MADGE was used (see below).
3.11 Use of the MADGE system
The volume of samples to be tested rendered the routine use ofvertical PAGE
impractical. The possibility of using the MADGE system to visualise the ARMS
products was therefore investigated. It proved possible to achieve adequate band
separation for reliable interpretation of results, and this method was used routinely
during the project for the visualisation ofARMS products. On the whole, clearer bands
were obtained by pre-staining the gel before the samples were loaded, than by staining
after electrophoresis, and pre-staining was performed for most of the gels.
3.12 Isolation of DNA from paraffin sections
The initial intention was to genotype DNA isolated from paraffin blocks obtained
from biopsies of the recipient s explanted liver in patients undergoing orthotopic
liver transplantation. It proved impossible, despite the use ofvarious different DNA
extraction and amplification techniques (see above) to obtain amplification ofDNA of
sufficient quality for genotyping.
3.1 3 Laboratory Measurement of Iron Stores
All measurements were performed according to the standard operating procedures of the
clinical chemistry laboratory of the Royal Infirmary ofEdinburgh.
3.13.1 Serum ferritin
A heterogeneous sandwich magnetic separation assay was performed on the Technicon
Immuno 1 system (Bayer Diagnostics, Newbury, UK).
3.13.2 Serum Iron
Assayed using Vitros Fe slides (Johnson & Johnson Clinical Diagnostics, Inc, Rochester,
USA) and a Vitros 250 analyser (Ortho-Clinical Diagnostics, Amersham, UK)
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3.13.3 Total iron binding capacity
Assayed using the alumina column method ofStarr (Starr, 1980) with reagents supplied
from Vitros (Johnson & Johnson Clinical Diagnostics, Amersham, UK) and a Vitros
250 analyser (Ortho-Clinical Diagnostics, Amersham, UK).
3.13.4 Transferrin saturation
This was calculated as: (serum iron + TIBC) x 100%.
3.13.5 Non-transferrin bound iron
This was assayed in the laboratory of Professor J B Porter at King's College, London (see
also section 7.3.6).
3.14 Statistical Analysis
Statistical analysis was performed with the aid of the Statistics Package for the Social
Sciences (SPSS), Chicago, Illinois. Relevant details are provided in each section of
the text.
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4. Investigation of the effect of HFE
genotype on blood donors who
make frequent red cell donations
4.1 Introduction
The donation of one unit of red cells results in the loss of 236 mg iron from male donors
(Garry, 1995). Regular blood donation, therefore, causes iron depletion in a significant
proportion of donors (Finch, 1977; Garry, 1995; Pederson, 1978). Alvarez-Ossario and
colleagues found an inverse relationship between donors' serum ferritin concentration
and the number of units of blood donated per year (Alvarez-Ossario, 2000). In a
study of otherwise healthy elderly blood donors, 10% ofmales and 15% of females
became iron deficient within one year of starting to donate blood and 7% of the females
developed iron deficiency anaemia (Garry, 1991). It is not clear whether sub-clinical
iron deficiency not associated with anaemia is harmful in adults. Nonetheless, blood
donors in the UK are currently permitted to donate red cells with a maximum frequency
of one unit every 12 weeks in an attempt to protect them from the development of iron
deficiency. Early in the development of iron deficiency, laboratory values may all be
normal. Scoog (1993) describes 3 phases: latent iron deficiency in which iron stores,
although depleted, are adequate for haemoglobin production; early iron deficiency
associated with a low normal to reduced mean cell volume (MCV) and haemoglobin
concentration; and established deficiency, when both MCV and haemoglobin
concentration are below normal. It is clear that early iron deficiency in blood donors is
often not accompanied by a fall in haemoglobin concentration (Finch, 1977). A recent
very large study showed that 0.9% ofmale blood donors and 8% of female donors
had a serum ferritin of less than 15 pg/L (Jackson, 2001). As the copper sulphate pre-
donation screening test used in the UK (Phillips, 1977) is dependent on haemoglobin
concentration rather than any direct measure of iron status, it is likely that many iron
deficient donors are able to continue donating (Jaime, 1988).
In Scotland, only five percent of the eligible population donates blood, so there is a
constant difficulty in maintaining supplies in the face of rising demand. It has been
suggested that using blood drawn from haemochromatosis patients could usefully
augment the blood supply (Worwood, 1991).
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However, the extent to which this would be so in practice has been fiercely debated. Attempts
to estimate the impact ofpermitting the use of the blood drawn from haemochromatosis on
the blood supply in the United States have produced widely differing results (Jeffrey, 1999a;
Conry-Cantilena, 2000). A study of Canadian patients with haemochromatosis (Levstik,
1998) estimated that 67% of the units withdrawn during iron-depletion therapy and 88%
of units withdrawn during maintenance treatment were potentially available for allogeneic
transfusion. In practice, however, only a very small proportion of those eligible to donate
were able to do so. In the majority of cases, this was found to be due to the diagnosis of
haemochomatosis itself, probably because of a lack of awareness at blood donor centres of the
elibibility of haemochomatosis sufferers to donate blood.
The main impediment to the use of blood from haemochromatosis patients for
allogeneic transfusion is the concern that this blood might not be safe as blood derived
from other donors. In particular, maintenance of the principle ofaltruism has been
considered ofvital importance in ensuring the virological safety of the blood supply
(Tan, 1999). The American Medical Association argued strongly (Tan, 1999) that
the acceptance of patients with haemochromatosis as donors would compromise this
principle. Haemochromatosis patients attending for phlebotomy may be motivated by a
concern for their own health or a wish to avoid the cost ofphlebotomy (where relevant)
as well as by altruism (Sanchez, 2001). It has been shown that even non-financial
incentives to donate are accompanied by an increase in the rate of positive virological
serology and medical deferral (Read, 1993).
Other important issues are the possibility of an increased risk of bacterial contamination,
particularly with organisms such as Yersinia enterocolitica, which depend on a ready
availability of iron in their micro-environment. Additionally, the greater load of free
iron in blood derived from haemochromatosis patients could theoretically be harmful
(Conry-Cantilena, 2000). On the other hand, blood drawn during the iron depletion
phase of treatment should in theory contain an increased percentage ofyoung red blood
cells compared with blood derived from patients not undergoing phlebotomy, which
may prolong the inter-transfusion interval in certain recipient groups (Anonymous, 1979).
These merits and demerits are all hypothetical and impossible to prove without a
clinical trial, which is highly unlikely ever to be possible to perform. Furthermore,
there are almost certainly many patients with undiagnosed haemochromatosis already
contributing to the blood supply (Ania, 1999). McDonnell reported that 37% of a
sample ofmore than 2000 haemochromatosis patients had been voluntary blood donors
before diagnosis (McDonnell, 1999b). In addition, blood from haemochromatosis
patients has been used for transfusion for a number of years in Australia, Norway,
Sweden, South Africa and Canada without any reports of adverse effects (Jeffrey, 1999a).
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The UK transfusion services have recently changed their guidelines to allow the use
ofblood from patients with haemochromatosis once they have been depleted of iron
(Guidelines for the Blood Transfusion Services in the UK, 2002).
Heterozygosity for haemochromatosis gene mutations may afford some protection
against iron deficiency, as discussed in section 2.3.4.1, above. This led to the hypothesis
that male heterozygotes might constitute a population of blood donors who are able
to donate blood with an increased frequency without becoming iron deficient and so
augment the blood supply, while avoiding the controversies surrounding the use of




366 male blood donors were recruited during their attendance to give blood at the
Scottish National Blood Transfusion Service s (SNBTS) donor centre in central
Edinburgh. Recruitment took place between July and October 1999. Sequential
donors who had given at least one unit ofblood in the Edinburgh Blood Donor Centre
in the previous 12 months were approached personally by the researcher or one of the
Donor Centre nursing or medical staff, as they waited to donate. First time donors were
not included because of ethical concerns about their ability to consent to participate
in a study involving repeated blood donation before they had fully experienced this
procedure for the first time. Donors who had not given within the previous year were
excluded in an attempt to increase compliance with a study in which participants were
asked to return to donate every 12 weeks (the minimum interval presently allowed by
SNBTS regulations). Donors were excluded also ifdonor centre records revealed deferral
of donation within the previous two years owing to failure of the copper sulphate
gravimetric assessment of haemoglobin concentration, inability to complete a previous
donation because of difficulties with venous access, or if they were unable to undertake
to donate blood every 12 weeks for the next year.
A verbal description of the study was given, supplemented by a written information
sheet (Appendix 1). Once the donation was completed, the donors were approached
again and, if they were willing to participate, written consent was obtained. They
were included in the study only if they returned for their next donation, as requested,
within approximately 14 weeks (98 days) ofgiving consent. In order to facilitate
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attendance at appropriate intervals, donors participating in the study were offered a
specific appointment (date and time) for their subsequent visit, although there was no
compulsion to accept this offer.
Donor centre medical and nursing staff and participating donors were blinded to the
results of iron studies and HFE gene analysis until the end of the study.
Donors' General Practitioners were informed of their participation in the study.
The study was approved by the Lothian Research Ethics Committee.
4.2.2 Sample collection
Study samples were taken during participants' first and subsequent visits for donation
after they had given consent. The initial intention was to exclude donors whose inter-
donation interval exceeded 98 days during the study period. Practical difficulties in
determining this for Donor Centre clerical staff led to some subjects' continuing in
the study despite a longer interval between donations. At each visit during the study,
participants were subject to the normal pre-donation screening procedure, and all the
standard criteria laid down by the UK blood transfusion services for deferral of donation
applied, including the requirement for a pre-donation haemoglobin concentration in
excess of 125 g/L laid down by the Scottish National Blood Transfusion Service during
the study period. Any donor whose donation was deferred for any reason (including low
haemoglobin concentraton) was excluded from further participation in the study. After
completion of the pre-donation questionnaire, the capillary haemoglobin concentration
was determined, and a sample ofvenous blood was taken from each donor. On the
first study visit, serum iron, total iron binding capacity (TIBC) and serum ferritin were
determined from the venous blood sample and 3.5 ml blood was taken into ethylene-
diamine-tetra-acetic acid (EDTA) for later extraction ofDNA and HFE gene mutation
analysis. On the second and subsequent visits, only haemoglobin concentration and
serum ferritin were measured. Samples for determination of ferritin, iron and TIBC
were dealt with under standard laboratory conditions in the clinical chemistry laboratory
of the Royal Infirmary ofEdinburgh. Samples for DNA extraction were stored at 4°C
until DNA extraction could be performed (within fourteen days).
In June 2000, a postal questionnaire was sent to all donors remaining in the study,
requesting information about participants' weight, red meat consumption and the use of
iron supplements. This is reproduced as Appendix 2.
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4.2.3 Sample analysis
Ferritin, iron and TIBC were assayed as described in sections 3.13.1 — 3.13.3. DNA
extraction and HFE gene analysis were performed as set out in Chapter 2.
Capillary haemoglobin concentration was measured using a HemoCue machine (HemoCue,
Sheffield, UK).
4.2.4 Data set
After consent was given, a record was made of each participants date of birth.
Information was also collected on the number of red cell donations made by the donor
in the previous two years. However, this information was not used in the analysis
because it proved impossible to be certain which previous donations had been of
whole blood and which of non-red cell components such as platelets or plasma. No
other demographic data were collected until the questionnaire referred to above was
administered.
4.2.5 Follow-up ofparticipants
Study participants who were found to be homozygous for the C282Y mutation of
the HFE gene were contacted individually and offered an appointment with either
the researcher or a consultant in transfusion medicine. When appropriate, further
investigation was planned and arrangements for family screening made.
Participants who were heterozygous for both the C282Y and H63D mutations
were offered individual appointments for counselling and, if appropriate, further
investigation.
Those with a significantly raised (>60%) non-fasting transferrin saturation were offered
an appointment for further investigation.
Heterozygotes for C282Y were sent written information (Appendix 3) about the
mutation and its consequences. They were also sent information to pass on to their
General Practitioner, if they wished to do so (Appendix 4).




The distribution of initial haemoglobin concentration, transferrin saturation and
ferritin among the genotypes was examined by one-way analysis of variance, for the
three commonest genotypes only (because the numbers ofdonors with the three least
common genotypes were considered too small for meaningful analysis). In addition,
non-parametric analysis was performed using the Kruskal Wallis test. The correlation of
change in haemoglobin concentration or ferritin during the study with donors' weight or
donors' red meat consumption was examined by both parametric (Pearson's coefficient of
correlation, r) and non-parametric (Spearman's rank correlation coefficient, p) methods.
It was felt that normal distribution of the variables concerned could not be assumed,
and if significance determination by the two methods differed, the result using non-
parametric tests was accepted.
4.4 Results
366 donors gave their consent to participate in the study. Of these, 297 (81%) were
eligible to begin blood donation within the study. The mean age of these donors was
41.6 years (range 18-63). Eligibility was determined by the return of the donor within
a pre-specified time (approximately 98 days) to give his first on-study donation. No
data were collected from the 69 donors who did not attend for their first study donation
and these individuals were not included in the subsequent analysis. 238 (65%) donors
attended for the second donation, 200 (55%) for the third and 159 (43%) for the fourth
and final study donation.
No attempt was made to contact donors who did not attend to donate on schedule.
Data on the reasons for dropping out are, therefore, incomplete. Insofar as they were
ascertainable, the reasons for failure to complete the four study donations are given in
table 4.1. Among the 37 donors deferred for medical reasons during the study period
were eight whose deferral resulted from a low pre-donation haemoglobin concentration.
Of these all had a serum ferritin less than 11 pg/L at the start of the study. Seven had a
normal HFE genotype. The remaining subject was a carrier ofH63D. See table 4.2 for
more details.
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Table 4.1 Reasons for failure to complete four study blood donations
Reason Number (%)* of subjects
Failure to attend within 98 days
from previous donation 162(44.3)
Medical deferral of donation** 37(10.1)
Incomplete donation obtained 1 (0.3)
Inability to obtain venous blood samples 5(1.4)
Started taking iron during the study 2 (0.5)
Uncertain 10(2.7)
Total 217(59.3)
*percentage of the total number (n=366) of donors initially enrolled.
**In addition to general medical reasons, includes travel to malarial region (3 donors);
recent tattoo (1 donor); syncopal episode after donation (1 donor); low Hb (8 donors)
- see text for details.





at each indicated study visit
Ferritin (pg/L) at




1 2 3 4 1 2 3 4
1 48 135 132 134 124 11 11 13 8 31 HC/HC
2 28 124 exc exc exc 6 exc exc exc 10 HC/HC
3 48 130 127 116 exc 5 <5 <5 exc 11 HC/DC
4 44 125 125 126 116 11 7 9 6 25 HC/HC
5 42 129 128 126 119 7 6 <5 5 11 HC/HC
6 36 135 137 132 123 9 9 7 7 12 HC/HC
7 51 135 129 118 exc 10 8 7 exc 12 HC/HC
8 44 n.a. 150 118 exc 10 8 8 exc 24 HC/HC
Legend: HFE = HFE genoptype
TS = transferrin saturation
exc = donor excluded because of previous low haemoglobin concentration
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Full laboratory data were obtained froml33 of 159 subjects who completed four
donations in the study. The reasons for incomplete data collection were: failure to
record HemoCue result (22 occasions); missing ferritin result (eight occasions); missing
transferrin saturation (five occasions); failure to extract DNA from blood for HFE gene
analysis (five occasions) (more than one item was incomplete for some individuals).
4.4.1 HFE genotypes
The distribution ofHFE genotypes in the study population is illustrated in figure 4.3
and table 4.4. The allele frequencies were 8.9% (95% confidence interval 7.1-10.6) for
C282Y and 14.8% (10.7-18.8) for H63D. A total of 70 donors (23.6% of the study
population) had a ferritin of less than 15 pg/L at their first study visit. The genotype
of one of these is not known. Of the remaining 69, 47 (68.1%) were ofwild type
genotype, 15 (21.7%) were H63D carriers, 5 (7.2%) were C282Y carriers and 2 (2.9%)
were C282Y homozygotes.
A total of seven donors had the HFE genotypes most commonly associated with
the development of significant iron overload: four were homozygous for the C282Y
mutation, and three were compound heterozygous for C282Y and H63D. The
characteristics of these individuals are summarised in tables 4.5 and 4.6.
Tables 4.7, 4.9 and 4.11 and the accompanying scatter plots (figures 4.8, 4.10 and 4.12)
give a breakdown ofmean ferritin, mean haemoglobin concentration at first visit and
mean transferrin saturation by genotype. Because of the small numbers concerned,
meaningful statistical analysis was not possible for genotypes HY/HY, DC/DC or
HY/DC. For the remaining three genotypes, there was no significant difference in initial
ferritin or haemoglobin concentration, but initial transferrin saturation was significantly
greater in genotype HY/HC than in HC/HC or DC/HC.
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Figure 4.3 Distribution of HFE genotypes
□ whole study population ■ population with initial ferritin <15
Legend: HC/HC = wildtype
HY/HC = C282Y carrier
DC/HC = H63D carrier
HY/HY = C282Y homozygote
DC/DC = H63D homozygote
HY/DC = compound heterozygote
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Table 4.4 Distribution of HFE genotypes in the study population
Genotype Number
(%* [95% confidence intervals])
of donors (total population)
Number
(%* [95% CI]) of donors
(initial ferritin <15)
Wild type (HC/HC) 178 (60.8 [55.2-66.3]) 47 (68.1 [55.8-78.8])
C282Y carrier (HY/HC) 36 (12.3 [8.5-16.0]) 5(7.2 [2.4-16.1])
H63D carrier (DC/HC) 67(22.9 [18.1-27.7]) 15 (21.7 [12.7-33.3])
C282Y homozygote (HY/HY) 4 (1.4 [0.4-3.5]) 2(2.9 [0.3-10.1])
H63D homozygote (DC/DC) 5 (1.7 [0.6-3.9]) 0
Compound heterozygote
(HY/DC) 3(1.0 [0.2-3.0]) 0
No data 5 1
*percentages ofpopulation for which there is data (n=293)
Table 4.5 Characteristics of subjects homozygous for C282Y
Donor Age TS* Initial haemoglobin Initial ferritin
(years) (%) concentration (g/L) (H9/L)
1 59 22 155 12
2 34 24 131 11
3 32 84 147 73
4 49 71 145 326
*TS = transferrin saturation
Table 4.6 Characteristics of compound heterozygote subjects
Donor Age TS* Initial haemoglobin Initial ferritin
(years) (%) concentration (g/L) (MQ/L)
1 32 51 142 55
2 21 50 140 50
3 28 40 139 40
* TS = transferrin saturation
Table 4.7 Breakdown of initial haemoglobin concentration (Hbl) by genotype
Genotype Mean Hbl (g/L) N Standard deviation
HC/HC (1) 145.68 174 8.89
HY/HC (2) 147.50 34 6.57
DC/HC (3) 146.33 67 9.52
HY/HY (4) 144.50 4 9.98
DC/DC (5) 148.25 4 8.66
HY/DC (6) 142.33 3 2.52
For the 3 genotypes with the most data, there was no significant difference in Hbl
(p = 0.5, analysis of variance)
Figure 4.8 Scatter plot representation of initial haemoglobin concentration
values (HB1 expressed in g/L) by genotype.































Table 4.9 Breakdown of initial ferritin (ferr) by genotype
Genotype mean ferrl (pg/L) N Standard deviation
HC/HC (1) 29.32 178 24.29
HY/HC (2) 30.33 36 15.78
DC/HC (3) 29.64 67 20.15
HY/HY (4) 115.25 4 154.44
DC/DC (5) 40.25 4 16.07
HY/DC (6) 56.33 3 7.09
For the 3 genotypes with the most data, there was no significant difference in ferrl
(p = 0.97, analysis ofvariance).
Figure 4.10 Scatter plot representation of initial ferritin values
(Ferrl expressed in p/L) by genotype.
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Table 4.11 Breakdown of initial transferrin saturation (ferr) by genotype
Genotype Mean TS (%) N Standard deviation
HC/HC (1) 26.23 178 9.91
HY/HC (2) 30.44 36 14.64
DC/HC (3) 28.99 67 9.35
HY/HY (4) 50.25 4 31.92
DC/DC (5) 42.00 4 5.48
HY/DC (6) 31.33 3 27.43
For the 3 genotypes with the most data, TS was significantly greater in genotype HY/HC
than in the other 2 genotypes (HC/HC and DC/HC) (p <0.05, analysis ofvariance).
Figure 4.12 Scatter plot representation of initial transferrin saturation values
(TS expressed as percentage) by genotype.





For those donors who completed all four planned study donations, the presence of
any correlation between the change in haemoglobin concentration (AHb) or ferritin
(Aferr) between the first and final study visit and genotype, donor weight or red meat
consumption was sought. The results are presented in table 4.13 and graphically in
figures 4.14- 4.18. (There was no similar analysis for transferrin saturation because
this was measured only at visit 1). There was no correlation between AHb or Aferr
and genotype. When AHb or Aferr were examined with respect to donor weight or
donor weekly red meat consumption, there was a negative correlation between red meat
consumption and Aferr ( r = -0.212, p<0.05), but not between Aferr and donor weight
(r = 0.041) or between either variable and AHb (r = 0.114 for weight; r = -0.19 for red
meat consumption). Only the scatter plot for AHb and donor weight is reproduced (as
figure 4.18).
Table 4.13 Change in ferritin and haemoglobin between
first and last study visits for individuals of different genotypes
Genotype Change in haemoglobin concentration Change in Ferritin
Number Mean (S.D.) Number Mean (S.D.)
HC/HC (1) 85 -1.74 (9.17) 89 -7.70 (10.10)
HY/HC (2) 23 -1.00 (8.14) 23 -9.43 (9.83)
DC/HC (3) 34 0.41 (8.12) 34 -6.53 (8.20)
HY/HY (4) 2 7.00 (11.31) 2 -26.00 (38.18)
DC/DC (5) 2 3.00 (5.66) 2 -17.00 (16.97)
Full data for either ferritin or haemoglobin concentration were not available for any of
the individuals with genotype HY/DC (genotype 6).
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Figure 4.14 Change in haemoglobin concentration between first and last










Figure 4.15 Change in ferritin between first and last study visit










































i Figure 4.16 Change in ferritin (CHANGEFERR expressed in ng/L)
between first and last study visit by donor weight
60 80 100 120 140 160 180 200 220
weight kg
87
Figure 4.17 Change in ferritin between first and last study visit
(CHANGEFERR expressed in ng/L)
by number of occasions red meat eaten per week
red meat per week
88
Figure 4.18 Change in haemoglobin concentration between first and last
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A total of 218 completed questionnaires were returned, a response rate of approximately
73%, assuming that all non-returned questionnaires reached their intended destination.
Donors provided information on their weight, their average weekly consumption of
meat (number of times per week that red meat is eaten) and on whether they were
presendy using iron or vitamin supplements or whether they had done so within the last
two years. A total of 11 donors (5.0% of respondents) were presently taking proprietary
dietary supplements, which included iron and one additional donor had previously done
so. Five donors (2.3%) reported taking non-iron containing dietary supplements at the
time of the study. 39 donors (17.9%) had taken non-iron containing supplements in the
previous two years.
Red meat was not consumed at all by 19 donors (8.6% of respondents). 145 donors
(66.5%) consumed it 1-5 times per week, 42 (19.2%) 6-10 times per week and 12
(5-5%) on more than 10 occasions per week.
4.5 Discussion
4.5.1 Genotype frequency
This was a small study in which some data were incomplete. The allele frequencies for
C282Y and H63D were similar to those obtained in other UK studies (Boulton, 2000;
Jackson, 2001; Miedzybrodska, 1999).
4.5.2 Iron deficiency among donors
Our results confirm that a significant proportion (23.6%) ofmale blood donors are iron
deficient, when this is defined as a ferritin of less than 15 pg/L. Why this is so much
greater than that found by Jackson and colleagues (Jackson, 2001) in their much larger
study is not certain. Although the inclusion criteria differed in that Jackson included
only donors who had given a minimum of 2 units of blood, while the criteria used in
the present study specified that one unit must have been donated in the previous year,
this is unlikely to account for the disparity in the number of iron deficient donors. It
is possible that the requirement in the present study for donors to commit to trying
to give blood every three months for a year biased inclusion in favour of donors who
were already donating frequendy and therefore who were more likely than less frequent
donors to be iron deficient.
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Consumption of iron supplements by donors could influence data such as those
presented here. Only a small minority ofdonors (5.5%) reported having taken
supplementary iron at any time in the previous two years. It is difficult to analyse
statistically whether or not this had any effect, but the numbers are sufficiendy small
that any major influence on the results is unlikely. However, it is recognised that the
reliability of the figure for the number of donors who had taken iron may be open to
question because both ofdonors' inaccuracy in remembering which supplements they
had taken in the previous two years and inability to be certain which supplements did
contain iron. (Information provided by donors was taken at face value; no attempt was
made to verify this independendy).
There was no significant difference in the HFE genotypes represented among the iron
deficient group and the whole study population although again the limitations imposed
by small numbers are recognised.
4.5.3 Haemochromatosis-associated genotypes
The point has been made in Chapter 2 that many individuals with the typical
haemochromatosis genotype do not express the iron-overloaded phenotype. Of the four
donors who were homozygous for C282Y in the present study, only two had evidence
of iron overload in terms of elevated transferrin saturation. Only the elder of the two
(aged 49) had a serum ferritin above normal (326 pg/L), and it is possible that both of
them had been protected from more severe iron accumulation by blood donation. The
remaining two C282Y homozygotes did not appear to express the haemochromatosis
phenotype and both had serum ferritin values in the iron deficient range. Both were of
an age (34 and 59 years) at which evidence of iron overload might have been expected
in expressing individuals. While none of the three individuals heterozygous for both
C282Y and H63D had elevated ferritins, two had transferrin saturations equal to
or greater than 50%. While it is difficult to draw conclusions from a single elevated
transferrin saturation result for the reasons explained in section 2.6.3 above, individuals
with this genotype are at risk of developing iron overload (Beutler, 1997).
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4.5.4 Iron status at study entry
Donors heterozygous for the C282Y mutation did not have a higher initial ferritin or
transferrin saturation than those with a wild type genotype or heterozygotes for H63D,
in contrast to what has been found in other studies of either blood donors (Jackson,
2001; Boulton, 2000) or the general population (Adams, 1994; Beuder, 2000). By
contrast, transferrin saturation at study entry was significantly higher in heterozygotes
for C282Y than in individuals with a normal genotype or heterozygotes for H63D.
4.5.5 Change in haemoglobin concentration and ferritin
Genotype alone had no influence on the change in haemoglobin concentration or ferritin
between the first and last study visits in donors who completed all four visits. However,
ferritin did fall by a smaller amount in those donors who consumed more red meat. It
has been suggested that heterozygosity for C282Y might afford protection from iron
deficiency (Datz, 1998). These data do not suggest that donors with this genotype
were protected to a greater extent than those with the wild type genotype against iron
depletion by blood donation. It is therefore unlikely that heterozygous men comprise a
group who could donate blood more frequendy than others without an increased risk of
iron deficiency.
4.6 Conclusions
It was not possible to identify a sub-population ofmale blood donors who, on the
basis of their HFE genotype, may be particularly resistant to the development of iron
deficiency. This is an important negative result in view of the current debate about
potential ways to augment the blood supply. It does not address the question ofany
potential evolutionary benefit of heterozygosity for C282Y such as protection from the
development of iron deficiency. However, it does suggest that any such protection is
limited and, if it does exist, cannot significandy mitigate the negative effects of frequent
blood donation on individuals' iron balance. The issue of the influence of heterozygosity
for C282Y on iron balance is discussed further in section 5.7 of this thesis.
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5. Study of the prevalence HFE genotypes
in iron deficiency
5.1 Background
In order to explain the persisting high allele frequency of the C282Y mutation ofHFE in
northern European populations, it has been proposed that possession of this mutation may
offer some evolutionary survival advantage in terms of relative protection against iron deficiency.
This theory was advanced recendy by Datz and colleagues (Datz, 1998). They studied
full blood counts, serum iron, transferrin and transferrin saturation in 468 female
healthcare workers aged 18-40. All individuals had their HFE C282Y genotype
determined. They found a significandy higher haemoglobin concentration, serum iron
and serum transferrin saturation in women who were heterozygous for C282Y. Further
support for a protective role for C282Y against iron deficiency was provided by the work
of Butterworth et al (Butterworth, 2002) who studied haemoglobin concentrations and
fasting serum iron levels as well as C282Y genotypes in 145 patients with coeliac disease.
Patients with the C282Y mutation had higher mean haemoglobin concentrations and
serum iron levels than those with the wild type genotype.
5.2 Aim
The aim of this study was to compare the distribution ofHFE genotypes in iron deficient
individuals with those in a control population drawn ffom the same geographic area.
5.3 Methods
Samples were collected over period of several weeks in 2000. No distinction was made
between samples received from general practitioners or those from the within the
hospital, and this information was not recorded.
5.3.1 Iron deficien t samples
Full blood count samples sent to the haematology department of the Western General
Hospital, Edinburgh, which were found to be iron deficient, were selected for DNA
extraction and HFE genotyping. The protocol followed by the laboratory entailed
measurement of serum ferritin on any full blood count sample with a mean cell volume
below the normal range or with blood film features suggestive of iron deficiency. Iron
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deficiency was defined as a plasma ferritin <15 pg/L. A random selection of each week's
iron deficient samples was tested for this study. The gender and age of the individual
from whom the samples were taken and the haemoglobin concentration and ferritin
from the sample were recorded. After selection, the samples were rendered anonymous
before DNA extraction was performed.
5.3.2 Control samples
Control samples were obtained from the department of haematology at the Royal Infirmary
ofEdinburgh. Samples were taken randomly from those received in the laboratory which
yielded normal full blood count results on standard laboratory analysers. Normal results were
defined as a haemoglobin concentration greater than 130 g/L for males or 115 g/L for females,
a total white cell count of4-11 x 109/L, a platelet count of 150-400 x 109/L and a mean cell
volume (MCV) of 76-100 fL. Samples were rendered anonymous before DNA was extracted.
The raw data from subjects of this study (full blood counts and serum ferritin
concentration) are presented in Appendix 9.
5.4 Statistical analysis
The iron deficient and non-iron deficient populations were compared by means of the X2
test. A p-value of s 0.05 was taken as significant.
5.5 Results
Samples were analysed from 520 iron deficient and 351 non-iron deficient individuals.
The characteristics of the two populations are presented in table 5.1. The HFE genotype
was ascertained in 474 (91.2%) of the iron deficient subjects and 335 (95.4%) of the
non-iron deficient subjects. The failure to ascertain a genotype resulted in all cases from
the inability to extract DNA. The distribution of genotypes in the iron deficient and
non-iron deficient populations is shown graphically in figure 5.2.
The iron deficient population contained 8.3% (95% confidence intervals 2.3% to
14.3%) more women than the non-iron deficient population (p=0.006). The iron
deficient population was older than the non-iron deficient (p<0.0001), while the iron
deficient population had a lower mean haemoglobin concentration than the non-iron
deficient population for both mean and women (p<0.0001 in each case).
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Table 5.1 Characteristics of iron deficient and normal propulations
Normal population Iron deficient
population
Total number 351 520
male 106 (30.2%) 114 (21.9%)
female 245 (69.8%) 406 (78.1%) p=0.006
Age in years (SD) 50.2(18.9) 55.8(21.0) p<0.0001
Ferritin (pg/L) Not measured 7 (5.6)
Hb in g/L (SD) male 144.7(8.8) 98.4 (20.2) p<0.0001
female 130.6 (9.3) 98.3 (16.8) p<0.0001
Genotype



























SD = standard deviation
Hb = haemoglobin concentration
ns= not significant
Values for age, ferritin and haemoglobin concentration are expressed as the mean.
* Percentages in this section of the table refer to the total number of samples in each
population for which a genotype was ascertained.
** The reason for genotype not being ascertained was either failure ofDNA extraction or
failure ofPCR. Percentages in this row refer to the total number of samples analysed.
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Figure 5.2 Distribution of HFE genotypes
in an iron deficient and a non-iron deficient population
9.3% (44/474) iron deficient individuals were heterozygous for the C282Y mutation,
compared with 9.9% (33/335) in the non-iron deficient group. This difference was not
significant (p=0.66). Ofall the study subjects only one, a male in the non-iron deficient
population, was homzygous for C282Y. None of the other HFE genotypes differed
significandy in its distribution between the two populations.
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5.6 Discussion
The proportion of individuals in the two populations with each of the six HFE
genotypes is consistent both with those found in other studies within this thesis and also
with those reported for a Scottish population (Miedzybrodska, 1999). In that there is
no difference in the proportion ofC282Y carriers between the iron deficient and non-
iron deficient population, these results do not provide support for the theory that the
C282Y mutation protects against iron deficiency.
The study is open to a number of criticisms. No attempt was made to obtain a
homogenous population of iron deficient patients and no demographic data were
collected other then age, sex and details of full blood count and ferritin results. There
must have been, therefore, a range of underlying pathologies contributing to the iron
deficiency; the efficacy of any protection afforded by C282Y against iron deficiency
I may depend at least in part on the cause of that deficiency. Additionally, some patients
were anaemic while others were not and it is possible that these two groups should
constitute two separate populations. No attempt was made to match the iron deficient
and non-iron deficient populations for age or sex, and there were in fact significant
differences between them. The definition of iron deficiency as a plasma ferritin of < 15
pg/L was arbitrary and took no account of the difference between the lower end of the
normal range for males and females, so that some iron deficient males were probably
missed. In addition, some of the iron deficient samples were likely to have been detected
on the basis of a plasma ferritin assay triggered by a low mean cell volume or other
morphological features of iron deficiency. This may have introduced some further bias
because of an under-representation of iron deficient individuals with a normal MCV.
However, the distribution of the HFE genotypes within each population was similar
to that expected from other surveys of populations of similar ethnicity. The control
population was by definition not "normal" in that it was composed of individuals
who had, for some health reason had a full blood count checked. Additionally, as this
population was screened for iron deficiency only on the basis of a normal full blood
count, it is likely that some iron deficient individuals were included.
Given, however, the similarity in the proportion ofC282Y carriers in each population,
it is unlikely that correction even of all these imperfections would have affected the
conclusion of the study.
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5.7 Conclusion
Notwithstanding the criticisms that may be levelled at the methodology of this study,
the finding that the prevalence ofC282Y amongst patients with iron deficiency does
not seem to be lower than that in a control population provides additional evidence
that possession ofC282Y does not protect against iron deficiency. This is in agreement
with results presented elsewhere in this thesis that show that heterozygosity for C282Y
does not protect male blood donors from the development of iron deficiency (see
sections 4.4 and 4.5). This contrasts with the conclusions reached by the smaller studies
ofDatz (Datz 1998) and Butterworth (Butterworth 2002). They analysed their data
differently however, comparing mean ferritin and transferrin saturations in individuals
with different HFE genotypes. Data presented in the present work (section 4.4) showed
that male blood donors who were heterozygous for C282Y had a higher mean transferrin
saturation than those lacking this mutation, but there was no significant difference in
mean ferritin values.
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6. HFE gene mutations and hepatic iron
depositon in patients undergoing
orthoptic liver transplantation
6.1 Background
As a result of the portal blood circulation, the liver is the first target organ in
haemochromatosis (Brissot, 2000). Unchecked iron accumulation in the liver may lead
ultimately to the development of hepatic fibrosis, cirrhosis and hepatocellular carcinoma.
However, individuals with haemochromatosis are now increasingly identified before
the development of evidence of hepatic damage. Many of these may be asymptomatic
(Leggett, 1990; Adams, 1991).
A common symptom at presentation with haemochromatosis is abdominal pain
(Niederau, 1996), the precise aetiology ofwhich remains uncertain. In particular, it is
unclear whether this is related to hepatic pathology. Among physical signs at diagnosis,
hepatomegaly is one of the most prevalent. In a series of 251 German patients with
haemochromatosis, 70% of those without and 89% of those with cirrhosis had
hepatomegaly (Niederau, 1996). A survey of over 1000 iron overloaded patients in
Brittany, France, also demonstrated the common occurrence of hepatomegaly, albeit at a
lower prevalence than that found in the German study (Moirand, 1999).
Individuals with hepatic cirrhosis and/or hepatocellular carcinoma as a result of
haemochromatosis may be treated with orthotopic liver transplantation (OLT). A
number of investigators have reported that patients with haemochromatosis fare less well
after OLT than patients with chronic liver disease of other aetiologies (Farrell, 1994;
Kowdley, 1995; Poulos, 1996; Brandhagen, 2000, Crawford, 2004). In addition, there
is evidence that in a considerable number of transplant recipients, haemochromatosis has
been undetected at the time ofoperation (Farrell, 1994; Kowdley, 1995; Brandhagen,
2000). Whether this is changing with the ready availability ofHFE mutation analysis in
recent years, is uncertain.
Interpretation of serum measures of iron overload in patients with liver disease may
be difficult, because many liver pathologies are associated with elevated values of
blood iron studies in the absence of haemochromatosis (Di Bisceglie, 1992). Even the
finding of increased hepatocellular iron on histological examination of liver tissue is
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not specific for haemochromatosis (Deugnier, 1997). Because of this, the hepatic iron
index (HII) which is the ratio of the hepatic iron concentration to the patients age has
often been used to try to identify cases of hepatic siderosis due to haemochromatosis
rather than other causes. An HII of greater than 1.9 has been considered indicative
of haemochromatosis. However, it has become clear that this value cannot be used
as an absolute: some patients, especially those with cirrhosis, may have HII values in
excess of 1.9 without having haemochromatosis, others with a definite diagnosis of
haemochromatosis have an HII of less than 1.9 (Ludwig, 1997; Kowdley, 1997).
It has been shown in previous studies that patients coming to liver transplantation
may have very significant hepatic iron deposition in the absence ofHFE linked
haemochromatosis (Farrell, 1994; Deugnier, 1997). In an American study of patients
who underwent liver transplantation at the Mount Sinai Medical Center, 19 out of
918 had hepatic iron deposition graded 3 or 4 (Fiel, 1999). The investigators showed
a poor correlation ofpre-transplant phenotypic diagnosis of haemochromatosis
with HFE genotype. Nine of the 19 patients had wild type HFE genotypes, three
were homozygous for C282Y, one was heterozygous for C282Y and six were H63D
heterozygotes. It was clear that serum measures of iron status in these patients did not
accurately reflect hepatic iron overload.
The aim of the present study was to determine the HFE genotype of all patients
transplanted on the Edinburgh liver transplant programme since its inception in 1992.
Furthermore, it was intended to determine the number of transplant recipients with
unsuspected haemochromatosis, and to ascertain whether any conclusions could be
drawn in this patient population about the effect ofHFE genotype on survival after OLT.
6.2 Methods
Ascertainment of the HFE genotype and iron status of liver transplant recipients under
follow-up at the Scottish Liver Transplant Unit, Royal Infirmary ofEdinburgh was
achieved by means of case note review. The transplant physicians were of the opinion
that it was clinically necessary to perform HFE genotyping on all their liver transplant




DNA was extracted from the peripheral blood of patients attending the liver transplant
follow-up clinic.
Where available, paraffin-embedded biopsy material from the explanted livers of patients
who had died was obtained from the University of Edinburgh Department of Pathology
and was subject to DNA extraction.
6.2.2 HFE genotyping
If the HFE genotype was documented in a patients case notes, this was recorded.
For all patients in whom this was not the case, genotyping for the C282Y and H63D
mutations ofHFE was performed. Because the results on the living patients were being
obtained for clinical purposes, it was considered important that the results entered into
the patients' notes were verified by a laboratory in which appropriate quality assurance
was operational. All DNA samples were therefore sent for repeat analysis to the Scottish
Molecular Genetics Consortium at the University of Dundee. The reports from this
source were forwarded to the transplant physicians. There was 100% concordance
between the study results and those from the Molecular Genetics Consortium.
6.2.3 Ascertainment of iron status
For the living recipients, post-transplant iron status (serum ferritin and transferrin
saturation) was recorded when this information was already documented in the notes. If
it was not recorded, blood was taken for the relevant analyses at the following clinic visit.
The case notes of all clinic attendees over a period of approximately nine months were
reviewed, and data were obtained on the majority of the surviving transplant population.
No attempt was made to try to standardise the time interval between the transplant
procedure and measurement of iron status.
Details of patients who had died following transplantation were obtained from the
database of the Scottish Liver Transplant Unit.
»
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6.2.4 Examination of liver biopsies
In those cases in which a Perls' stain for iron had been performed on a biopsy of the
explanted liver, this was examined by an independent pathologist who was unaware of
the ferritin or genotype results. Hepatocyte iron deposition was assessed on a scale of 1
to 4+ according to the criteria of Searle etal. (1994). In this method, grade 0 is absence
of granules or barely visualised granules at x 400; grade 1 is granules visible at x 250 and
easily seen at x 400; grades 2 - 4 are granules seen at x 100, x 25 and x 10 (or with the
naked eye) respectively.
6.3 Statistical Analysis
The distribution ofHFE genotypes among patients with different Perls' stain grades
was examined by Fisher's exact test, as 86.7% of cells in a 2 x 2 table for %2 analysis had
an expected count of less than 5. The distribution ofhepatic iron grade, ferritin values
and length of stay in the transplant unit could not be assumed to be parametric, so
correlation of ferritin with hepatic iron deposition and HFE genotype and length of stay
was examined,by calculation of Spearman's rank correlation coefficient (p).
6.4 Results
The Scottish Liver Transplant unit performed 307 orthotopic liver transplants on 271
recipients between its inception in 1992 and May 2000 when this study was performed.
Of these, 62 transplant recipients had died. An HFE genotype was obtained on 180
of the 209 living recipients (86%). A serum ferritin value was obtained for 183 (88%)
individuals and a transferrin saturation for 173 (83%). Failure to obtain blood for
testing for these parameters resulted in nearly every case from the failure of the patient
to attend successive review appointments at the transplant clinic. No effort was made to
pursue patients to obtain specimens. Some of these patients may have been under only
infrequent review at the transplant unit because, for example, of the distance they lived
away from Edinburgh.
A total of 135 Prussian Blue stained liver biopsy slides of samples taken from the
explanted livers of 126 living transplant recipients were available for grading of iron
deposition. Of these, 102 (75.6%) stained at grade 0, 13 (9.6%) at grade 1, 11
(8.1%) at grade 2, 6 (4.4%) at grade 3 and 3 (2.2%) at grade 4. For one specimen, the
pathologist was unable to grade it definitely as 3 or 4. This has been arbitrarily included
as grade 3.
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The distribution ofHFE genotypes among the liver transplant patients is shown in table
6.1. Three transplant recipients were homozygous for C282Y - this was not known
before the transplant in any of the cases. The characteristics of these recipients are
summarised in table 6.2.
Table 6.3 shows the characteristics of the seven patients who were compound
heterozygous for the C282Y and H63D genotypes.
Nine patients had evidence of severe hepatic iron deposition (defined as Perls' stain grade
3 or 4) on their liver biopsy specimens. These patients are presented in table 6.4.
The distribution of serum ferritin values in patients with differing grades of hepatic iron
deposition is illustrated graphically in figure 6.5. No correlation between serum ferritin
and hepatic iron deposition was found (Spearman's p = 0.139; 2-tailed p = 0.15).
Figure 6.6 illustrates the distribution of hepatic iron distribution according to the
patient's HFE genotype. No correlation either was found between these two variables (p
= 0.161, Fisher's exact test).
Figure 6.7 shows the effect ofgenotype on length of stay in the Transplant Unit.
There was no correlation identified between these variables (Spearman's p = 0.037; 2-
tailed p = 0.661)
It proved impossible, despite the use ofvarious techniques (discussed in the general
Methods chapter), to extract DNA from the paraffin sections of liver biopsy. There are
therefore no data on HFE genotype for those patients who had died before the present
study began.
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Table 6.1 Distibution of HFE genotypes among liver transplant recipients
Genotype Number Percentage 95% CI
HC/HC 108 60.0 52.8-67.2
HY/HC 21 11.7 7.0-16.4
DC/HC 38 21.1 15.1-27.1
HY/HY 3 1.7 0.3-4.8
DC/DC 3 1.7 0.3-4.8
HY/DC 7 3.9 1.6-7.8
CI = confidence intervals
Data were unavailable on 46 patients out of a total of 226. Percentages quoted are
calculated on the basis of a total of 180 patients for whom there were data.
Table 6.2 Characteristics of liver transplant recipients with genotype HY/HY
Patient number Ferritin (pg/L) TS (%) Perls' stain grade
1 8 <10 0
2 832 14 0
3 32 27 0
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Table 6.3 Characteristics of liver transplant recipients with genotype HY/DC
Patient number Ferritin (|jg/L) TS (%) Perls' stain grade
1 350 25 3
2 429 44 0
3 11 31 0
4 870 73 0
5 518 50 0
6 23 28 Not known
7 157 31 0
Table 6.4 Characteristics of patients
with severe hepatic iron overload (grade 3 or 4)
Patient Perls' stain grade Genotype Ferritin (pg/L) TS (%)
1 3 HY/DC 350 25
2 3 HC/HC 42 13
3 3 HC/HC 179 26
4 3 nd nd nd
5 3 nd nd nd
6 3 nd nd nd
7 4 DC/DC 157 22
8 4 DC/HC 219 33
9 4 nd nd nd
nd = no data available
105
Figure 6.5 Scatter plot of the distribution of serum ferritin (in ng/L)














Figure 6.6 Scatter plot of the distribution of hepatic iron stain grades
among patients with the various HFE genotypes
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Figure 6.7 Scatter plot of the distribution of length of stay in transplant
unit (days) according to HFE genotype
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The distribution among genotypes among the liver transplant recipients is similar to that
expected, based on other studies in Celtic populations (Boulton, 2000; Jackson, 2001;
Miedzybrodska, 1999) and on results obtained in other sections of this work.
Because of small numbers, it is impossible to analyse the numbers ofpatients in each
genotype statistically with respect to the number expected. However, seven patients
(3.9% of those for whom data were available) with the genotype HY/DC is possibly a
greater number than expected.
None of the patients with genotype HY/HY had a raised post-transplantation
transferrin saturation, while only one had a raised ferritin. In all three cases, the iron
stain on the explanted liver showed no evidence of iron overload, suggesting that the
haemochromatosis in these patients was not phenotypically expressed.
Although five of the seven patients with genotype HY/DC had an elevated serum
ferritin, only two had transferrin saturations greater than 50% and in only one case
(patient number 1 in table 6.3) was there any significant hepatocellular haemosiderosis.
Nine patients had markedly increased hepatic iron deposition (grade 3 or 4 siderosis)
(table 6.4). Of the five whose genotypes were known, one was a compound
heterozygote for C282Y and H63D (HY/DC), one was heterozygous for H63D (HC/
DC), one homozygous for H63D (DC/DC) and two were wild type (HC/HC).
Unfortunately, because data collection was incomplete for this group of patients, it is
impossible to identify any clear pattern ofgenotype or any definite correlation with
serum ferritin or transferrin saturation values. However, it appears to be the case that a
significant number of liver transplant recipients with severe hepatic iron overload do not
have evidence of HFE-linked haemochromatosis, as suggested in earlier studies. Further
weight is given to this conclusion by the fact that no correlation was found between
HFE genotype and serum ferritin.
In addition, a wide distribution of ferritin and transferrin saturation values was found
in the patients with grade 3 and 4 hepatic iron staining. As was touched upon in the
introduction to this chapter, blood iron indices such as serum ferritin fail to reflect
accurately the presence or absence of tissue iron overload in those patients with end-stage
hepatic disease (Fiel 1999). Data were not collected on pre-transplant serum ferritin
or transferrin saturation and the values reported here were obtained at time intervals
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between a few months and seven years after transplantation. It is reported that patients
with haemochromatosis who receive a liver transplant may have a post transplant fall
in their serum ferritin and transferrin saturation to normal within six months of the
transplant procedure (Powell, 1992). As accumulation of iron may take many years, it is
possible that there will be a gradual reaccumulation of iron in these patients, but data on
this are not yet available.
It is difficult to make any comment from these results on any influence ofHFE genotype
on outcome of transplantation. There was no correlation between genotype and length
of admission to the transplant unit. However, length of stay could be affected by a large
range of factors that were not controlled for in this study, and is not a validated measure
of transplant outcome. There have been suggestions that outcome at a year after
transplantation is worse in patients with haemochromatosis than in other transplant
patients (Farrell, 1993; Kowdley, 1995; Poulos, 1996; Brandhagen, 2000). Data on
one-year survival could not be collected for the present study: all patients included in the
data presented here were still alive at the time of analysis. Patients who had died were
excluded because of the failure of attempts at extracting DNA from paraffin sections of
liver tissue. This fact renders it even more difficult to comment on outcome, since the
data are by definition skewed in favour of patients who survived.
This study has some significant limitations in its methodology. Data collection was
not complete, largely for logistical reasons. More demographic detail on the patients
would have added to the value of the observations presented here (for example, it
would have been useful to know the pre-transplant and histological diagnoses of the
patients). Collecting these data was not feasible because of resource considerations.
Additionally, some standardisation of the time in a patients post-transplant course at
which blood iron indices were assessed would have aided interpretation of these results.
The lack of information on pre-transplant ferritin and transferrin saturation values is also
unfortunate.
6.6 Conclusion
As has been reported in other studies, there were a number ofpatients who had received
liver transplants for indications other than haemochromatosis who were subsequently
found to be homozygous for the C282Ymutation ofHFE. These patients may not
have expressed phenotypic haemochromatosis. It was not possible to identify a
correlation between HFE genotype and hepatic iron deposition as assessed by
histological examination.
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7. Iron status and HFE gene mutations in
patients with coronary artery disease
shown at coronary angiography
7.1 Introduction
The extent to which iron has a role in the pathogenesis of coronary artery disease has
been the subject of intense debate (Sullivan, 1981; Koster, 1995; Sullivan, 1999; de
Valk, 1999; Niederau, 2000; Ma, 2002).
Theoretical mechanisms certainly exist by which iron may have a role in the pathogenesis
of atherosclerosis. The generation ofhydroxyl radicals (OH"), which are very reactive
and can attack a variety of cell constituents can occur via the Fenton and Haber-Weiss
reactions (Britton, 2000). In the Fenton reaction, the hydroxyl radical is produced by
the reaction of iron with hydrogen peroxide:
Fe2+ + H202 Fe3* + OH* + OH
Ferric iron is reduced to ferrous iron by the superoxide radical (02" ) in the Haber-Weiss reaction:
Fe3+ + 02*" —> Fe2+ + 02
Fe2+ + H202-^ Fe3* + OH* + OH"
Net reaction: 02*" + H202—— > 02 + OH" + OH"
Hydroxyl radicals may initiate the process of lipid peroxidation, which may be an
important factor in the formation ofatherosclerotic lesions (de Valk, 1999). It is also
possible that iron depletion exerts a protective effect on the myocardium by mechanisms
other than the inhibition of atherogenesis (Sullivan, 1999).
In healthy individuals, free plasma iron cannot be detected. However, in sera from
iron-overloaded patients, in which serum iron-binding capacity is fully saturated,
non-transferrin bound iron (NTBI) may be found (Batey, 1980; Gutteridge, 1985;
Grootveld, 1989). Iron in this form may be particularly capable of causing tissue
damage by the mechanisms mentioned above (Gutteridge, 1985). It has been shown
that heterozygotes for hereditary haemochromatosis, whose serum iron, transferrin
saturation and ferritin did not differ from those of controls, did nonetheless have
significantly higher NTBI than controls (de Valk, 2000).
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In 1981, Sullivan advanced the argument that the difference in the incidence of heart
disease in men and women was explicable by differences in the levels of stored iron. As
a corollary of this, iron depletion should protect against the development of ischaemic
heart disease (Sullivan, 1981). Sullivan has subsequendy made the case that the change
over time in the risk of coronary artery disease parallels changes in iron stores as reflected
in serum ferritin values (Sullivan, 1983; Sullivan, 1989).
There is some evidence in support ofSullivan's hypothesis. A study of 1931 men in
eastern Finland indicated that an elevated serum ferritin was a strong risk factor for
acute myocardial infarction and that the dietary intake of iron was strongly associated
with this disease (Salonen, 1992). A further study conducted on essentially the same
population after the discovery ofHFE concluded that male carriers ofC282Y are at a
two-fold increased risk for first acute myocardial infarction compared with non-carriers
(Tuomainen, 1999). A Dutch study of over 12 000 postmenopausal women found
an association between heterozygosity for C282Y and cardiovascular death, especially
in women with other classical risk factors (Roest, 1999). Women who were smokers,
hypertensive and carriers ofC282Y had an 18.85-fold increased risk of cardiovascular
death compared with women without these risk factors. Women who smoked and
were hypertensive but did not carry C282Y had a relative risk of 2.06 compared with
non-smoking, normotensive non-carriers ofC282Y. A positive association was also
found between serum ferritin and ultrasonic measurement of progression of carotid
atherosclerosis over a five-year follow-up period (Kiechl, 1997). Two groups have
suggested that blood donors have a lower risk of coronary heart disease than non-donors,
which might reflect a protective effect of a reduction in body iron stores (Meyers, 1997;
Salonen, 1999).
By no means all the published studies have supported the existence of a relationship
between atherosclerosis and iron stores and/or HFE gene mutations, however. Nassar
et al studied 300 patients, half ofwhom manifested early onset (before the age of 50)
coronary artery disease (Nassar, 1998). The other half of the study population presented
for the first time with coronary artery disease over the age of 65 years. Males in the
early onset group had a higher plasma ferritin than those in the later onset population.
There was, however, no correlation with carriage ofHFE mutations. Ferritin did not
differ significandy between women in the two groups. No other data on coronary risk
factors were collected in this study. 546 Italian patients with angiographically confirmed
severe coronary artery disease were compared with 303 patients found to have non-
diseased coronary arteries on angiography (Bozzini, 2002). The authors collected a full
data set to enable assessment of coronary risk factors and found no correlation between
coronary artery disease and iron stores or HFE mutations (only C282Y was assessed).
Similar negative results were produced by a Brazilian study of 160 individuals who had
survived myocardial infarction and had severe coronary atherosclerotic on angiogram
(Calado, 2000). Age, sex, and race-matched healthy individuals were used as a control
population. No data on iron stores were presented, but there was no increase in the
prevalence ofC282Y or H63D in the population with coronary artery disease. A
possible criticism of this study is that the control population, while free of symptoms of
coronary artery disease, did not undergo coronary angiography and the true prevalence
of coronary artery disease among the controls should probably not be assumed to be
zero. HFE genotypes (C282Y and H63D) were determined in subjects from two case
control studies: the ECTIM study designed to identify genetic polymorphisms affecting
the susceptibility to myocardial infarction in patients and controls from France and the
UK; and the GENIC study, examining the genetic susceptibility to brain infarction
in patients from 12 French departments of neurology. Additionally, genotypes were
obtained on participants in the AXA study, which was designed to investigate risk factors
for early stages of atherosclerosis (Hetet, 2001). In this study, healthy individuals
underwent Doppler ultrasonographic assessment ofatherosclerosis in the femoral
and carotid arteries. The results of the AXA study suggested a correlation between
H63D and atheroma in smokers. The other two studies did not show any significant
relationship between HFE mutations and risk either ofcoronary heart disease or
brain infarction.
Other studies (Baer, 1994; Eichner, 1998) also foiled to support a correlation between
iron and atherosclerosis, and in a meta-analysis ofpublished studies, Danesh and
Appleby concluded that there was no evidence for a strong epidemiological association
between iron status and coronary heart disease (Danesh, 1999). Two more recent large
studies have also failed to show a correlation between elevated serum iron parameters
and HFE gene mutations. Waalen and colleagues (Waalen, 2002) screened in excess of
30 000 men and women attending a health appraisal centre and found no consistent
association between either of the common HFE gene mutations, serum ferritin or serum
transferrin saturation and coronary heart disease, as assessed by review of medical records
and completion of a questionnaire. Similar results were obtained in a cross-sectional
evaluation of 2326 inhabitants of the Australian town ofBusselton (Fox, 2002).
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7.2 Aim
Against this background of conflicting evidence, the aim of the present study was
to examine the hypothesis that iron stores and /or mutations in the HFE gene are
risk factors for coronary artery disease. Further, to test the hypothesis that levels of
potentially more reactive iron in the form of non-transferrin-bound iron (NTBI) might
correlate more closely with coronary artery disease than levels of serum ferritin, NTBI
was measured in a number of the study's subjects.
7.3 Method
7.3.1 Subject recruitment
286 patients attending for consecutive day-case coronary angiography lists over a
number ofmonths at the Royal Infirmary ofEdinburgh were enrolled. Shortly after
arrival at the hospital, patients were given a brief verbal description of the study and
a sheet ofwritten information (Appendix 6) by one of the cardiology clinical nurse
specialists. When they had read the information sheet, written informed consent for
inclusion in the study was sought. The general practitioners of patients agreeing to
participate were informed of this by means of a pre-printed letter.
7.3.2 Sample collection
Blood was taken from consenting patients for determination of serum ferritin and
erythrocyte sedimentation rate (ESR). A sample in EDTA was taken for extraction
ofDNA and later HFE gene mutation analysis and a serum sample was taken from
39 subjects out of the first 120 included (selected randomly) for measurement
of non-transferrin-bound iron (NTBI). All samples were taken in the morning
(usually before ten o'clock) with the patient fasting, as demanded by the protocol
for coronary angiography. All samples were taken and conveyed to the laboratory
at ambient temperature. The samples for ESR and ferritin were dealt with under
standard laboratory conditions in the clinical chemistry and haematology laboratory
respectively of the Royal Infirmary ofEdinburgh. The samples for DNA extraction
were stored at 4°C until DNA extraction was performed (within seven days). The
samples forNTBI determination were centrifuged at 1500g for ten minutes as soon
as possible after arrival in the laboratory, serum was removed and frozen at minus
75° C for several weeks before NTBI could be measured.
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7.3.3 Data collection and analysis
The cardiology nursing staff assigned patients in the study consecutive numbers at
the time that they gave consent. Study blood samples were identified by this number
alone. The angiogram results were assessed by a cardiologist and reported as showing
atherosclerotic disease in zero, one, two or three coronary arteries. The patients' age and
smoking history, body mass index (BMI), and presence or absence of hyperlipidaemia,
hypertension and diabetes mellitus were taken from the pre-angiography admission
sheet, whenever this information was provided. The full case notes of the patients were
not available for further extraction of data.
The author of this thesis was blinded to the angiographic and epidemiological data
until all laboratory analyses had been completed. The results of the angiogram and
epidemiological information were identified by study number only, and once the
reporting of the angiograms was complete, anonymity was assured by the destruction of
the master list relating study number to patient name. Patients with no coronary artery
disease (no vessels affected) at angiography were taken as the control group and patients
with one or more diseased vessels as the study group.
7.3.4 Coronary Angiography
Diagnostic coronary angiography was performed from the femoral artery using a
standard protocol. Five views of the left coronary arterial system and two views of the
right coronary arterial system were taken and each angiogram was reviewed by two
independent cardiologists, who were unaware of the results of iron studies and HFE
gene mutation analysis. For each angiogram a score of one was given to each diseased
arterial system and a score of two to disease in the left main coronary artery. An arterial
system was considered diseased if there was a lesion of greater than 50 percent of the
vessel diameter in an epicardial vessel or of greater than two millimetres in the left
anterior descending, the left circumflex or the right coronary systems.
7.3.5 Assay of non-transferrin bound iron
Professor J B Porter (Kings College, London) kindly agreed to perform the non-
transferrin bound iron assays. Frozen plasma samples were therefore posted to his
laboratory for this purpose. For a representative method, see for example Singh, 1990.
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7.4 Statistical Analysis
Correlation between number of affected coronary vessels and non transferrin-bound
iron and between genotype and non transferrin-bound iron was examined by the
Kruskal Wallis test for non-parametric variables. The association of disease in 0 vessels
and disease in 1 or more vessels with genotype was examined with the X2 test. The
presence of an association between ferritin and the presence of disease in 0 or 1 or more
vessels was examined with the F test for equality ofvariances and the t-test for equality
ofmeans of non-paired data. The other characteristics of the two populations were
compared by X2 analysis.
7.5 Results
62 patients had no significant coronary artery disease at angiography and 213 patients
had angiographically identifiable coronary disease. Those 11 patients for whom there
was no angiographic data could not be allocated to either group and were excluded
from analysis. The characteristics of these two groups are displayed in table 7.1. Data
collection was incomplete for a large number ofpatients. The numbers concerned are
illustrated in table 7.1 for each category of data. Data on the gender of the patients were
not collected in this study.
The HFE genotype was determined for 245 out of a total of 286 patients. 55.3% of
the patients for whom a genotype was available were wild type for HFE, 10.7% were
heterozygous for C282Y and 16.7% heterozygous for H63D. The genotyped study
population contained no C282Y homozygotes, 1.5% homozygotes for H63D and 2.4%
compound heterozygotes for C282Y and H63D. The distribution of these genotypes
between the two study groups is illustrated in table 7.2.
There was no significant difference between the two groups in terms of the mean
body mass index (BMI), age, or other cardiovascular risk factors (previous myocardial
infarction (MI), hyperlipidaemia, established hypertension, diabetes mellitus (DM) or
smoking habit (current versus non-smoker or ex-smoker combined)). Mean serum
ferritin also did not differ between the groups. The ESR was measured as a global
assessment of acute phase activation (because ferritin is an acute phase protein) and did
not differ between the groups.
Table 7.1 Characteristics of the populations
with and without coronary artery disease at angiography
Number of affected vessels P
0 1-3
N 62 213
Age 62 (60.8-63.2) 60.6 (58.3-62.9) ns
BMI 28.4(27.1-29.7) 28.0 (27.4-28.6) ns
ESR 9.9 (8.4-11.4) 12.3(8.7-15.8) ns
ferritin 130.9 (108.5-153.4) 123.5 (97.3-149.5) ns
ntbi See text
diabetes yes 4 30 ns
no 27 101
no data 31 82
hypertension yes 20 53 ns
no 12 79
no data 30 81
hyperlipidaemia yes 17 90 ns
no 18 40
no data 27 83
smoking current 5 21 ns
no or ex 27 104
no data 30 88
previous Ml yes 4 47 ns
no 27 92
no data 30 74
ns = not significant
Table 7.2 Distribution of HFE genotypes between the two study populations
Number of vessels
0 1-3
Genotype n (%) P
HC/HC 36 (66.7) 118(64.8) ns
HY/HC 5 (9.3) 25 (13.7) ns
DC/HC 10(18.5) 30 (16.4) ns
HY/HY 0 0 ns
DC/DC 1 (1.8) 4 (2.2) ns
HY/DC 2 (3.7) 5 (2.7) ns
ns = not significant
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Figure 7.3 Scatter plot of the relationship between















Figure 7.4 Scatter plot of the distribution of non-transferrin-bound iron





The selection of 39 samples analysed for non-transferrin bound iron was envisaged as a
pilot possibly to be followed by analysis ofmore samples if there was enough evidence
from the results of these initial samples to justify this. Of the 39 samples in which
NTBI was assayed, 33 were from patients in the group with coronary artery disease and
only four from the other group (assignment of samples for NTBI measurement was
random and was performed before the results of the angiography were available). Two
samples were from patients excluded from analysis because of lack of angiographic data.
The values ranged between -0.833 and 2.006 (normal control: -2.412; high control
(thalassaemic patient): 5.368). There was no correlation between NTBI and gentoype (p
= 0.685, Kruskal Wallis) or NTBI and number of coronary vessels diseased (p = 0.434,
Kruskal Wallis). These data are presented as scatter plots in figures 7.3 and 7.4.
7.6 Discussion
Evidence from other studies, the details ofwhich are given in section 7.1 above, has
suggested the possibility of a relationship between body iron stores and coronary
artery disease (Sullivan, 1983, Salonen, 1992, Tuomainen, 1999). Furthermore, it
is postulated that iron not in the form of ferritin, but in a form more readily able
to promote free radical formation and lipid peroxidation may be most implicated
(McCord, 1991).
This study was designed to investigate both these postulates. In the two groups
investigated, individuals with or without angiographic evidence of coronary artery
disease, there was no significant difference in iron loading as expressed by the serum
ferritin. In the group with evidence of coronary artery disease, 20 individuals had a
ferritin <20 pg/L, indicating possible iron deficiency, and 38 had ferritin values in excess
of 200 pg/L. The numbers for the group without coronary artery disease were 8 and
10 respectively. The work of Salonen and colleagues (1992) suggested a value of 200
pg/L for ferritin, above which the risk of coronary heart disease increased. However,
these values are not directly comparable because Salonen's patient group was composed
entirely ofmen whereas the present study population comprised patients of both genders.
The measurement of non-transferrin bound iron (NTBI) provides an assay of the
amount of free-radical forming iron (Breuer, 2000). There is very little clinical data
available to indicate whether there is a correlation between NTBI levels and coronary
artery disease. It is known that individuals with iron overload, whether genetic
(Gutteridge, 1985) or secondary (Hershko, 1978) have increased NTBI in their
serum, whereas this is not found in normal individuals who have a largely unsaturated
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transferrin (Al-Refaie, 1992). It seems reasonable to suggest, therefore that a correlation
between raised serum ferritin and coronary artery disease would be mirrored in a
correlation between NTBI and coronary artery disease. The present study did not
find evidence to support this, although the number of individuals in whom NTBI
was measured was very small (particularly in the group with no disease on coronary
angiography). The small number concerned clearly limits the ability to draw general
conclusions from these data. Many of the NTBI results produced negative values. This
has been noted by others (Singh, 1990) and is an artefactual finding in patients with
normal iron stores. It may be due to the ability of unsaturated transferrin to remove
iron contamination from nitrilotriacetic acid used in the assay (Al-Rafaie, 1992).
No C282Y homozygotes were found among the patients studied. The frequency of
C282Y heterozygotes was 18.5% in the group with no coronary artery disease and
16.4% in the group with abnormal angiography and that of heterozygotes for H63D
was 9.3 and 13.7% respectively (table 7.2). These values are comparable to those
obtained in other population studies (Boulton, 2000; Jackson, 2001; Miedzybrodska,
1999) and also in other parts of this work.
7.7 Conclusions
This study did not find evidence of an association between serum ferritin and coronary
artery disease. This is an important negative result, which contributes to the on-going
debate about the role of iron in the pathogenesis of coronary artery disease.
There was no correlation either between or non-transferrin bound iron (NTBI) and
coronary artery disease or HFE genotype. The potential role ofNTBI merits further
investigation, as it is recognised that the unequal distribution ofNTBI data between
the control and study groups limits the advisability of drawing very definite conclusions
about the role of this moiety in causing coronary artery disease.
8. Survey of General Practitioners'
attitudes to and experiences of
haemochromatosis
8.1 Introduction
The weight ofevidence that haemochromatosis is under-diagnosed has been discussed
at some length in section 2.5, above. A survey conducted in Alabama in the United
States (Barton, 1997) revealed that over 85% of haemochromatosis probands were
diagnosed by physicians working in primary care (66.7%), gastroenterology (10.5%)
and haematology/oncology (10.5%). Many of the physicians interviewed identified
difficulties in diagnosing haemochromatosis, including:
1. The misconception that haemochromatosis is rare;
2. Lack of understanding of the diagnostic criteria for haemochromatosis
3. Unfamiliaritywith the multi-system disease caused by iron overload;
4. The belief that haemochromatosis could be diagnosed only in those persons with
bronze skin colouration, diabetes and cirrhosis.
These difficulties were addressed in an intensive education programme (see section 2.6.2).
In 1997, a conference on Iron Overload, Public Health and Genetics was held in the
United States, sponsored by the Centers for Disease Control and Prevention. As part
of this conference, a working group was established to identify strategies to increase the
detection of haemochromatosis. The report of their recommendations (McDonnell,
1998a) identified physician education as a priority.
As far as the researcher is aware, there is no comparable information on physicians'
attitude to haemochromatosis in the United Kingdom. It is very likely that, because of
the very different organisation of health care in the United Kingdom and the United
States, a very significantly lower proportion of patients with haemochromatosis are
diagnosed by general practitioners in the United Kingdom than by primary care
physicians in the United States.
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If, in the future, it is proposed to institute population screening for hereditary
haemochromatosis, the participation of general practitioners is likely to be crucial to the
success of the programme.
In light of this the aim of the present study was to assess the level of knowledge about
haemochromatosis and some of the attitudes to the condition prevalent among general
practitioners (GPs) in Edinburgh and the surrounding area by means of a postal survey.
8.2 Data collection - theoretical considerations
The group whose attitudes were to be assessed was well-defined and potentially easily
accessible. It was decided to use a questionnaire to obtain the data, but a number
of issues relating to the methods of data collection to be used required addressing: a
questionnaire may be administered face-to-face, over the telephone, by post or by e-
mail. All these methods have strengths and weaknesses. Personal interviews may be
best at dealing with complex topics and at eliciting responses to questions that could
be considered boring (de Vaus, 1996). In addition, the personal contact of face-to-face
interviews means that these can last longer than the other two methods. Traditionally,
it has been held that face-to-face interviews elicit a better response rate, particularly in
comparison to postal surveys. However, Dillman (1978) contends that a well-conducted
postal survey of the general public may achieve a response rate of 60-75%, which
compares reasonably favourably with his achievement of 85% response in telephone
surveys. When a specific, more homogeneous group (such as GPs) is surveyed, the
response rate to postal surveys is about the same as that for surveys conducted by other
means. This is especially so when the subject of the survey is of particular relevance to
the group (de Vaus, 1996).
Issues ofpracticability and resource must also be considered. General Practitioners are
subject to so many requests to complete questionnaires that this is viewed by many
of them as an irritation (Dr Scott Murray, personal communication, 1999). It was
considered, therefore, that time taken to complete the questionnaire and the degree
to which those surveyed felt it an intrusion on their working day would be important
factors in determining response rate. For this reason, taking into account also issues
of cost and allocation of the researchers time, it was decided to develop a postal
questionnaire with a maximum length of one side ofA4 paper.
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The areas ofknowledge about haemochromatosis to be assessed by the questionnaire were:
1. Perceptions about prevalence
2. Laboratory tests and clinical features useful and/or necessary to make the diagnosis
3. Natural history
In addition, it was desired to gather information about individual physicians' experience
of patients with haemochromatosis within their own practice and their attitude to
screening for haemochromatosis. The questionnaire used is reproduced in Appendix
8. In formulating questions about laboratory tests for diagnosing haemochromatosis,
clinical features of the disease and its natural history, an "agree-disagree" format without
any Likert-style rating scale was favoured. This was for ease of completion; the ease of
analysis of the response data may have suffered as a result.
8.3 Method
Before the questionnaire was distributed to the whole study group, it was piloted it
among general practitioners in two large practices, one an academic practice with six
partners, the other an urban practice of eight partners. Prior discussions with one
physician from each of these practices had been very helpful in the development of the
format of the questionnaire and the questions themselves. Responses from the piloting
exercise were favourable, and no major changes were made to the questionnaire as a
result of this.
A list ofmailing addresses for all general practitioners in the Lothian Health Board
area was obtained from Lothian Healths Directorate ofPrimary Care Development in
January, 1999. The list contained 540 names.
In order to raise awareness of the forthcoming study, a short paragraph about it was
published in the March, 2000 issue of GPs Only, the newsletter for GPs published
by Lothian Local Medical Committee and distributed to all GPs in the Lothian area.
This gave very basic details about the study, intimated that a questionnaire about
haemochromatosis would shordy be posted to all GPs, and provided contact details for
the researcher.
Within a month of the distribution of the newsletter, the questionnaire was sent
out with a personally signed covering letter to all the GPs in the area. The covering
letter was printed on Lothian University Hospitals NHS Trust headed notepaper and
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identified the resercher s position as Lecturer in Haematology. As the pilot had involved
14 GPs, a total of 526 questionnaires were posted. The Health Board van delivery
service, which covers all the practices, was used to distribute the questionnaire. To
facilitate the return of completed replies, every questionnaire was accompanied by a
pre-addressed return envelope bearing a second class stamp. The name of the physician
returning the questionnaire or of the practice in which he or she worked was not recorded.
8.4 Results
The number of completed questionnaires returned was 258. In the absence of any
evidence to the contrary, non-return of questionnaires was interpreted as refusal to
answer, rather than failure of the questionnaire to reach its intended recipient. The
response rate was, therefore:
258 x 100/540 = 48%
Table 8.1 displays the data provided in response to question 1 about the practice sizes of
the physicians returning the questionnaires.
Table 8.1 Distribution of GP practice size among respondents








Question 2 asked GPs how many patients with haemochromatosis they were aware of
in their own practice. The majority (178 (69%)) of respondents were not aware ofany
patients in their practice with haemochromatosis. One respondent, whose practice size
was between 6000 and 9000 was aware of seven patients with haemochromatosis in the
practice. The full data are presented in table 8.3.
Table 8.2 Number of patients with haemochromatosis identified
by physicians within their own practice (responses to question 2)
Number of patients Number (percentage) of physicians identifying










Question 3 asked GPs about the relative prevalence ofhaemochromatosis and cystic fibrosis.
37 (14%) responding physicians considered haemochromatosis commoner than cystic
fibrosis; 98 (38%) thought the two conditions were "about as common" as each other;
112 (44%) considered cystic fibrosis more common; 9 (4%) failed to answer the question.
Question 4 asked about the laboratory tests that would be helpful in confirming a
diagnosis of haemochromatosis. The results are displayed in table 8.3.
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Table 8.3 Laboratory tests that would be helpful
in confirming a diagnosis of haemochromatosis
Test Number (%) of respondents classifying test as useful
Full blood count 130 (50)
Ferritin 209 (81)
Urea & electrolytes 239 (93)
Iron/TIBC 191 (74)
Genetic test 77 (30)
It was permitted to choose any number of the five test options in this question. A total
of five respondents (2%) selected no test. Of those who selected at least one of the
options provided, only five (2%) did not include either serum ferritin or iron/TIBC.
One of these selected full blood count alone, two, full blood count and genetic test, and
two, genetic test alone.
Question 5 asked respondents about the necessity or otherwise ofgiven symptoms and
signs to make a diagnosis ofhaemochromatosis. The response data are presented in table
8.4:
Table 8.4 Opinions on the necessity of various clinical signs and symptoms
for the diagnosis of haemochromatosis to be made
Number (%) of respondents identifying sign/symptom as:
Sign/symptom Necessary Unnecessary Don't know
Skin discolouration 42 (16) 175 (68) 41 (16)
Abnormal LFT 68 (27) 140 (54) 49 (19)
Diabetes 12(4) 211 (82) 35 (14)
Arthritis 12(4) 211 (82) 35 (14)
Question 6 asked physicians to agree or disagree with statements about the natural
history of haemochromatosis. The responses are displayed in table 8.5.
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Table 8.5 Opinions on the treatment and presentation of haemochromatosis
Number (%) of respondents stating
reporting following attitudes to each statement:
Statement Agree Disagree Don't know
/no answer
Early treatment restores
normal life expectancy 135 (52) 27 (10) 95 (37)
If untreated, it is often fatal 183 (71) 23 (9) 48 (19)
Treatment involves the use
of expensive drugs 11 (4) 154(60) 91 (35)
Younger patients
are often asymptomatic 204 (79) 9(3) 44 (17)
In response to question 7, 88 physicians (34%) said that they had ever suspected that
a patient might have haemochromatosis. 178 physicians (66%) had never suspected
that a patient of theirs had haemochromatosis. In question 8, those physicians who
had suspected such a diagnosis were asked to state the grounds for their suspicion. 84
respondents replied to this question, often giving more than one symptom that had
aroused their suspicion. The percentages that follow, therefore, add up to more than 100
and the figures to more than 84. Abnormal liver function tests (LFT) was quoted by 24
(30%) respondents with one remarking that he/she always tests for haemochromatosis
as part of his screen for causes of abnormal LFT. A family history of haemochromatosis
and skin discolouration were the next two most common prompts to testing for
haemochromatosis, both quoted by 24 (29%) of those who responded. The changes
in skin colour were variously reported as "cyanosed", "brownish", "high colour", "easily
tanned" (1 respondent each) or simply "discoloured". Abnormalities in serum ferritin,
iron or total iron binding capacity were the next most common, reported by 17 (20%).
A diagnosis of diabetes mellitus was quoted by 11 (13%) and 8 had become suspicious
on the basis of an elevated haemoglobin concentration. In 4 cases (5%), joint pains were
the stimulus to further investigation, as were abdominal pain and tiredness in 2 cases
(3%) each and in 1 case each (2%) recurrent transfusions, iron therapy, liver ultrasound
appearance and hepatomegaly. One physician tested a patient because of previous
experience with another similar patient and one reported that he/she would normally
seek specialist advice before testing.
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The penultimate question, question 9, asked about physicians' attitudes to screening for
haemochromatosis. The response data are presented in table 8.6.
Table 8.6 Physicians' attitudes to screening for haemochromatosis
Number (%) of respondents reporting these
attitudes to statements about a screening
programme for haemochromatosis
Would you see screening as: Agree Disagree No answer
A useful addition
to the work of primary care 69 (27) 108(42) 81 (31)
Something of no relevance
to primary care 49 (19) 110(43) 99 (38)
An extra burden on primary care 190 (74) 20 (8) 48 (19)
8.5 Comments from General Practitioners
At the end of the questionnaire, in question 10, respondents were given an opportunity
to comment. 89 (34%) respondents commented, mostly to amplify their attitudes to
screening. As they provide an interesting insight into the opinions of respondents, I have
reproduced a selection below. For ease of reading, I have divided the comments into
three broad groupings each under a separate sub-heading:
Expression of lack of knowledge about (aspects of) haemochromatosis
"Sorry I'm so ignorant."
"IfI knew more about it Imight be in a betterposition to judge ifscreening would be useful."
"Who wouldyou be screening?"
"I don't know enough to answer this."
"Cannot comment without knowing more aboutfrequency ofcondition, cost-effectiveness."
"This has brought to my attention that I know very little about the condition — Iwill be
reading up about it in my Davidson tonight."
"Unfortunately, my knowledge ofincidence etc is sopoor I am unable to answer Q?
[screening] sensibly."
"Incidence has to be ofan order to merit the extra workload -1 have no idea what the
incidence is."
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Need for improved resources
"Extra resources would have to be identified to put into placeprimary screening. "
"Too, too busy! What would be thepick up rate!"
"Depends on resources given — who is to do the work?"
"Screening would be another thing to add to the lengthening list, but don't know enough
about it."
"Would have to be targeted andfinanced. NHS won'tpayfor myMultistix atpresent! Or in
house FOB! Or in housepregnancy tests!"
"Primary care may be theplace to screen, but huge burden onprimary care team who already
have too much to do in too little time. "
"There are no resources oftime or money in primary care to carry this out."
Expressions ofuncertainty about justification for screening or for GPs' role in it.
"I would have to be sure a screeningprogramme met all the criteria required."
"Primary care unable to take on any more screening— this is not our role. "
"I am worn out screening! GPs should screenfor common pathologies (ie 1:100patients).
Stillfind a lot with raised bloodpressure, lipids; wouldfind none with hereditary
haemochromatosis. GPs are good at decision-making. Nurses are good atfollowing
protocols. This is a jobforMr Blair's new nurses."
"In more than 30years I have only seen 2patients, both in hospitalpractice. Suggestyou
work as a GPfor 6months, thenyou will see truly common conditions."
"Screening is only useful iftreatment at an early stage improvesprognosis. "
"I have thefeeling that this is extremely rare."
"I've only seen haemochromatosis once in 20years ofpractice — I see dozens ofcervical, breast
andprostate cancers which would benefit morefrom screening."
"Never seen a case in 15years ofpractice. I would think there are a lot morepriorities than
haemochromatosis."
"Have enough workload ++ without more screeningprogrammes in practice. Leave the GP
to screen opportunistically ifhe suspects the condition clinically orpositivefamily history."




The use of surveys as research tools has a number ofpotential pitfalls. In particular,
they have been accused of being basically empiricist - of collecting a mass of facts and
figures while providing nothing of theoretical value (Mills, 1959). Further, they may
abstract people s opinions and actions out of the context in which they are formed,
making it difficult to draw valid conclusions about the significance of the data collected.
Additionally, their scope may be felt limited by the very fact that they rely on pre-written
questions — a "one size fits all" approach that may not always be appropriate and may
severely hamper flexibility in data collection.
Certainly, the use in this study of a questionnaire to assess GPs' opinions about
hereditary haemochromatosis may be open to these criticisms and others. A longer
questionnaire may have provided more detailed information and avoided the somewhat
arbitrary selection of questions made for reasons of space, but would have risked a very
significantly lower response rate. Face to face interviews would have allowed more in
depth exploration of and expansion on physicians' views but again risked a higher rate of
refusal to participate and would have been limited in practice for reasons of resource.
The issue ofvalidity of the questionnaire as an instrument for investigating a hypothesis
was raised by at least one respondent. It is difficult to know what the ideal way of
validating the questionnaire would have been - a point that de Vaus (1996) makes about
questionnaires in general. The questions were developed to be as open as possible, to
avoid the pitfall of leading respondents to support the hypothesis under examination,
that is that there may be scope for improved awareness ofhaemochromatosis among
physicians in primary care. The aim of piloting the study before distributing it more
generally was to identify questions that were unhelpful, biased or leading. The piloting
process and resulting minor adjustments to the questionnaire can equally well be seen as
an attempt at validation.
The aim of the questionnaire was to formulate questions which would indicate
the awareness of respondents about what could be considered key areas of
haemochromatosis: its prevalence; how it is diagnosed; how it may present clinically; its
natural history and treatment.
In formulating a question about prevalence, I chose comparison with another genetic
condition (cystic fibrosis) which has a relatively high incidence (1:2500 live births
(Crompton, 1999)). The validity of this comparison could be questioned because of
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the very different natural histories of the two diseases, and particularly the fact that
cystic fibrosis is often diagnosed in infancy, while classical hereditary haemochromatosis
never is. However, the alternative to this, supplying a choice of different incidence
figures, was considered likely to be less meaningful to most of those answering the
question. The hypothesis that this question was designed to test was that many GPs
consider haemochromatosis a rare condition. Had a scale of incidences been used, it
would have been necessary to make an arbitrary decision about the incidence at which
rarity began. As it was, a large majority (82%) of the responding GPs thought that
haemochromatosis was less common or about as common as cystic fibrosis, whereas,
in fact, C282Y homozygosity occurs at about ten times the incidence of clinical cystic
fibrosis. Notwithstanding the issue discussed in sections 2.5 and 2.6.1, above, whether
the homozygous state for C282Y does or does not equate to haemochromatosis, the
consensus that hereditary haemochromatosis is under-diagnosed makes the question an
important one. The rarity of haemochromatosis was also a recurring topic in the free
comments in response to question 10.
Questions about the diagnosis and clinical presentation of the disease present their
own problems. Exacdy which tests one would perform if one suspected a patient had
haemochromatosis would, of course, depend on the clinical context. The hypothesis
here was that most physicians would be aware of the utility ofmeasuring body iron
stores in assessing a patient with possible haemochromatosis and this was borne out
by the responses. "Genetic test" was included as one of the choices for a laboratory
investigation. The nature of the test was not specified, and its role in diagnosis is
controversial as already discussed. It is probably not surprising and possibly appropriate,
therefore, that only a minority of respondents thought it ofpotential use. The
symptoms and signs in the question about clinical presentation were chosen to cover the
"classical" textbook presentation of advanced haemochromatosis. Again, the criticism of
arbitrariness can be made (and, as one respondent pointed out, no mention is made of
hypogonadism). However, the aim was to assess the extent to which GPs may be relying
on the presence of these symptoms and signs to guide them in their clinical decision¬
making. For each symptom and sign, there was a small minority of respondents who
thought that it was necessary for diagnosis. 121 (47%) of respondents, however, were of
the opinion that none of the four listed was required.
The statements about the natural history and treatment of haemochromatosis were
chosen for their pertinence to screening. Two features of the responses to this question
are remarkable: first, the large minority of respondents to every question who declared
that they did not know the answer. Failure to provide an answer was also interpreted as
"do not know". Secondly, in each of the four constituent parts to the question, the large
majority of those who did answer gave responses that accord with current expert opinion.
The responses to these questions taken together with the comments provided may
support the contention (McDonnell, 1998a and 1998b; Barton, 1997) that there is
scope for increasing the awareness of primary care physicians about haemochromatosis.
Many GPs seem aware that their level of knowledge about the condition could be
improved. This does not, of course, imply that they would see participation in an
education programme as a priority to be included their already packed timetables. As
one respondent commented:
"GPs can't be expected to know all illnesses/conditions in detail"
The small proportion of respondents who had ever suspected a diagnosis of
haemochromatosis in one of their patients may reflect this knowledge deficit or the
perception that it exists. The relatively low level of awareness of haemochromatosis
patients by responding physicians is difficult to interpret in detail as no information
was requested about the means of information gathering. For example, some practices
may have the facility to call up patients with a particular diagnosis from a computerised
database, while others may not have access to such information. Additionally, some GPs
may have preferred to answer the question in terms of their own awareness, regardless
of the availability of a database. However, it supports the contention ofHo (2001)
and others (Merryweather-Clarke, 1998) that the number of known patients with
haemochromatosis is far less than population prevalence studies would suggest.
That skin discolouration featured so prominendy in the list of features that led
respondents to suspect the diagnosis of haemochromatosis in their patients is perhaps
surprising. It is clear from the data presented in table 8.4 that the majority of physicians
are aware that skin discolouration is not a necessary feature in haemochromatosis.
A recent series reported an incidence of skin colouration of only 5% (Bacon, 1997).
Earlier reports suggested that the majority of patients displayed alteration in skin colour,
and the fall in this proportion must reflect earlier diagnosis, as there is a clear correlation
between hyperpigmentation and hepatic iron concentration (Adams, 1997).
Responses to questions on screening illustrated once again the substantial
degree of uncertainty that exists in this population ofhealth professionals about
haemochromatosis and its relevance to their practice. Many of the comments reflected
the degree to which some primary care physicians already feel swamped by among
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other things, demands that they participate in screening programmes. The balance of
the responses suggests that any moves to introduce population screening in primary
care in the UK would require not only a substantial injection of resources but also may
be likely to meet with considerable scepticism among primary care physicians about
its usefulness.
8.7 Conclusion
This study is, at the time ofwriting, the only one to attempt a comprehensive survey
of general practitioners in any part of the UK about haemochromatosis. Despite its
imperfections (discussed above) it has yielded some valuable results and indicated
that there appears to be significant variation in general practitioners' experience and
awareness of this condition. Some are clearly aware of recent advances in diagnosis our
knowledge of pathogenesis, while others are less so. It may be reasonable to assume that
this variability is not confined to physicians in primary care, but may extend also into
secondary and tertiary care. Respondents' comments make plain, however, that dealing
with this variability may not be straightforward. It is not clear, for example, what the
uptake would be ofany physician education programme that was introduced.
The debate about wider population screening continues. It is clear that many physicians
in primary care in the UK remain to be convinced about its utility.
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9. Concluding Comments
The last decade has seen huge progress in our understanding of both the genetics of
inherited iron overload and also of the molecular mechanisms responsible for the
regulation of iron absorption and storage in the body in both health and disease.
The identification of the genetic basis for the most common form ofhereditary
haemochromatosis led initially to widespread calls for the development of a programme
ofpopulation screening to enable the detection of affected individuals early in the course
of the disease, before the development ofany permanent organ damage caused by iron
overload. In recent years, however, the early enthusiasm for population screening has
waned with the realisation that the penetrance of the C282Y mutation ofHFE appears
to be very low. It is, nonetheless, clear that it is vital to identify those individuals who
are accumulating iron early in the course of the disease if treatment is to be effective
at preventing morbidity and mortality from iron overload. An increased awareness of
haemochromatosis among healthcare personal may be crucial in ensuring that this can
occur.
The extent to which information about progress in understanding iron overload has
permeated the healthcare community is, however, uncertain. Research in the United
States has demonstrated that considerable ignorance about the diagnosis, natural history
and treatment ofhereditary haemochromatosis persisted among healthcare workers in
the late 1990s. It is difficult to be certain how well informed British health care workers
are about hereditary haemochromatosis. The survey of general practitioners presented as
part of this thesis suggests that there is wide variation in awareness of iron overload and
in willingness to be involved in any screening programme that might be proposed. This
provided a useful and interesting snapshot ofopinion - and it is probably reasonable
to assume that general practitioners in the southeast of Scodand would not differ
dramatically in their answers from those elsewhere in the UK. However, whether such
surveys are a valid tool to estimate detection rates and outcomes of haemochromatosis
patients in the practices of those surveyed is by no means certain, as remarked upon by
at least one of the respondents. It is this information that is crucial in the planning of
any future public health strategies targeting hereditary haemochromatosis.
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Speculation about the reasons for the continuing high prevalence of the C282Y
mutation in the population of northern Europe has been focussed on the possibility that
it may provide some measure ofprotection against iron deficiency and therefore afford
carriers some evolutionary advantage. It is difficult in practice to demonstrate that this
is the case, and the findings presented in this thesis did not show any differences in the
prevalence of the various HFE genotypes in an iron deficient and a non iron deficient
population. Furthermore it has become clear that it is not feasible to take advantage
of the putative iron retaining tendencies of heterozygotes for C282Y to provide a
population of blood donors who are able to donate more frequendywithout themselves
becoming deficient in iron.
The results of iron studies and HFE genotyping among patients undergoing coronary
angiography found in this work make a useful addition to the debate on whether iron
and/or C282Y heterozygosity is a risk factor for coronary artery disease. The difficulty
in controlling for other coronary risk factors goes some way to explaining the conflicting
results produced by the various studies that have examined this question, but the
balance may be moving against the hypothesis that either of these two variables is a
significant risk factor. In principle, it is iron which is not bound to transferrin in the
circulation that might be expected to be most active in the promotion of tissue damage,
and it is interesting that no correlation was found in the work presented here between
non-transferrin bound iron and the severity ofcoronary artery disease (albeit with the
methodological caveats set out in chapter 7 of the thesis).
The role of iron and, by extrapolation, of the HFE mutations in other pathological
states has been widely examined in the decade since the discovery ofHFE. It is, of
course, well known that the liver is particularly prone to damage in patients with
untreated hereditary haemochromatosis. The extent to which undiagnosed hereditary
haemochromatosis may be contributing to liver damage in patients coming to
orthotopic liver transplantation is illustrated by the results ofHFE genotyping of the
patients transplanted in the Scottish Liver Transplant Unit presented as part of this
thesis. This is important not only to allow the identification ofpatients who may be
at risk of reaccumulation of iron after transplantation, but also because of considerable
evidence that patients with hereditary haemochromatosis may be more prone to
complications after liver transplantation than patients with other causes ofhepatic
failure, notwithstanding the failure of the results presented in this thesis to demonstrate
such a less favourable outcome.
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The role played by HFE in normal and pathological iron metabolism remains
tantalisingly unclear. When eventually, the mechanisms are teased out, it may become
clearer at the molecular level whether or not C282Y is likely to contribute to iron-
mediated tissue damage. Many further cohort and population-based studies will
doubdess also continue to add to our knowledge in this area.
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Appendix 1:
Information sheet for donors
As a blood donor, you provide a vital support to the Health Service. Without donated
blood, many operations could not go ahead, and the treatment of some illnesses, such as
leukaemia, would be impossible. The amount of blood needed is continuing to increase,
and we are looking for ways to increase the amount which is donated.
Your contribution as a regular donor is gready appreciated and your comfort and safety
during the process of donating are of the highest importance to us. As you know,
donors are currently allowed to donate red cells only once every three months. The
reason for this is, that with every donation of red cells you make, you lose a certain
amount of iron from your body. Your body responds to this by increasing the amount of
iron which is absorbed from food and drink, to make up for what has been lost. Ifyou
continue to lose iron, the absorption from food and drink may not be able to keep up,
and your body may become deficient in iron. This may result in anaemia.
It is possible that some people have a greater ability than others to make up for this
iron loss of blood donation. This may be related to genetic make-up. We would like
to know more about the relationship between the genetic make-up, blood iron levels
and blood donation, and hope that this information may be useful in determining how
often any given donor can donate. We are asking you to consider helping us in this by
participating in a study which will gather the required information over the course of
your next few donations.
The "iron" gene
A gene has been found which is involved in determining how much iron your body
takes up from food. About 10% of the population have a change in this gene, which
seems to have no harmful effects and, indeed, might afford protection against becoming
deficient in iron. However, some people (fewer than 1%) have a double dose of the
changed gene, and they are at risk of developing illness due to iron overload in the long
term. If, as a result of taking part in this study, you were shown to have the double
gene, we would refer you to a specialist to see whether any further investigation might
be necessary. (It could be argued that this is a benefit of screening, but there is still some
doubt about the long-term significance of the double gene when it is picked up by
chance in this way.)
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What we are asking you to do
We would like you to agree to let us have an extra blood sample prior to each of your
next few donations, so that we can monitor your exact haemoglobin and iron levels
and we will carry out the tests for the "iron" gene and compare results. This will tell us
whether it will be possible to use these tests to predict who can donate most frequendy,
and who is at risk of anaemia from donating.
Ifyou take part, you will be given a specific appointment date and time for your next
donation (to fit in with what is convenient for you — it should also save some time). You
will not have to queue when you arrive. Instead of checking your haemoglobin from a
finger-prick as at present, we will take a small (15 mis or 3 teaspoonsful) blood sample
from a vein in your arm before you give blood. We will use this sample to check your
haemoglobin before you donate and also to check your iron levels and analyse the gene
referred to above.
In all other respects, your visit will be the same as usual. Ifyou have the changed gene,
this will be discussed with you at the end of the study.
Ifyou decide to take part in the study, we will tell you General Practitioner ifwe find
any evidence that you may be at risk of iron overload, or if you become anaemic. You
must not feel under any pressure to take part. Ifyou decide not to, your donations will
be treated in exacdy the same way as usual, and you will continue to receive the best care
we can give while you are here.
Ifyou would like to speak to a doctor who is not involved in the study about any aspect
of it, please contact:
Dr P L Yap, Consultant, Edinburgh Blood Transfusion Service. Tel: 0131 536 5302
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Appendix 2:
Questionnaire for Participants in
Study of Blood Donors' Iron Levels
1. What is your weight (in stones and pounds or kilogrammes)?
2. Approximately how many times in a typical week do you eat red meat (ie beef, pork,
lamb, sausages, ham, bacon, etc)? Count each meal that contains red meat as "one".
3. Are you taking iron tablets or vitamin pills at the moment? If so, please give the
name of the tablets and the number you take per day.
4. Have you, as far as you remember, taken iron or vitamin tablets
during the last two years?
Ifyou answered "YES" to Q. 4:
5. How long did you take them for?
6. What were they called? (if you can remember)
THANK YOU FORYOUR HELP
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Appendix B:
Letter to C282Y heterozygotes
Dear Donor
Iron Study
Thank you very much for participating in this study. Whether you gave only one or
up to five donations in the study, you provided valuable information. We will be in a
position to let everyone know what we found in the next few weeks.
I would like to let you know that, when we tested you, we found that you have inherited
one changed copy of the gene we were looking at. This gene controls how much iron
the body takes from the diet. You have two copies of this (and all other genes). Ifboth
copies are changed, there is a risk of the accumulation ofpotentially harmful amounts
of iron in the body. However, in your case, where one copy only is changed, there is no
evidence that you are at risk from a build up of iron. In fact, having one changed copy
of the gene seems to have no consequences at all for your health. It is quite common in
the general population (about 12% of the Scottish population have it).
You can pass on this changed copy of the gene to your children. For them, as for
you, there will be no ill-effects if they inherit only one changed copy. However, as the
changed genes are quite common, there is a possibility that your partner may also have a
changed gene. In this case, your children could inherit a changed gene from both ofyou,
and therefore be at increased risk of iron accumulation.
It may be that you will wish to find out whether this might be the case with your
children. One step you could consider would be to ask your partner if she would be
prepared to be tested for the changed gene. This can be arranged through your GP. I
enclose a letter for you to take to your GP ifyou would like to proceed with this. If
your partner does not have the changed gene, your children should not be prone to
excess iron accumulation.
Please note that the test results take 2-3 months to come back. Any health effects from
excess iron take 20 or more years to occur.
>
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Ifyou have any questions about this, please address them to Dr J Gillon, Consultant










Letter to General Practitioner
of C282Y heterozygotes
Dear Doctor
Your patient has participated in a study we were running to look at iron stores and
haemochromatosis (HFE) gene mutations in blood donors. You received notification of
this in autumn 1999.
Your patient has been found to be heterozygous for the C282Y mutation in the HFE
| gene. Homozygosity for this mutation predisposes to the development of hereditary
haemochromatosis. Heterozygosity, however, has not been shown to have any harmful
effects at all.
About 12% of the local population are heterozygous. There is therefore a significant
chance that your patient s partner (if he has one) is also heterozygous. In this situation,
there would be a 50% chance of any children being homozygous, and so potentially
affected by haemochromatosis.
Ifyou patient s partner would like to be tested, this can be done by sending a red topped
(full blood count) tube to the Department of Haematology at the RIE. We forward the
sample to Dundee for analysis, and results usually take 2-3 months to return.
If you patient wishes his children tested, this can be arranged in the same way. We
I would not recommend genetic testing on any children less than 18 years old (iron
overload virtually never causes any clinical problems before the mid 20s).
If anyone requires counselling about results of these tests, this can be arranged by referral
to Dr PRE Johnson, Consultant Haematologist, Western General Hospital, Edinburgh.
Ifyou require further information, please contact Dr J Gillon.
Yours faithfully
Andrew Stewart Jack Gillon
Specialist Registrar in Haematology Consultant Physician
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Appendix 5:
Letter to Participants wild-type for C282Y
Dear Donor
Iron Study
Thank you very much for participating in this study. Whether you gave only one or
up to five donations in the study, you provided valuable information. We will be in a
position to let everyone know what we found in the next few weeks.
I would like to let you know that when we tested you, we found no evidence that you
should be prone to accumulate excess iron in your body.
Ifyou have any further questions about the study, please address them to Dr J Gillon,
Consultant Physician, South East Scotland Blood Transfusion Service, Lauriston
Building, Lauriston Place, Edinburgh.
Yours faithfully
Andrew Stewart
Specialist Registrar in Haematology
181
Appendix 6:
Information sheet for patients participating
in coronary angiography study
There are a large number of factors which can contribute to the development of disease
or narrowing of the arteries which supply the heart. Some of these, such as smoking, are
very well known, but many others have been suggested. We would like to invite you to
take part in a study to look at whether there is a connection between the amount of iron
stored in the body and the development of heart disease.
Iron is taken into your body from food and drink. The amount taken in each day
is normally closely controlled, so that only what is needed is absorbed. A recendy
discovered gene seems to be involved in this control mechanism. Changes in this gene
are quite common, and may affect the amount of iron which is stored in the body. The
effect on the amount of iron stored is nearly always very small, and we do not think that
it has any effect on health at all. A very small number of people do have a larger change
in the gene, which causes the build-up of large amounts of iron in the body.
Ifyou take part in the study, all that will happen is that some extra blood (about 3
teaspoonsful) will be taken along with the blood tests you will be having anyway to
prepare you for your angiogram. We will use this blood to test for the amount of iron
stored in your body and to look for any changes in the iron control gene. The blood
samples we use for the study will be identified by a code number, which means we will
not know whose blood we are testing. You will, therefore, not receive any results from
this study, and no results from it will be entered into your medical records.
You are completely free not to agree to have this extra sample taken. Whether you
take part in the study or not will not affect in any way the care you receive, the way the
angiogram is performed or the treatment of the results of the angiogram.
Ifyou would like to speak to a doctor who is not involved in this study about any aspect




The Hardy-Weinberg equilibrium states that:
In the absence ofmutation non-random mating, selection and genetic drift, the genetic
constitution of the population remains the same from one generation to the next.
The Hardy-Weinberg equation relates the frequencies of a normal gene (p) and that of its
abnormal counterpart (q) in a population:
p + q= 1
p2 + 2pq + q2 = 1
Here, p2 is the frequency of the normal homozygote, q2 the frequency of the abnormal
homozygote and 2pq the frequency of the heterozygote.
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Appendix 8:
Questionnaire for GP survey
1. What is the list size of your practice?
□ <3000 □ 3000-6000 0 6000-9000 □9000-12000 □ >12000
2. How many patients with haemochromatosis, if any, are there in your practice?
3. Compared with cystic fibrosis, do you think haemochromatosis is (please tick one):
□ Commoner □ about as common □ rarer
4. Which of the following would be of use in confirming the diagnosis of
haemochromatosis: (please tick as many as you wish)
□ Full blood count □ ferritin □ U&E
□ serum iron/TIBC □ genetic test
5. Please indicate whether or not the following symptoms and signs are necessary for a
diagnosis of haemochromatosis:
Skin discolouration □ necessary □ not necessary
Abnormal LFTs □ necessary □ not necessary
Diabetes □ necessary □ not necessary
Arthritis □ necessary □ not necessary
6. Please indicate whether you agree or disagree
with the following statements about haemochromatosis:
Early treatment restores normal life expectancy
□ agree □ disagree □ don't know
If untreated, it is often fatal
□ agree □ disagree □ don't know
Treatment involves use of expensive drugs
□ agree □ disagree □ don't know
Younger patients are often asymptomatic






7. Have you ever suspected that a patient may have haemochroatosis?
□ YES □ NO
8. Ifyou answered "yes" to Q.7, what led you to suspect haemochromatosis?
9. Would you see a screening programme for haemochromatosis as
(you may indicate more than one)
• A useful addition to the work ofPrimary care □ agree □ disagree
• Something ofno relevance to Primary care □ agree □ disagree
• An extra burden on Primary Care □ agree □ disagree
10. Any other comments?
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Appendix 9:
Raw data from studies reported in Chapter 5










1 41 F 141 7.0 293 97 5
2 32 F 133 8.9 330 94
3 38 F 123 6.8 308 91 1
4 39 F 128 5.8 257 98 1
5 37 M 131 5.2 208 96 1
6 69 F 135 5.3 322 91 1
7 32 F 118 4.4 251 94 1
8 64 M 144 7.6 254 88 1
9 62 F 147 7.5 291 95 1
10 70 M 142 5.9 227 91
11 55 F 131 7.4 271 85 1
12 50 F 126 5.1 309 91 1
13 31 F 119 5.7 233 82 1
14 63 M 144 7.8 333 85 3
13 44 F 130 5.4 164 96 3
16 50 F 137 5.5 195 89 2
17 44 M 154 5.7 201 93 5
18 25 F 135 5.9 194 91 6
19 87 F 132 9.4 251 92 5
20 17 F m 120 9.5 282 91 2
21 29 F 137 7.2 214 92 5
22 47 M 146 8.5 183 89 1
23 59 F 129 8.8 293 92
24 51 F 139 7.9 263 93
25 64 F 137 5.1 223 94 1
26 34 F m 135 5.3 285 88 1
27 77 F 138 5.4 233 89 1
28 65 M 150 6.8 228 92 1
29 89 F 129 8.8 308 89 2
30 61 M 134 6.8 174 85 1
































































































































































69 62 M 137 5.3 325 89 1
70 68 M 131 7.5 267 85 3
71 88 F 137 6.2 307 91 1
72 71 M 137 4.9 185 91 1
73 58 M 142 5.8 290 91 1
74 64 F 128 4.8 247 88 1
75 35 F 125 7.2 234 93 1
76 79 F 139 7.1 232 93 1
77 46 M 137 4.3 285 93 1
78 39 F 126 5.3 227 91 3
79 48 F 127 5.2 252 94 1
80 74 F 129 6.7 326 94 1
81 24 F 142 6.0 272 93 1
82 48 M 142 8.1 238 95 1
83 33 M 136 7.3 312 91 1
84 32 F 116 7.0 167 86 1
85 40 M 147 6.8 341 89
86 47 M 154 7.5 178 99 1
87 54 M 142 7.7 214 92 1
88 75 F 126 7.0 230 95 3
89 39 M 154 5.7 211 93 3
90 14 M 130 7.6 353 83 3
91 22 F 135 5.9 264 88 1
92 82 F ■ 115 7.0 364 87 1
93 41 M 158 4.5 218 94 3
94 71 F 136 7.9 263 93
95 54 M 136 6.6 259 90 1
96 30 F 136 7.4 385 92 1
97 67 F 116 5.2 218 94 3
98 22 F 143 7.6 273 92 3
99 51 F 129 6.1 243 91
100 29 M 146 5.4 329 94 3
101 74 F 145 6.6 306 95 3
102 45 M 150 5.5 231 88 1
103 48 F 117 6.3 378 92 1
104 32 F 125 5.7 241 88 1







































Age Sex Hb (g/L) WCC Platelets MCV (fL) Genotype
(years) (109/L) (109/L)
16 F 116 7.4 318 82
55 F 132 7.8 272 90
42 F 130 8.6 253 98
82 M 134 6.6 272 92
61 F 135 4.9 267 92
31 F 139 5.4 264 91
65 F 141 6.5 186 84
31 F 135 6.5 374 91
44 F 145 6.9 276 96
45 M 155 5.2 185 88
84 F 131 5.0 192 87
55 F 151 8.0 173 91
67 M 146 8.0 269 92
72 F 132 5.9 343 95
71 F 125 5.6 254 93
78 M 135 8.6 244 90
51 F 135 9.6 327 92
45 M 155 7.9 209 86
70 F 128 9.1 324 91
41 F 138 7.7 331 91
50 F 123 7.5 232 92
91 F 126 8.8 232 81
83 F 123 5.7 302 95
62 F 123 8.4 257 94
28 F 126 4.7 242 86
61 F 144 5.8 162 90
49 F 132 6.0 311 91
47 M 143 5.5 252 91
30 M 167 6.2 237 88
30 M 134 9.8 270 89
22 F 120 7.5 327 98
22 F 123 6.1 249 91
55 F 123 6.5 244 87
71 F 134 7.3 223 88
75 M 159 7.3 196 91
25 M 152 9.0 241 79











143 72 F 143 6.1 282 91 1
144 36 F 119 6.0 203 88 1
145 53 F 124 6.2 203 88 1
146 51 F 146 5.3 247 89 1
147 48 M 142 11.0 230 89 2
148 59 M 136 7.4 242 90
149 60 M 159 9.6 214 87 3
150 28 F 127 6.0 150 96 1
151 74 M 152 9.9 277 86 3
152 80 F 122 6.8 281 100 1
153 30 F 137 89 285 89 1
154 26 F 115 7.7 259 86 1
155 41 M 134 10.0 280 89 1
156 54 F 136 8.9 212 91 3
157 18 M 157 8.4 243 83 1
158 44 F 131 7.4 305 94 1
159 55 M 157 7.6 354 94 3
160 19 F 117 7.6 281 89 1
161 55 F 139 7.0 288 94 3
162 73 M 141 10.5 293 90 1
163 59 F 115 6.6 198 89
164 45 M 135 4.6 306 92 1
165 84 F 119 8.0 294 99 3
166 39 M 143 4.7 246 89 3
167 88 F 117 7.7 318 95 1
168 36 F 129 6.0 318 89 1
169 55 M 143 73 332 84 1
170 60 F 144 8.4 256 89 3
171 59 F 121 6.2 294 93 1
172 81 F 139 4.6 214 88 1
173 60 F 127 7.5 230 93 1
174 65 F 115 7.1 277 92 1
175 60 F 128 5.4 268 86 1
176 41 M 137 9.3 189 84 3
177 59 F 136 7.7 281 89 1
178 48 M 146 6.1 248 91 3
179 78 F 124 5.7 305 93 3
190
Study Age Sex Hb (g/L) WCC Platelets MCV (fL) Genotype
number (years) (109/L) (109/L)
180 58 F 128 4.9 252 94 3
181 49 F 131 6.0 294 93 3
182 62 M 150 5.3 175 88 1
183 54 F 125 7.8 310 83 1
184 27 F 124 6.5 217 94 1
185 33 F 140 8.9 215 94 1
186 43 M 139 5.9 167 85 2
187 38 M 153 5.4 229 92 3
188 56 F 127 7.9 252 91 3
189 18 F 116 6.5 247 92 1
190 46 M 148 7.1 212 99 1
191 30 F 119 6.8 279 90 1
192 85 F 138 5.1 190 89 3
193 38 F 127 6.7 255 89 2
194 40 M 144 6.3 260 91 1
195 18 F 118 83 343 93 1
196 69 F 116 5.7 270 87 1
197 31 F 124 8.2 165 96 1
198 24 F 131 7.4 358 91 1
199 53 F 134 7.9 316 97 5
200 74 F 132 6.9 36 83 1
201 36 M 150 9.2 264 94 3
202 67 M 139 6.1 180 91 3
203 35 F 131 7.8 215 89 1
204 37 F 121 5.5 188 92 1
205 62 M 135 8.0 241 95 2
206 62 M 152 7.4 219 95 1
207 39 F 137 8.6 256 89 1
208 85 F 121 6.8 344 97 1
209 52 F 138 7.5 210 92 2
210 77 F 118 5.9 238 82 1
211 39 F 132 10.2 305 96 1
212 18 F 125 7.3 254 84 1
213 35 F 134 5.9 198 94 1
214 20 F 133 53 276 95 1
215 68 F 135 8.5 383 91 1
216 22 F 132 6.6 392 90 1
>
191
Study Age Sex Hb (g/L) WCC Platelets MCV (fL) Genotype
number (years) (109/L) (109/L)
217 70 F 147 6.9 253 90 1
218 30 M 139 9.9 297 93 3
219 22 M 158 5.1 269 88 1
220 70 F 137 5.3 257 91 2
221 78 F 141 8.8 319 89 1
222 62 F 151 8.4 352 89 5
223 36 F 131 7.8 372 94 3
224 43 F 137 7.4 185 90 1
225 37 M 138 6.6 245 86 3
226 41 F 124 8.7 291 86 1
227 37 F 137 7.6 244 93 3
228 49 M 151 6.6 269 92 1
229 46 M 133 5.1 266 92 1
230 45 M 149 8.0 254 91 1
231 21 F 140 5.2 237 93 3
232 71 M 139 5.4 271 96 2
233 70 F 149 9.2 355 90 3
234 20 M 141 7.6 224 95 1
235 67 M 145 6.5 177 90 1
236 nm F 131 7.2 301 92 1
237 78 F 119 6.9 331 93 3
238 82 F 142 5.9 206 95 HDH
239 77 F 115 5.8 278 94 i
240 60 F 147 6.5 237 96 i
241 57 M 154 6.9 253 87 i
242 54 F 130 6.6 240 95 i
243 85 F 130 7.9 255 99 i
244 20 F 125 5.7 305 90 i
245 72 F 126 7.2 269 90 i
246 32 F 125 7.7 394 91 HEH
247 32 F 124 8.0 242 83 i
248 69 F 128 7.6 292 89 3
249 34 F 144 6.4 258 92 1
250 44 F 138 6.9 318 98 2
251 55 M 157 8.2 215 86 1
252 32 F 136 10.4 251 83 1












254 67 F 119 7.2 227 95 3
255 56 F 139 6.7 295 89 3
256 33 M 155 6.0 259 88 3
257 73 F 133 4.8 247 93 hbh
258 37 F 117 7.7 333 86 i
259 68 F 121 9.3 292 90
260 66 F 129 7.9 264 95 i
261 59 F 129 5.0 289 94
262 65 F 131 5.5 269 86 i
263 70 F 117 6.2 329 85 i
264 19 F 126 5.7 234 89
265 22 M 143 10.6 295 89 i
266 37 M 152 7.8 198 87 i
267 33 M 134 10.2 253 96
268 28 F 125 7.4 362 92 i
269 19 ■ M 139 8.7 179 bhu
270 63 F 118 6.4 325 84 i
271 90 M 146 8.4 281 91 i
272 28 F 116 6.8 277 88 i
273 38 F 139 8.3 235 92 i
274 38 F 123 8.0 245 84 i
275 29 F 148 6.1 276 82
276 66 F 162 5.8 247 97 i
277 30 F 119 8.4 316 87 i
278 49 M 137 7.7 259 95 i
279 57 F 128 6.4 389 98 i
280 52 F 116 73 315 99
281 77 M 134 7.6 241 97 i
282 73 F 136 6.5 264 92 i
283 61 M 159 5.6 245 93 i
284 22 F 124 7.4 258 92 2
285 54 F 155 7.3 207 95
286 66 F 115 9.6 273 86 1
287 46 F 144 7.5 305 92 3
288 31 F 130 4.6 302 95 3
289 26 M 142 7.3 230 91 2

























































































































































Study Age Sex Hb (g/L) WCC Platelets MCV (fL) Genotype
number (years) (109/L) (109/L)
328 58 F 132 4.9 291 94 1
329 69 M 134 6.6 209 86 1
330 54 F 143 8.7 331 99 1
331 69 M 143 9.1 313 94 1
332 60 F 130 5.9 190 88
333 78 F 136 5.9 193 96
334 69 F 116 8.2 252 88 1
335 33 F 125 9.9 382 92
336 56 F 140 7.2 265 85 1
337 54 F 150 9.6 344 93 1
338 19 F 128 7.3 243 87 1
339 70 F 128 5.2 273 90 1
340 42 M 153 4.9 223 85 4
341 32 F 139 5.8 293 92
342 33 F 133 6.3 229 96 5
343 62 F 124 7.5 395 98 1
344 41 F 125 5.8 277 89 3
345 73 F 127 5.8 281 89 1
346 58 F 134 8.1 317 90 1
347 41 F 133 6.8 233 97 1
348 62 F 122 6.8 298 100 2
349 79 M 158 8.9 264 97 2
350 81 M 141 5.5 186 83 3
351 00 F 125 5.4 263 89 3
352 34 F 130 6.8 157 95 2
195
B. Iron deficient subjects
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
1 52 F 84 3 1
2 11 F 98 2 1
3 78 F 105 9 1
4 51 F 109 5 1
5 47 F 88 3
6 29 F 73 2 1
7 43 F 93 6
8 65 F 104 4
9 90 M 67 7 3
10 43 F 92 4 3
11 35 F 103 3 3
12 77 F 93 5 3
13 39 F 90 7 1
14 38 F 100 4 1
15 24 F 83 5 2
16 35 F 96 3 1
17 72 F 93 5 1
18 30 M 104 3 1
19 62 F 69 10 3
20 29 M 91 3
21 50 M 124 7
22 83 F 86 6 3
23 67 M 119 7
24 36 M 99 3 1
25 45 F 110 8
26 78 F 79 7 2
27 43 F 103 5 1
28 43 F 123 5 2
29 32 F 113 6
30 91 F 82
31 80 F 99 7 1
32 64 F 143 13
33 76 M 138 9 1
196
Study number Age (years) Sex Hb (g/L) Ferritin (jrg/L) Genotype
34 44 F 90 3 3
35 44 F 112 3
36 50 F 98 3 3
37 36 F 83 5 3
38 82 M 86 13 3
39 36 F 88 4 1
40 60 M 69 5 3
41 17 F 123 7 1
42 37 F 77 3
43 37 F 121 13
44 18 F 98 4 1
45 79 F 44 7 1
46 51 F 104 4 1
47 38 M 101 3
48 23 F 70 5 3
49 68 M 146 13 1
50 30 F 109 5 1
51 70 M 77 12 1
52 F 50 99 10
53 36 F 102 5 1
54 41 M 56 6
55 39 F 96 3 1
56 77 M 87 10 1
57 41 F 89 4
58 28 F 97 7 1
59 70 F 87 7
60 68 F 51 2 1
61 59 F 94 6
62 34 F 104 4 1
63 48 F 107 7 1
64 27 M 116 5 1
65 86 F 98 8
66 61 F 99 4 1
67 32 F 118 8
68 35 F 88 3 1
69 73 F 93 6
70 44 F 95 4 1
I
197
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
71 51 F 104 6 1
72 73 F 103 4 1
73 70 M 103 10 1
74 81 F 109 8 1
75 41 F 88 3
76 66 F 78 8 1
77 45 F 114 3
78 39 F 77 3 1
79 53 F 105 9 1
80 72 F 104 4
81 34 F 107 4
82 31 M 115 10
83 79 F 52 8 1
84 83 F 75 11
85 65 F 111 11 1
86 85 F 68 11 3
87 51 F 99 11 1
88 65 F 123 13
89 58 F 91 13 1
90 39 F 115 13 1
91 25 F 101 11 1
92 53 F 108 10
93 22 F 111 8 2
94 29 F 105 5 3
95 65 M 65 2 1
96 50 F 55 12 1
97 49 F 101 4 1
98 49 F 108 4 3
99 51 F 104 12 1
100 31 F 93 4 3
101 35 F 97 5 1
102 48 F 111 12 1
103 50 F 111 8 5
104 57 M 92 4 1
105 79 F 98 13 1
106 74 F 114 8
107 76 M 104 7
)
198
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
108 68 F 109 8 1
109 87 F 96 13
110 79 M 97 7 3
111 77 M 101 7 3
112 51 F 103 7 1
113 38 F 72 3 1
114 10 F 112 3 3
115 51 F 109 6 1
116 87 F 73 11
117 28 F 98 5 1
118 49 M 103 6
119 49 M 116 12
120 88 F 77 6 1
121 51 F 67 6 1
122 30 F 109 5 1
123 88 F 84 8 1
124 35 F 113 10 1
125 24 F 127 9 j
126 76 F 87 7 1
127 78 F 51 5
128 73 F 125 12 2
129 83 F 98 9 1
130 26 F 106 6 1
131 19 F 72 3
132 45 F 94 3 1
133 23 F 111 4 1
134 52 F 105 5 1
135 69 F 88 7
136 41 F 129 9 1
137 36 F 79 7 1
138 87 F 88 11 1
139 74 M 114 5 1
140 87 M 103 11 1
141 77 F 94 9 1
142 37 F 109 7 3
143 77 M 89 5 1
144 40 F 84 3 1
199
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
145 90 F 70 5 1
146 71 M 103 10
147 52 F 94 6 3
148 15 F 112 4 1
149 40 F 111 2 3
150 70 F 79 5 3
151 82 M 73 7 3
152 71 M 93 6 1
153 78 F 76 9 1
154 41 F 97 6 3
155 76 M 113 14 3
156 69 F 94 5 2
157 43 F 88 4 1
158 40 F 101 1
159 56 M 80 7 2
160 88 M 99 8
161 83 F 75 13 3
162 80 F 95 12
163 15 F 93 5 3
164 47 F 105 6
165 40 F 12 5 1
166 86 M 99 11 2
167 30 F 93 3 1
168 29 F 79 3 1
169 70 M 82 8 1
170 82 F 98 10 3
171 47 F 97 6 3
172 76 F 72 6 1
173 40 F 116 6 1
174 30 F 104 10 1
175 50 F 63 6 6
176 43 M 99 7 1
177 52 F 79 3 1
178 23 F 109 7 5
179 86 F 60 10 1
180 63 F 84 9 2
181 65 F 112 7 1
200
Study number Age (yean) Sex Hb (g/L) Ferritin (jxg/L) Genotype
182 57 F 145 14 2
183 19 F 118 13 1
184 61 F 63 5 3
185 37 F 102 14 3
186 46 M 130 8 3
187 40 F 90 5 3
188 54 F 111 6 1
189 43 F 137 10 1
190 75 F 88 12 1
191 79 F 83 3 1
192 28 F 124 12 1
193 93 108 11 3
194 48 M 101 6 6
195 31 F 107 5 3
196 18 M 91 7 3
197 44 F 104 5
198 49 M 89 4 1
199 57 F 96 5 3
200 92 F 88 9 1
201 86 F m 61 11 1
202 37 F 111 8 1
203 62 F 115 12 1
204 90 F 82 6 1
205 62 F 125 10 3
206 45 F 106 7 1
207 76 M 96 6 2
208 70 F 106 11 1
209 51 F 103 5 2
210 29 F 124 10 1
211 42 F 106 4 1
212 39 F 118 6 1
213 37 F 101 3 1
214 31 M 109 7 3
215 62 M 93 10 3
216 78 F 105 10 1
217 82 F 88 8 3
218 91 M 99 10 2
201
Study number Age (years) Sex Hb (g/L) Ferritin (|ig/L) Genotype
219 77 F 91 7 3
220 89 M 92 12 1
221 59 F 96 4 3
222 50 F 109 5 3
223 40 F 102 5 3
224 91 F 78 9 1
225 41 M 153 10 2
226 35 F 99 3 2
227 46 F 81 3 2
228 72 M 70 4 1
229 46 F 99 4 1
230 40 F 92 4 1
231 36 F 95 7 1
232 45 F 96 5 1
233 37 F 133 9 1
234 40 F 111 2
235 29 F 89 2
236 68 M 77 6 1
237 81 F 107 14 1
238 22 F 124 5 1
239 91 F 90 13 1
240 52 F 78 5 1
241 48 F 76 4
242 48 F 66 7 1
243 66 F 99 8
244 47 F 108 4 1
245 47 F 100 3 1
246 88 M 105 12
247 48 F 114 4 1
248 49 F 92 6
249 60 M 93 8 1
250 41 M 79 6 1
251 21 F 105 5 1
252 28 F 105 4 1
253 35 F 104 3 1
254 83 F 109 9 1
255 66 F 96 7 1
►
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Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
256 35 F 97 11 3
257 86 F 94 13 5
258 77 M 76 5 1
259 44 F 87 4 1
260 37 M 76 14
261 81 F 76 14 1
262 88 F 71 7 1
263 32 F 81 8 1
264 78 M 114 8 1
265 38 F 101 4 1
266 43 F 99 4 1
267 36 F 108 4 1
268 79 F 83 6 1
269 51 F 98 6 1
270 78 M 87 5 1
271 48 F 91 6 3
272 72 M 118 5 1
273 90 F 70 12 1
274 47 F 105 4 1
275 46 F 85 3 1
276 52 F 115 8 1
277 21 M 118 5 1
278 47 F 86 3 3
279 51 F 94 7 3
280 40 F 129 7 3
281 41 F 112 4 3
282 36 F 124 5 3
283 65 F 99 4 1
284 25 M 110 5 1
285 45 F 96 4 1
286 81 F 54 4 1
287 88 F 106 8 1
288 87 F 101 8 1
289 43 F 110 4 1
290 72 M 113 14 2
291 87 F 55 11 1
292 47 F 106 4 2
203
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
293 43 F 109 7 2
294 80 F 105 7 1
295 55 M 88 4 3
296 73 F 86 4 1
297 85 F 101 10 3
298 68 F 97 12 3
299 47 F 131 5 1
300 73 M 129 11 1
301 78 F 117 13 1
302 48 F 99 3 3
303 31 F 111 4 3
304 29 F 72 2 3
305 65 F 126 10 2
306 79 F 107 6 1
307 29 F 123 4 1
308 39 F 103 3 1
309 41 F 104 4 1
310 18 F 100 3 >
311 86 F 98 10 1
312 36 F 121 9 1
313 41 F 96 2
314 77 F 103 9 1
315 74 M 98 14
316 60 M 87 4 1
317 45 F 91 9 1
318 74 F 105 8 1
319 35 F 107 4 1
320 77 F 114 9
321 52 F 106 5
322 79 F 86 10 1
323 47 F 105 7 1
324 16 M 135 8 1
325 31 F 92 6 1
326 89 F 68 5 1
327 79 F 102 10 1
328 69 M 72 5 1
329 44 M 76 8 1
204
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
330 42 F 78 3 3
331 88 F 99 9 2
332 86 F 95 12 1
333 68 F 109 9 1
334 72 F 82 4
335 75 M 118 10 1
336 30 F 110 3 1
337 45 M 89 13
338 48 F 96 5 1
339 41 F 88 3 1
340 50 F 106 5
341 86 F 109 9
342 43 F 124 4
343 66 F 106 9 1
344 48 F 122 10 ?
345 46 F 96 3 5
346 45 F 122 12 1
347 45 F 107 4
348 30 F 95 4 1
349 52 F 99 5
350 35 F 101 5
351 42 F 149 6 >
352 35 F 124 8 5
353 78 M 86 6 1
354 86 F 115 8 2
355 50 F 108 3 3
356 82 F 92 11 3
357 42 F 102 4 1
358 78 M 125 7 3
359 87 F 81 7 1
360 90 F 74 11 1
361 3 M 113 6 3
362 47 F 94 6 1
363 77 M 108 6 1
364 76 F 106 6 >
365 72 M 89 9 3
366 90 F 94 11 1
205
Study number Age (years) Sex Hb (g/L) Ferritin (jrg/L) Genotype
367 29 M 135 9 1
368 68 F 106 6 1
369 49 F 113 5 1
370 70 F 94 7 1
371 91 M 76 10 2
372 20 F 86 5 3
373 39 M 106 3 1
374 85 F 125 12 6
375 82 F 108 11 6
376 44 F 116 10 *
377 68 F 11 6 1
378 42 M 129 12 1
379 40 F 113 11 1
380 82 F 99 8 1
381 44 F 92 3 1
382 78 F 96 5 1
383 54 F 126 8 1
384 24 F 94 7 1
385 63 F 111 6 1
386 78 F 70 7 1
387 85 F 71 4 >
388 35 F 120 6 1
389 39 F 124 12 2
390 41 F 107 6 1
391 78 M 90 5 6
392 80 M 117 13 1
393 84 M 100 4 12
394 40 F 101 4 2
395 71 M 107 9 3
396 63 M 111 4 2
397 56 M 96 2 1
398 48 M 112 6 1
399 40 M 117 2 3
400 30 F 116 5 -
401 79 F 69 4 3
402 66 M 113 5 1
403 85 F 87 10 6
206
Study number Age (yean) Sex Hb (g/L) Ferritin (jxg/L) Genotype
404 68 M 107 5 3
405 74 F 98 7 -
406 30 F 76 1 1
407 31 F 102 3 1
408 44 F 102 8 1
409 82 F 100 7 1
410 71 F 140 9 1
411 32 F 121 11 1
412 80 F 89 5 1
413 45 F 94 3 1
414 59 M 117 6 1
415 86 M 49 3
416 35 F 98 4 1
417 64 M 92 6 1
418 48 F 82 7 1
419 59 F 108 9 2
420 83 F 62 13
421 88 F 101 9 mmmm
422 85 F 63 13 i
423 70 M 116 7 i
424 32 F 119 7 3
425 60 F 104 3 6
426 88 M 94 10 1
427 83 M 85 14 1
428 74 F 109 11 1
429 44 F 73 2 3
430 26 F 124 7 1
431 19 F 130 14 3
432 39 F 99 3 3
433 18 F 98 14 1
434 18 F 127 13 1
435 27 F 86 3 1
436 42 F 101 6 3
437 65 M 76 4 2
438 67 F 112 7 1
439 89 F 109 7 1
440 72 F 95 8 1
207
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
441 47 F 103 5 1
442 42 F 66 2 3
443 74 M 69 5 3
444 89 F 86 6 1
445 38 F 90 5 1
446 72 F 94 8 1
447 79 F 95 7 1
448 71 M 52 4 1
449 23 F 93 6 1
450 41 F 76 8 1
451 65 F 112 6 1
452 50 F 91 9 3
453 66 F 94 4 2
454 69 M 141 9 1
455 38 F 94 4 1
456 72 F 86 11 1
457 66 F 95 7 3
458 39 F 111 6 3
459 79 F 86 7 3
460 21 F 122 6 1
461 19 M 102 7 3
462 19 F 105 5 3
463 79 F 112 10 1
464 60 M 90 8 1
465 37 F 81 7 1
466 81 F 10
467 24 M 84 5 1
468 84 M 108 11 1
469 39 F 106 8
470 78 F 106 8 1
471 80 F 62 7 1
472 44 F 106 4 3
473 96 F 58 6 3
474 71 F 116 4 3
475 79 M 61 4 2
476 42 F 113 9 1
477 76 F 83 4 1
208
Study number Age (years) Sex Hb (g/L) Ferritin (pg/L) Genotype
478 82 M 98 7 1
479 47 M 55 3 2
480 64 F 112 6 3
481 70 M 55 3 1
482 35 F 109 4 1
483 29 F 119 5 3
484 45 F 107 1 3
485 47 F 101 5 1
486 76 F 105 7 3
00 47 F 110 3 2
488 38 F 63 2 1
489 77 M 126 6 1
490 39 F 89 4 -
491 43 F 77 2 1
492 46 M 119 6 6
493 83 F 98 8 1
494 77 M 104 8 -
495 47 F 111 4 3
496 36 F 114 11 1
497 71 F 98 10 2
498 67 F 95 6" 2
499 43 F 123 7 2
500 96 F 92 M3 1
501 80 M 85 8 1
502 88 F 113 14 1
503 81 M 110 6 1
504 83 M 69 6 1
505 32 F 80 3 1
506 44 F 117 6 1
507 57 F 90 8 1
508 58 F 89 4 3
509 20 F 114 4 1
510 48 F 104 3 2
511 74 M 87 6 2
512 46 F 108 4 1
513 40 F 82 6 1
514 77 M 96 11 -
I
209
I
£
210
